# BioAsset: full site text > BioAsset is a student-run research platform at the intersection of life sciences and capital markets. A global team of student analysts publishes deep dives, company analyses, educational primers, and open financial models, and interviews leaders across biotech, healthcare finance, and the life sciences. Website: https://bioasset.info/ · Email: bioasset@bioasset.info · Updated 2026-11-16 The most important developments in healthcare are driven by capital, science, and policy working together. BioAsset exists to make that intersection legible to the next generation of analysts, investors, and physicians. ## Frequently asked questions **What is BioAsset?** BioAsset is a student-run research platform at the intersection of life sciences and capital markets. A global team of student analysts publishes deep dives, company analyses, educational primers, and open financial models, and interviews leaders across biotech, healthcare finance, and the life sciences. Its tagline is “Where Medicine Meets Markets.” **Who founded BioAsset?** BioAsset was founded by Dmitry Vysotskiy, its Founder & President, a student at NYU Stern. Alay Galvankar is Lead Analyst & Vice President and Joy Wu is Lead Analyst. **What does BioAsset publish?** BioAsset publishes research posts on biotech, pharma, and healthcare companies: company analyses, industry deep dives, FDA approval explainers, investment pitches, and financial models. This site has 47 posts by 10 analysts, including “The Quiet (and Growing) Giant of US Healthcare: Cardinal Health”, “Long Aktis Oncology (AKTS): Investment Pitch”, “The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsy”. Every post can also be read as an article. **Who has BioAsset interviewed?** BioAsset has interviewed Sofia Axelrod (Co-Founder & CEO, Circadian OS); Jay Schiff (Addinex Technologies); Andy Bolt (Deloitte Life Sciences); Dr. Ron Marks (Biostatistician); Annika Lundström (Co-Founder & CEO, ReMinded); Dr. Ayoub Glia (Scientist & Engineer, AMMLab, NYU Abu Dhabi); Dr. Paul Glimcher (Professor of Neuroscience & Economics, NYU); Dr. Michele Pagano (Chair, Department of Biochemistry & Molecular Pharmacology, NYU); Dr. Hao Su (Director, Biomechatronics & Intelligent Robotics Lab, NYU Tandon). Upcoming: Dr. Omar B. Lateef (President & CEO, RUSH University System for Health). **Who are BioAsset’s clients and partners?** ReMinded, a New York medtech building clinical-grade saliva testing, starting with cortisol, is BioAsset’s official partner and a client since Fall 2026. The work together covers strategic marketing and campaigns, with a consulting project or case study to follow. **What does the BioAsset Fall 2026 curriculum cover?** The Fall 2026 curriculum runs 11 weeks: (1) Introduction to BioAsset and Life Sciences + Careers + Resume Workshop; (2) How Money Flows Through the Healthcare Ecosystem; (3) Biotech & Pharma Fundamentals; (4) Clinical Trials & Clinical Data; (5) FDA, Regulation & Catalysts; (6) Commercialization & Market Access; (7) Healthcare History, Ethics & Current Problems; (8) Biotech Revenue Forecasting; (9) How to Analyze a Public Healthcare Company; (10) Biotech Valuation & Investment Thinking; (11) M&A, Licensing & Strategic Finance + Fun Activities. Throughout the term, analysts create weekly posts, and the program includes potential field trips to life sciences startups and guest speakers on Zoom. **How can I join BioAsset?** Students can apply through the team application on the Join page of bioasset.info. BioAsset looks for student analysts interested in the intersection of healthcare and capital markets. **How can I work with or contact BioAsset?** Professionals can take part in an expert interview, students and early-career writers can publish a guest analysis, and organizations can partner on content and events. Details are on the Collaborate page. Email bioasset@bioasset.info, or find BioAsset on LinkedIn, Instagram, TikTok, and YouTube. ## Team - **Dmitry Vysotskiy**, Founder & President (NYU Stern, Finance & Quantitative Economics). Founder and President of BioAsset. Finance and Quantitative Economics student at NYU Stern with a minor in Computer Science. Prior research experience at NYU Langone and Weill Cornell, with clinical exposure in surgery and gastroenterology. Leads strategy, editorial direction, and partnerships, focused on making the intersection of life sciences and capital markets accessible to a broader audience. LinkedIn: https://www.linkedin.com/in/dmitryvysotsky/ - **Alay Galvankar**, Lead Analyst & Vice President (NYU, Global Public Health & Biology). Lead Analyst and Vice President at BioAsset. Studies Global Public Health and Biology at NYU, with minors in Chemistry and Business Studies. Leads research direction across biopharma and pharma strategy, focused on bridging scientific innovation with capital markets and broader public understanding. LinkedIn: https://www.linkedin.com/in/alay-galvankar-348997259/ - **Joy Wu**, Lead Analyst (NYU, Biology & Business Studies). Lead Analyst at BioAsset. Biology and Business Studies student at NYU with prior clinical exposure at Shanghai Shuguang Hospital. Leads research coverage and weekly biotech news analysis, with a focus on how immunology and physiology shape drug development. LinkedIn: https://www.linkedin.com/in/joy-wu-018473398/ - **Brendan Seo**, Research Analyst (NYU, Economics). Research Analyst at BioAsset. Economics student at NYU focused on the intersection of finance, investing, and biotech. Contributes company analyses, sector overviews, and editorial commentary on developments shaping the life sciences industry. LinkedIn: https://www.linkedin.com/in/brendanseo/ - **Jingqiu Tian**, Research Analyst (University of Cambridge, Biological Natural Sciences). Research Analyst at BioAsset. Biological Natural Sciences student at the University of Cambridge. Brings a scientific lens to biotech market analysis, focused on translating clinical and pipeline developments into accessible, investor-relevant insights. LinkedIn: https://www.linkedin.com/in/jingqiu-t-577637286/ - **Yaz Arulthasan**, Outreach (NYU, Biology). Outreach team member at BioAsset. Biology student at NYU. Focused on building partnerships, expanding organizational reach, and connecting BioAsset’s content with the broader biotech and healthcare finance community. LinkedIn: https://www.linkedin.com/in/yasvinth-arulthasan-005142266/ - **Benjamin Shar**, Research Analyst (NYU Stern, Finance). Research Analyst at BioAsset. Finance student at NYU Stern. Contributes company analyses, sector deep dives, and financial modeling across the biopharma and healthcare landscape, with a focus on drug development and market dynamics. LinkedIn: https://www.linkedin.com/in/ben-shar/ - **Sharath Venkatesan**, Research Analyst (NYU, Biochemistry). Research Analyst at BioAsset. Biochemistry student at NYU focused on the intersection of medicine and the financial decisions that shape patient care. Contributes research coverage and editorial commentary across the biopharma and healthcare landscape. LinkedIn: https://www.linkedin.com/in/sharath-venkatesan-b6880b318/ - **Neev Mohindroo**, Research Analyst (Rutgers University, Finance). Research Analyst at BioAsset. Finance major and biology minor at Rutgers University with a STEM-focused high school background and experience sourcing biotech startups through Rutgers Venture Capital Club. Drawn to the intersection of healthcare innovation and markets, with a focus on making biotech and healthcare finance ideas quicker to understand for readers who are curious about both fields. LinkedIn: https://www.linkedin.com/in/neev-mohindroo-2021a4282/ - **Viren Jain**, Research Analyst (NYU CAS, Economics). Research Analyst at BioAsset. Economics & Business student at NYU interested in the intersection of pharmaceuticals, finance, and business strategy. Brings prior experience in equity research and competitive analysis, and is focused on developing a deeper understanding of the business and investment decisions shaping the biopharma industry. LinkedIn: https://www.linkedin.com/in/virenjain0409/ - **Judy Dalati**, Research Analyst (NYU CAS, Global Public Health & Biology). Research Analyst at BioAsset. Global Public Health and Biology student at NYU with a minor in Business Studies. Focused on how biology, technology, and finance can work together to strengthen healthcare systems and make care more accessible and efficient, with particular interest in how biological innovations become real-world solutions. LinkedIn: https://www.linkedin.com/in/judy-dalati-8603032a5/ - **Olga Spasic**, Research Analyst (NYU, Biology). Research Analyst at BioAsset. Biology and Business student with hands-on experience in next-generation sequencing, genomic data analysis, and a broad range of molecular biology techniques at PathoQuest SAS. Pursuing a minor in Business Studies to bridge laboratory research with patient outcomes and healthcare contexts. LinkedIn: https://www.linkedin.com/in/olga-spasi%C4%87/ ## Expert interviews - **Dr. Omar B. Lateef**, President & CEO, RUSH University System for Health (upcoming conversation) - **Sofia Axelrod**, Co-Founder & CEO, Circadian OS: Circadian medicine, optimizing cancer treatment timing, and translating circadian rhythm research into clinical impact - **Jay Schiff**, Addinex Technologies: Medtech innovation, bringing devices from concept to commercialization - **Andy Bolt**, Deloitte Life Sciences: How consulting intersects with biopharma strategy, and navigating a non-linear career path - **Dr. Ron Marks**, Biostatistician: The role of statistics in drug development, clinical trial design, and interpreting endpoint data - **Annika Lundström**, Co-Founder & CEO, ReMinded: Building a cortisol biotech startup - **Dr. Ayoub Glia**, Scientist & Engineer, AMMLab, NYU Abu Dhabi: Microfluidic innovation, paper-based diagnostics, 3D tumor models, and accessible biomedical engineering for global health - **Dr. Paul Glimcher**, Professor of Neuroscience & Economics, NYU: Neuroeconomics, decision-making under uncertainty, and the convergence of neuroscience and finance - **Dr. Michele Pagano**, Chair, Department of Biochemistry & Molecular Pharmacology, NYU: Cell cycle control, ubiquitin-proteasome system, and translating fundamental research into oncology drug discovery - **Dr. Hao Su**, Director, Biomechatronics & Intelligent Robotics Lab, NYU Tandon: AI-powered wearable robotics, exoskeletons, and minimally invasive surgical robots transforming rehabilitation and medical procedures Video interviews on Instagram: - Why and how ReMinded was started, with Co-Founder & CEO Annika Lundström (https://www.instagram.com/p/DV-O6FdjsG7/) - ReMinded Co-Founder & CEO Annika Lundström on prioritizing what actually matters (https://www.instagram.com/p/DWc_Xa0jst4/) - Co-Founder & CEO Annika Lundström on the future trajectory of ReMinded (https://www.instagram.com/p/DWfdu9zDsqJ/) ## Fall 2026 curriculum Weeks 1–4 - Week 1: Introduction to BioAsset and Life Sciences + Careers + Resume Workshop - Week 2: How Money Flows Through the Healthcare Ecosystem - Week 3: Biotech & Pharma Fundamentals - Week 4: Clinical Trials & Clinical Data Weeks 5–8 - Week 5: FDA, Regulation & Catalysts - Week 6: Commercialization & Market Access - Week 7: Healthcare History, Ethics & Current Problems - Week 8: Biotech Revenue Forecasting Weeks 9–11 - Week 9: How to Analyze a Public Healthcare Company - Week 10: Biotech Valuation & Investment Thinking - Week 11: M&A, Licensing & Strategic Finance + Fun Activities Applied throughout: analysts create weekly posts in their chosen position; potential field trips to life sciences startup headquarters; guest speakers on Zoom. ## Clients Clients ### Our Clients Life sciences companies work with BioAsset to reach the next generation of analysts, investors, and physicians, and to put a team of student analysts to work on real questions. ### Current Clients What We Do for Clients ### How We Work Together ### Strategic Marketing & Campaigns Our team works closely with a client on marketing strategy and campaigns across our channels. ### Founder Stories & Explainers Founder conversations, office visits, and short explainers that make the science and the business behind a company clear. ### Consulting Projects & Case Studies A team of student analysts takes on a question the client chooses and presents its research. Work With Us ### Become a Client Tell us what you are building and what you need. We’ll find the right way to work together. Start a Conversation bioasset@bioasset.info ## Partnerships Official Partner · Fall 2026 ### BioAsset Is Partnering With ReMinded A New York medtech building clinical-grade saliva testing, starting with cortisol, now working with the student platform where science meets finance. Visit ReMinded Our Conversations Official Partner The Company ### Clinical-Grade Saliva Testing, Starting With Cortisol ReMinded is building the leading saliva-testing platform for hormones and metabolic markers, making it as easy for patients and clinicians to monitor biology as it is to check blood pressure. 94% Agreement with standard laboratory cortisol assays in real human saliva NYC · LA Clinics preparing for deployment as the first commercial customers 2027 Target for FDA clearance from the U.S. Food and Drug Administration, and first revenue Current clinical focus: long-term cortisol monitoring for endocrinology and precision mental-health clinics. Final clinical validation is underway at Hoag Hospital. 1. Agreement with standard laboratory cortisol assays in human saliva samples. Source: ReMinded company materials, November 2026. The Founder ### Annika Lundström Co-Founder & CEO, ReMinded Athlete Former Youth Olympian Scientist Molecular bioscientist, University of Helsinki Founder Moved alone from Finland to the U.S. two years ago to build ReMinded in New York Since Then Several million dollars raised, a top-tier scientific and engineering team assembled in the heart of NYC, saliva-based cortisol testing advanced through human-sample validation, and clinical partnerships established with leading U.S. healthcare institutions. Source: ReMinded company materials, November 2026. What’s Next ### Where This Partnership Goes ### Inside the Office We’re heading into ReMinded’s NYC office to film the team and a full end-to-end demo of the device, from saliva strip to result. ### The Story Behind the Science Founder conversations and short explainers on what cortisol reveals, and where saliva testing goes next: other hormones and metabolic markers. ### Students at the Table The BioAsset team will work closely with ReMinded on strategic marketing and campaigns, with a consulting project or case study to follow. On Instagram ### Our Conversations With ReMinded For Organizations ### Partner With BioAsset We work with student groups, platforms, and organizations on cross-promotion, co-produced content, and joint events. Start a Conversation How to Collaborate ## Advisory Board Guidance ### Advisory Board BioAsset is forming an advisory board of industry leaders, researchers, and founders to guide our research, our programs, and our growth. ### Members The Board’s Role ### Research Standards Advisors will help keep our company analysis, valuation work, and reading of clinical data at a professional standard. ### Mentorship Members will share career guidance with our student analysts across biotech, healthcare finance, and medicine. ### Industry Perspective The board will connect our research and programs with what is happening inside companies, funds, and health systems. Get in Touch ### Interested in Advising BioAsset? Reach out directly and we’ll find the right way to work together. bioasset@bioasset.info ## About About BioAsset ### Where Medicine Meets Markets Healthcare finance intelligence for the next generation of analysts, investors, and scientists. ### Our Mission The most important developments in healthcare are driven by capital, science, and policy working together. BioAsset exists to make that intersection legible to the next generation of analysts, investors, and physicians. We publish rigorous, accessible research. We build open financial models. We train student analysts to think across disciplines. And we do it all in public. 120+ Insights 10+ Members 8+ Collaborators 9 Expert Interviews What We Do ### Research & Analysis Deep dives, company analyses, educational primers, and open financial models from our global analyst team. Explore Insights ### Interviews & Media Conversations with leaders across biotech, healthcare finance, and the life sciences. Explore Conversations ### Our Team BioAsset is built on a simple belief: the best work happens when curious people are given real ownership. Meet the Team ### Fall 2026 Curriculum Eleven weeks that take our analysts from life sciences fundamentals to biotech valuation, M&A, and strategic finance. See the Curriculum ### Clients & Partnerships Life sciences companies work with BioAsset on strategic marketing, founder stories, and analyst-led projects. ReMinded is our first official partner. See the Partnership ### Advisory Board An advisory board of industry leaders, researchers, and founders is being formed to guide our research and programs. Advisory Board Questions ### Frequently Asked Questions Companies & Labs ### Past Interviews Contact ### Get in Touch Whether you want to read, write, model, or just learn, there’s a place for you. bioasset@bioasset.info Collaborate ## Collaborate Work With Us ### Collaborate With BioAsset We partner with professionals, students, and organizations operating at the intersection of life sciences and capital markets. If your work touches biotech, healthcare finance, or drug development, there’s likely a way we can work together. Collaboration Tracks ### How to Get Involved Whether you’re an industry veteran, an aspiring analyst, or a student organization, we’ve built structured ways to collaborate. For Professionals ### Expert Interviews Share your perspective with our audience of students and industry professionals across biotech, pharma, and healthcare finance. Format: 30–45 min recorded conversation, published as editorial content across our channels. Ideal for: Biotech investors, sell-side analysts, pharma executives, academic researchers, and clinician-scientists. Express Interest For Students & Early-Career ### Guest Analysis Publish a biopharma or healthcare finance deep dive with full author credit, reviewed by our editorial team. Format: Written analysis piece — company breakdown, sector overview, or financial model walkthrough — edited and published under your name. Ideal for: Students, graduate researchers, and early-career professionals building a public portfolio in healthcare finance. Featured each month: One standout submission is selected as our Research Post of the Month, distributed across all BioAsset channels for maximum visibility. Submit a Pitch For Organizations ### Partnerships We work with student groups, platforms, and organizations on cross-promotion, co-produced content, and joint events. Format: Flexible — audience swaps, co-hosted panels, shared research projects, or event sponsorship. Ideal for: University finance and biotech clubs, healthcare-focused media platforms, and life sciences organizations. Start a Conversation Get in Touch ### Have Something Else in Mind? Reach out directly and we’ll find the right way to work together. bioasset@bioasset.info Companies & Labs ### Past Interviews ## Join Join the Team ### Team Application BioAsset is built by a global team of student analysts passionate about the intersection of healthcare and capital markets. If that sounds like you, we’d like to hear from you. Team Application ### Team Application Form Tell us about your background, interests, availability, and the kind of work you want to do with BioAsset. Open Team Application Community ### Join the Conversation Whether you want to read, write, model, or just learn, there’s a place for you. Collaborate With Us Our Team ### Serious Work, Real Ownership If you want to do serious, professional-level work in healthcare finance alongside people who are just as driven and curious as you are, BioAsset is the place. Meet the Team # Research (47 posts) Each post is given as an article written from its slides; the two memos are in their own words, taken from the PDFs. ## The Quiet (and Growing) Giant of US Healthcare: Cardinal Health By Alay Galvankar, Lead Analyst & Vice President at BioAsset · Company Analysis · 7 slides In brief: Cardinal Health buys, stores and delivers drugs between manufacturers and pharmacies, and with McKesson and Cencora holds a 96% share of distribution. Fiscal 2026 revenue rose 14% to $254.2 billion, yet only about $1 to $1.40 of every $100 remains after costs. The post argues Cardinal is growing faster than McKesson, with adjusted EPS up 37%. Text page: https://bioasset.info/research/the-quiet-and-growing-giant-of-us-healthcare-cardinal-health.html Cardinal Health is one of the three largest drug distributors in the country, and it moves almost entirely unnoticed. It is the middleman behind your prescriptions, earning pennies per dollar on billions per year. Its fiscal 2025 revenue was $222.6B, more than twice Johnson & Johnson's revenue and more than twice Walgreens' pharmacy sales. In US healthcare, the spotlight usually falls on drugmakers (Johnson & Johnson, Merck, Eli Lilly), pharmacies (CVS, Walgreens) and insurers (UnitedHealth, Aetna, Cigna). They get the most attention and the most controversy, and most people assume they also bring in the most money. Johnson & Johnson had $94.2B in 2025 revenue, Walgreens about $89B in U.S. pharmacy sales in fiscal 2024, and UnitedHealth Group $447.6B in 2025, nearly 5x J&J. The company that actually makes the medicine isn't the one bringing in the most money. Between them sits the distributor. Ozempic doesn't travel from Novo Nordisk's plant to the CVS fridge by itself. About 16 million U.S. adults use prescription stimulants like Adderall each year, and every one of those controlled-substance fills passes through a middleman. Even a basic generic like rosuvastatin takes the same route. Brand, generic or controlled substance, Cardinal buys it, stores it and delivers it, and takes a cut along the way. It is part of the reason millions of Americans can pick up their prescriptions every day. ### Following the money Drugs move from manufacturer to distributor to pharmacy to patient. Money moves back the other way, with insurance paying the pharmacy alongside the patient's co-pay. Without the distributor, the flow is broken. How much each party really makes is harder to see, because contracts and rebates are confidential. This estimate is based solely on published industry averages, in this case for Zepbound. The patient pays a $25 copay at the pharmacy, plus an insurance premium that varies. The pharmacy buys its inventory from the wholesaler for $995, and the wholesaler buys the drug from the manufacturer for $975. Insurers do not deal directly with drugmakers or pharmacies. They hire a pharmacy benefit manager (PBM), so the insurer sends the PBM $975 in claim funding and the PBM reimburses the pharmacy $975. The manufacturer pays the PBM a $400 rebate, of which $380 goes on to the insurer. After rebates, the manufacturer has $575 in revenue before costs. The wholesaler's gross spread is $20 and the pharmacy's is $5, neither of which is profit. The PBM retains $20 of the rebate, also not profit, and the insurer's net drug cost is $595. The manufacturer and the insurer look like they make the most from the sale of one Zepbound product, and in the end the insurer does. The manufacturer only makes money when its own drug is the one being sold. If it's Novo Nordisk's Ozempic, Eli Lilly makes nothing and Novo does. Cardinal Health, CVS, UnitedHealth and the PBMs still get their cut. At the end of the day, it's all about the competition. There are about 18 large-cap drugmakers ($10B+ market cap). In distribution, the big three (Cardinal Health, McKesson and Cencora) account for 96% of the market, on PCMA-reported share for 2026. In pharmacies, CVS Health had 14.7% of 2024 dispensing revenue and Walgreens 14.6%, with other companies at 70.7%. In health insurance, UnitedHealth had 16% of 2024 commercial enrollment, Elevance and CVS/Aetna 12% each, Cigna 9% and HCSC 8%, with other insurers at 43%. ### The finances According to studies and publicly released material, distributors like Cardinal Health make significantly more money selling generic drugs than brand names. They can make about 15-50% profit on a generic because of its low price, against about 1% on an expensive brand-name drug. In its latest full year, fiscal 2026 (ended June 30), Cardinal's revenue rose 14% to $254.2 billion, mostly from selling more branded and specialty drugs to new and existing customers. Drug distribution made up about 92% of that, at $234.8 billion, up 15%. Medical products were about 5%, at $12.7 billion, up 1%, and smaller growth businesses about 3%, at $6.8 billion, up 26%. What Cardinal keeps is very little per dollar. Of every $100 that comes in, about $96 goes straight back out to pay for the drugs and products it bought. About $3.86 is left as gross profit (full-year gross margin was $9.8 billion, up 20%), and $1 to $1.40 remains after paying for warehouses, trucks and staff. ### Why Cardinal and not McKesson Cardinal isn't even the biggest distributor. McKesson has almost double its market cap (about $100B vs. about $50B) and brings in about 1.5x more a year. But Cardinal is the one that's moving. Its revenue grew 14% against McKesson's 12%, and its adjusted EPS grew 37% against McKesson's 18%. Since 2022, Cardinal's adjusted EPS has more than doubled, from $5.07 to $11.26, and its market cap has roughly tripled, from about $14B to about $50B. McKesson is the quiet giant everyone in the industry already respects. Cardinal is the quiet giant the market just started paying attention to, and that's why it's worth watching. Cardinal's plans for the future: - Buying into doctors' offices: acquiring the companies that run physician practices in urology, GI and oncology, supporting about 2,200 providers. - Doubling down on specialty drugs: specialty revenue grew 25% to over $50B, with oncology, urology and autoimmune care as the priorities. - Automating its warehouses: new high-tech distribution centers are planned across the U.S. - Locking in big customers: deals with CVS and Kroger. - Growing profit steadily: a target of 13-15% EPS growth in fiscal 2027 and 12-14% a year after that. ### The past year Cardinal Health (NYSE: CAH) closed at $237.57 on Oct 9, up 53.96%, or $83.26, over the past year. On normalized earnings per share, it beat estimates in all four quarters of fiscal 2026, by $0.38, $0.26, $0.38 and $0.18. The estimate for the first quarter of fiscal 2027, due Nov. 5, is $2.94. Morgan Stanley raised its price target to $265 from $255 and kept its Overweight rating, and JPMorgan moved its target to $260 from $215 while maintaining a Neutral rating. Wells Fargo raised its outlook, citing broad business strength, and Citi kept its Buy rating. Another headline reported Bank of America purchasing 2,900,596 Cardinal Health shares, and Cardinal entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health. ## Long Aktis Oncology (AKTS): Investment Pitch By Dmitry Vysotskiy, Founder & President at BioAsset · Investment Pitch · 18 pages · PDF In brief: The pitch recommends buying Aktis Oncology, then $18.52 a share, citing differentiated drug design, broad development potential and $517.3 million in cash expected to fund operations into 2029. Aktis is advancing AKY-1189 (Nectin-4) and AKY-2519 (B7-H3), which deliver actinium-225 to tumors, with preliminary clinical data expected in 2027. Its Eli Lilly collaboration paid $60 million upfront. Text page: https://bioasset.info/research/long-aktis-oncology-akts-investment-pitch.html Full Pitch (PDF): https://bioasset.info/files/Long-Aktis-Oncology-Pitch.pdf - Recommendation: Buy - Date: 10/5/26 - Share Price: $18.52 - Market Capitalization: $1.030B - Cash & Investments: $517.3M - Cash Runway: Into 2029 - 52-Week Low: $14.72 - 52-Week High: $34.19 Aktis Oncology (NASDAQ: AKTS) is a clinical-stage biotechnology company developing targeted radiopharmaceuticals with the potential to expand precision cancer treatment across a broad range of solid tumors. Its proprietary miniprotein platform uses small, engineered proteins to deliver radiation directly to tumors, combining deep tumor penetration and prolonged retention with rapid clearance from healthy tissues. This approach is designed to address a central challenge in oncology: delivering sufficient treatment to destroy cancer cells while limiting damage to surrounding organs. Aktis is advancing two clinical programs, AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, with potential applications spanning urothelial, breast, prostate, lung, and other cancers. Together, these programs offer multiple opportunities to establish the platform’s clinical value and expand its commercial reach. Aktis enters its next phase of development with substantial financial resources and external support for its technology. The company reported $517.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which management expects to fund its operating plan into 2029. Its collaboration with Eli Lilly provided $60 million upfront and includes eligibility for up to $1.2 billion in additional milestone payments, plus royalties, while preserving Aktis’ rights to its proprietary pipeline. Preliminary clinical data is expected for AKY-1189 in the first quarter of 2027 and AKY-2519 during 2027, creating identifiable opportunities to assess the platform’s therapeutic potential. In our view, the investment opportunity lies in this combination of differentiated drug design, broad development potential, and funding that extends beyond anticipated clinical milestones. ### Business Overview Aktis’ proprietary miniprotein radioconjugate platform is designed to deliver actinium-225 (Ac-225), an alpha-emitting radioisotope, to cancer cells to damage their DNA and kill them. Its two lead drug candidates, AKY-1189 and AKY-2519, target the cell-surface proteins Nectin-4 and B7-H3, respectively. In February 2026, the FDA granted Fast Track designation to AKY-1189 for adults with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies. This designation facilitates closer interaction with the FDA and may help expedite development and review, supporting Aktis’s pursuit of a treatment option for patients with limited alternatives. Aktis has not yet generated revenue from product sales and funds its operations primarily through equity financing and collaboration payments. In January 2026, the company completed its IPO, raising approximately $365.4 million in gross proceeds, including the underwriters’ full exercise of their option to purchase additional shares. Its financial backers include MPM BioImpact, Vida Ventures, EcoR1 Capital, Blue Owl Capital, and RA Capital Management. Additionally, Eli Lilly participated as an anchor investor, purchasing approximately $100 million of shares in the IPO, further strengthening its existing relationship with Aktis. - March 2021: Series A, $72M. Co-led by MPM Capital, EcoR1 Capital and Vida Ventures. - August 2022: Series A extension, $84M. Participation from all existing investors; new investors included Merck’s MRL Ventures Fund. - May 2024: Eli Lilly Collaboration, $60M upfront. Additional equity investment; eligibility for up to $1.2B in milestone payments and tiered royalties. - September 2024: Series B, $175M. Led by RA Capital; co-led by RTW Investments and Janus Henderson Investors. - January 2026: Initial Public Offering, $365.4M. Gross proceeds at $18 per share, including full exercise of the underwriters’ option. ### Management Aktis’s team combines experience in drug discovery, clinical development, radiopharmaceutical manufacturing, and biotechnology finance. Members of its leadership have contributed to the approval and commercialization of 14 FDA-approved products. We view this combination as a strength as Aktis advances its pipeline and builds manufacturing capacity. Equity awards held by senior executives also provide incentives tied to shareholder value. - Matthew Roden, PhD (President and CEO): Previously held senior strategy and business development positions at Bristol Myers Squibb, where he led teams on transactions cumulatively valued at more than $125 billion. Before entering pharmaceutical management, he covered biotechnology as an equity research analyst at UBS and J.P. Morgan. His background brings both scientific and financial expertise to evaluating pipeline opportunities, negotiating partnerships, and communicating Aktis’s investment case. - Kyle Kuvalanka (CFO): Brings more than 20 years of senior leadership experience in biopharmaceuticals. Previously held executive roles at Blueprint Medicines and Syros Pharmaceuticals, where he built finance and business functions and helped guide both companies through their IPOs. His experience is particularly relevant to financing clinical development, managing cash requirements, and evaluating future partnership opportunities. - Akos Czibere, MD, PhD (Chief Medical Officer): Formerly led Pfizer’s hematology-oncology therapeutic area and has been directly involved in the approval of six oncology drugs, including Elrexfio and Talzenna. He oversees Aktis’s clinical development activities. His experience leading global registration programs provides a foundation for designing trials and navigating regulatory requirements as Aktis advances its investigational therapies. - Paul Feldman, PhD (Chief Scientific Officer): Spent more than 27 years at GlaxoSmithKline and contributed to the discovery of five approved drugs. He also co-founded Phoundry Pharmaceuticals, which Intarcia acquired in 2015, and subsequently led discovery and translational medicine at Intarcia. At Aktis, he directs discovery platforms and new radiopharmaceutical candidates, bringing experience in both drug discovery and peptide therapeutics. - Tyler Benedum, PhD (Chief Technical Officer): Spent more than 16 years at Avid Radiopharmaceuticals, now part of Eli Lilly, ultimately leading chemistry, manufacturing, and controls development and manufacturing. He helped advance the radiopharmaceutical imaging agents Amyvid and Tauvid through approval and commercialization. His experience is particularly relevant to establishing reliable manufacturing and clinical supply for Aktis’s radioactive therapies. - Shulamit Ron-Bigger, PhD (Chief Operating Officer): Previously led strategy and operations for Bristol Myers Squibb’s research and early development organization, overseeing portfolio strategy, budgets, and operating models. Her background provides relevant experience for prioritizing programs, coordinating development activities, and allocating resources as Aktis expands its pipeline. ### The Science Miniprotein radioconjugates are small, engineered proteins that carry a radioactive payload to tumors. The miniprotein acts as a delivery vehicle: it recognizes and attaches to a selected protein on cancer cells. The attached radioactive material then delivers radiation that damages the cells’ DNA. Aktis uses actinium-225, which releases powerful alpha particles over a very short distance, only about a few cell widths. This is intended to concentrate cancer-killing radiation around the targeted cells. Aktis’s approach aims to balance three properties: penetrate tumors, remain inside cancer cells, and clear quickly from healthy tissues. Miniproteins are much smaller than antibodies, allowing them to move more readily through tumor tissue. Once they reach their target, they are designed to enter cancer cells and remain there, extending radiation exposure at the tumor while limiting exposure elsewhere. The potential benefit is a more effective treatment at a tolerable dose. Additionally, Aktis can attach an imaging isotope to its miniproteins, allowing doctors to see whether they reach a patient’s tumors before therapeutic treatment. This is extremely beneficial as it supports tumor uptake and retention. ### Industry Outlook Oncology remains the pharmaceutical industry’s largest therapeutic market, supported by sustained investment in new treatments and expansion into earlier stages of disease. Vision Research Reports estimates that global oncology medicine market reached $356 billion in 2025 and forecasts approximately 10% annual growth over 2026–2034. Innovation is increasingly concentrated in treatments that improve tumor selectivity or engage the immune system, including antibody-drug conjugates, multispecific antibodies, and targeted radiopharmaceuticals. However, at the same time, this expanding opportunity is accompanied by increasingly competitive treatment standards and greater pressure to demonstrate meaningful clinical differentiation. Aktis operates within several established oncology markets, including urothelial, breast, lung, colorectal, cervical, head and neck, and prostate cancers. Its Nectin-4 program, AKY-1189, benefits from the target validation established by Padcev, while its B7-H3 program, AKY-2519, offers a different targeting approach from PSMA-directed radiopharmaceuticals such as Pluvicto. Pluvicto generated approximately $2.0 billion in 2025 sales, demonstrating the commercial potential of targeted radiotherapy. Aktis has also expanded AKY-2519’s clinical development beyond prostate cancer, initiating a second Phase 1b trial in NSCLC and other B7-H3-expressing tumors in October 2026. In our view, Aktis’s commercial opportunity depends on identifying patient populations in which its miniprotein radioconjugates can provide meaningful benefit despite an increasingly effective standard of care. Established drugs demonstrate substantial spending across the company’s target indications, but do not establish the size of Aktis’s addressable market. ### Thesis: Underappreciated Science and Commercial Potential We believe Aktis’s differentiated tumor targeting and retention justify a more favorable assessment of clinical success than a generic framework would suggest. Our thesis centers on the human evidence already supporting its miniprotein platform: its candidates can reach tumors, remain within them, and clear from healthy tissues. These are essential conditions for delivering an effective radiation dose without unacceptable toxicity. Although therapeutic efficacy remains to be established, treating Aktis solely according to its development stage risks overlooking the uncertainty that its human imaging and dosimetry studies have already reduced. AKY-1189 provides the clearest initial evidence. In its first human imaging assessment, all 15 patients evaluable for tumor uptake were uptake-positive, out of 20 patients administered the imaging conjugate. Uptake was observed across urothelial, breast, lung, cervical, and colorectal cancers. Representative imaging with the lutetium-177 conjugate also demonstrated tumor retention through 48 hours, alongside clearance from normal tissues. In eight evaluable patients, median absorbed-dose coefficients were 0.30 Gy/GBq to the kidneys and 0.01 Gy/GBq to bone marrow. These findings support the possibility of maintaining tumor exposure while limiting radiation delivered to organs that could otherwise constrain treatment. The small cohort cannot establish population-wide eligibility or efficacy, but it provides direct human evidence for the drug’s intended delivery profile. AKY-2519 strengthens this argument by demonstrating a similar delivery profile against a different target, B7-H3. Its initial mCRPC assessment demonstrated tumor retention through at least six days. Using lutetium-177 measurements to model an actinium-225 regimen of four 8 MBq administrations, investigators projected absorbed doses of 1.3 Gy to bone marrow, 4.2 Gy to salivary glands, and 16 Gy to kidneys, with an assumed relative biological effectiveness of five. This separation between tumor retention and normal-organ exposure supports a potential therapeutic window across a second program. These remain surrogate-based projections, but observing favorable delivery characteristics with two different targets strengthens our confidence that the platform’s design could have broader application. For AKY-1189, the competitive opportunity is particularly compelling in urothelial cancer after existing treatments. Padcev’s success has established Nectin-4 as a clinically actionable target, while AKY-1189 introduces a different tumor-killing payload through targeted radiation. We believe this creates a plausible opportunity to treat patients whose tumors remain accessible through Nectin-4 after developing resistance to Padcev’s cytotoxic payload. This is a mechanistic hypothesis requiring clinical confirmation, and it makes patients progressing after Padcev a particularly informative population for upcoming studies. Meaningful, durable responses in these patients could establish a differentiated treatment role without requiring immediate displacement of Padcev plus Keytruda in first-line care. Patient selection could further improve the development proposition. Aktis’s imaging conjugates allow investigators to assess whether the drug reaches a patient’s tumors before therapeutic administration. This matters because target expression is heterogeneous: a published study found absent membranous Nectin-4 expression in 39.4% of the metastatic urothelial specimens examined. Imaging offers a way to identify patients with sufficient uptake despite this variability. Our inference is that selecting patients on demonstrated delivery could improve the likelihood of detecting a meaningful therapeutic signal. Such selection would also narrow the eligible population, making observed uptake rates an essential input into commercial forecasts. AKY-2519 adds a complementary competitive opportunity because it targets B7-H3, whereas Pluvicto targets PSMA. Aktis is studying AKY-2519 in both Pluvicto-naïve and Pluvicto-experienced patients. Activity following Pluvicto would be particularly valuable evidence that the program can serve a distinct treatment need. We therefore view the second program as an additional opportunity to establish clinical differentiation, while recognizing that shared platform characteristics also create correlated development risks. The financial significance lies in the sensitivity of early-stage drug valuations to changing success probabilities. For every $1 billion of commercial present value conditional on success, a five-percentage-point increase in approval probability adds $50 million of risk-adjusted value, before changes in spending assumptions. We believe Aktis’s human delivery evidence provides a concrete basis for considering such an upward revision as therapeutic data emerge. Preliminary AKY-1189 results are expected in the first quarter of 2027, followed by preliminary AKY-2519 mCRPC data during 2027. Confirmed, durable responses at repeatable doses would connect the existing targeting evidence to clinical benefit and provide the strongest basis for a higher valuation. AI drug discovery research provides an additional reason to examine whether conventional development benchmarks fully capture Aktis’s potential. In a 2024 Drug Discovery Today study, Jayatunga and colleagues reported that 21 of 24 AI-discovered molecules completing Phase I were successful (87.5%) compared with historical industry benchmarks of approximately 40–65%. The finding suggests that AI-assisted discovery may help identify molecules with properties favorable to early clinical development. The study is relevant as Aktis documents using AI for target selection, miniprotein design, and candidate optimization, integrated with laboratory screening and proprietary experimental data. Our interpretation is that this discovery approach provides supporting context for the platform’s scientific differentiation. The study’s 87.5% figure should not be assigned directly to Aktis. Instead, it strengthens the rationale for investigating whether Aktis’s actual molecular and clinical characteristics support better outcomes than broad historical averages imply. Additionally, we believe Aktis’s current valuation may understate the commercial implications of its scientific differentiation. If the tumor delivery and retention observed in early human assessments translate into durable responses at tolerable doses, AKY-1189 and AKY-2519 could establish meaningful treatment roles across multiple cancer indications. Our mispricing thesis therefore concerns both the probability of successful development and the revenue opportunity that clinically differentiated therapies could capture. Demonstrating this opportunity requires translating the platform’s scientific promise into explicit commercial assumptions. We begin by estimating eligible patient populations, treatment access, market penetration, expected doses, and net pricing under different adoption scenarios. We then apply development probabilities, commercialization timelines, and associated costs to assess the present value attributable to shareholders. This framework allows us to evaluate whether the commercial prospects supported by our interpretation of the science justify a valuation above the current share price. ### Modeled Revenues Our valuation framework begins with an indication-level assessment of Aktis Oncology’s commercial opportunity across AKY-1189 and AKY-2519. For each indication, we estimate the population entering the relevant treatment line and apply successive adjustments for clinical eligibility, target expression or tumor uptake, screening, treatment access, and market penetration. We then multiply the resulting treated population by expected doses received and an assumed net price of $45,000 per dose, expressed in 2026 dollars. Our price of $45,000 is benchmarked against Pluvicto’s published price of approximately $51,168 per dose. Applying a 10–15% discount produces a range of approximately 43,500–46,100, supporting $45,000 as a reasonable central assumption. This approach anchors our forecast to an established radiopharmaceutical while avoiding reliance on a premium price for Aktis’s investigational technology. On a six-administration basis, Aktis’s drug cost would total $270,000, approximately $37,000 below six doses of Pluvicto at its published list price. Padcev provides an additional benchmark for AKY-1189’s potential positioning in advanced urothelial cancer at approximately $300,424, about $30,000 above the six-dose Aktis course. This potential pricing strengthens Aktis’s commercial proposition if AKY-1189 delivers competitive, durable clinical benefit through a limited treatment course. A lower total drug cost can support payer negotiations and adoption in indications and treatment settings where it becomes an approved alternative. Furthermore, this pricing for Aktis’s therapy represents a hypothetical full course while our model uses expected doses received, amounts generally lower than the maximum six doses. The following tables present four commercial adoption scenarios: Conservative, Moderate, Strong, and Exceptional. These scenarios describe market penetration conditional on successful development and approval; they do not represent the probability that approval occurs. Under the supplied assumptions, modeled annual revenue ranges from approximately $813 million to $4.66 billion for second-line and later treatment alone, and from $2.28 billion to $15.52 billion when first-line treatment is included. The combined estimates incorporate the model’s adjustment for reduced later-line treatment among patients already treated in first line. These revenue estimates establish the commercial foundation for the valuation. To translate that opportunity into an investment assessment, we subsequently apply development probabilities, adjust prices to the year in which revenue is generated, and account for the timing and costs of commercialization. This approach distinguishes the potential scale of the portfolio from the portion of that opportunity attributable to shareholders today. Treatment lines describe the sequence in which therapies are used within a particular disease setting. First-line treatment (1L) is the initial treatment regimen used in that setting, while second-line and later treatment (2L+) includes subsequent regimens, typically given after an earlier treatment stops working or cannot be tolerated. These terms refer to treatment sequence, rather than cancer stage. The 2L+ table estimates annual revenue assuming Aktis’s therapies are approved only for second-line and later use. The combined 1L & 2L+ table estimates the broader opportunity if approval also encompasses first-line treatment, incorporating an adjustment to reduce double counting of patients treated across multiple lines. Our valuation incorporates two layers of probability weighting: the likelihood of achieving a particular approval outcome and the distribution of commercial performance conditional on that outcome. For each modeled asset-indication opportunity, we assign a 20% probability to approval limited to second-line and later treatment, a separate 10% probability to broader approval encompassing first-line and later treatment, and a 70% probability to neither modeled approval outcome. Throughout this analysis, “1L+” refers to the combined first-line-and-later opportunity. These outcomes are mutually exclusive. The 20% weight applies to the 2L+-only revenue opportunity, while the 10% weight applies to the combined 1L+ opportunity. Together, they imply a 30% probability of achieving some form of modeled approval. These are analyst assumptions measured from the current development stage, rather than probabilities conditional on an already successful Phase 1 trial. The odds of approval represent a substantial premium to historical oncology development outcomes. BIO, Informa, and QLS reported a 5.3% probability of approval from Phase 1 for oncology programs during 2011–2020, including 4.6% for solid-tumor programs. The corresponding oncology probability from Phase 2 was 10.8%. These figures provide historical reference points, although they do not separately estimate the likelihood of first-line versus later-line approval. Our assumptions therefore reflect a differentiated investment judgment rather than established industry success rates. Our rationale for assigning above-average probabilities rests principally on patient selection and evidence of tumor delivery. Aktis’ platform allows clinicians to visualize tumor uptake before administering the therapeutic radioisotope, potentially reducing uncertainty about whether treatment reaches its intended target. Historical evidence supports the relevance of patient selection: the same BIO study reported Phase 1-to-approval rates of 15.9% for programs employing patient-preselection biomarkers, compared with 7.6% for programs without them. These results span therapeutic areas and support the direction of our adjustment, while leaving the magnitude of the assumed premium subject to analyst judgment. Program-specific evidence provides additional support. Nectin-4 is clinically validated as a therapeutic target in urothelial cancer through Padcev, and Aktis has reported human imaging evidence of AKY-1189 tumor uptake. For AKY-2519, its 2026 ASCO disclosures reported tumor uptake and retention alongside favorable predicted normal-tissue radiation exposure. The smaller probability assigned to broader first-line approval reflects the additional challenge of competing against effective established regimens. In urothelial cancer, for example, Padcev plus Keytruda demonstrated median overall survival of 31.5 months versus 16.1 months with chemotherapy in its pivotal first-line trial. Moving into this setting requires evidence supporting a compelling role alongside or against existing treatment, making first-line expansion a more demanding development objective. Within each successful approval outcome, we apply a distinct distribution across the Conservative, Moderate, Strong, and Exceptional commercial adoption scenarios. For 2L+-only approval, the respective weights are 20%, 45%, 25%, and 10%. For combined 1L+ approval, the weights are 5%, 30%, 45%, and 20%. The greater weighting toward Strong and Exceptional adoption in the first-line-inclusive scenario reflects our assumption that successful expansion into earlier treatment would be associated with a more compelling clinical profile and stronger competitive positioning. Strong and Exceptional outcomes collectively receive a 65% conditional weight under 1L+ approval, compared with 35% under 2L+-only approval. These distributions represent assumptions about commercial performance following approval; first-line approval itself does not guarantee exceptional uptake. Applying the commercial scenario weights produces conditional expected annual revenue of approximately $2.30 billion under 2L+-only approval and $9.58 billion under combined 1L+ approval. We then apply the separate approval probabilities: Expected annual revenue = (20% × $2,297.821 million) + (10% × $9,583.795 million). The resulting $1.42 billion in expected annual revenue incorporates both clinical-development uncertainty and variation in commercial adoption. It preserves the treatment-overlap adjustment already embedded in the combined 1L+ estimates. The higher revenue contribution from the first-line-inclusive outcome reflects its larger commercial opportunity and its greater conditional weighting toward strong adoption. Pricing represents an additional source of potential revenue growth. The model’s $45,000 net price per dose is expressed in 2026 dollars, while commercialization and broader adoption would occur in future years. Pluvicto provides a relevant historical reference: its reported U.S. launch wholesale acquisition cost was $42,500 per dose in March 2022, while Novartis lists a price of $51,168.13 effective January 7, 2026. This represents a cumulative increase of approximately 20.4%, equivalent to roughly 5.0% annually over 3.79 years. However, list-price increases do not necessarily translate into equivalent growth in manufacturer net revenue. Merck’s historical disclosures illustrate this distinction (table in the PDF). We assume 3% annual net-price growth, below Pluvicto’s observed list-price growth but above the approximately 2.2% compounded annual increase implied by Merck’s reported 2019–2023 net-price changes. This is a modeling judgment informed by historical observations, rather than an established radiopharmaceutical industry average. Before commercialization, it represents escalation of the assumed future launch price; after commercialization, it represents growth in realized net pricing. However, competition, discounts, and Medicare inflation-rebate obligations could restrict actual increases. Holding patient populations, treatment access, doses, market penetration, and probability weights constant, 3% annual net-price growth increases expected annual revenue from $1.42 billion at 2026 prices to approximately $1.91 billion in 2036 (table in the PDF). Under the 3% assumption, price escalation adds approximately $487.7 million in annual revenue relative to holding prices flat. This quantifies the potential conservatism of a constant nominal-price forecast while separating the contribution from pricing from changes in clinical success or commercial adoption. The 2036 illustration does not independently establish when the portfolio would achieve the modeled penetration levels. ### Risk-Adjusted Net Present Value Calculations To translate the probability-weighted commercial opportunity into present value, we apply a risk-adjusted net present value framework that incorporates commercialization timing, cash-flow conversion, remaining development expenditure, and the portfolio’s modeled economic life. The preceding 2036 pricing illustration represents the mature revenue opportunity expressed at future prices. Our annual cash-flow forecast separately accounts for the time required to launch each indication and achieve the assumed market penetration. We assume initial later-line commercialization of AKY-1189 in urothelial cancer in 2031 and AKY-2519 in prostate cancer in 2032. Other modeled indications launch in 2033 and 2034, respectively. Under the broader approval outcome, the incremental first-line contribution begins two years after the corresponding later-line launch. These dates are analyst assumptions rather than company guidance. Following each launch, revenue reaches 5%, 15%, 30%, 50%, 70%, 85%, and 100% of the applicable mature commercial opportunity over seven selling years. The first-line contribution follows its own delayed adoption schedule, bringing the entire modeled portfolio to mature penetration in 2042. The combined 1L+ forecast preserves the treatment-overlap adjustment embedded in the underlying revenue estimates. The assumed net price of $45,000 per dose increases by 3% annually from its 2026 base (P_t = 45,000 × 1.03^(t − 2026)). Here, P_t represents the modeled net price per dose in year t. Before commercialization, this adjustment increases the assumed future launch price; after commercialization, it represents annual growth in realized net pricing. This price escalation is incorporated into the annual revenue forecasts before discounting. We then convert commercial revenue into cash flow using an assumed 45% after-tax cash-flow margin. This margin incorporates manufacturing and isotope costs, distribution, selling expenses, royalties, ongoing commercial research and development, and sustaining investment. Separately modeled development expenditure and unallocated corporate overhead are deducted outside this margin. We extend the forecast through 2047 to capture the portfolio’s modeled commercial life. Aktis’ disclosures identify expected 2044 expiration dates for relevant AKY-1189 patents and applications, and for AKY-2519 applications if patents are issued, excluding potential patent-term adjustments or extensions. These disclosures provide a reference point for our economic-life assumptions rather than establishing a guaranteed date of competitive entry. We maintain mature penetration through 2044, then apply revenue-retention factors of 50%, 25%, and 10% in 2045, 2046, and 2047, respectively, relative to the otherwise projected revenue in each year. We assign no residual value after 2047. This erosion schedule is an informed assumption. Next, cash flows are discounted at a 12% nominal annual rate, using 2026 as the valuation base year. The clinical probabilities account for the expected loss of commercial cash flows from unsuccessful development. The discount rate serves a separate purpose: compensating investors for waiting and for exposure to market-related risks that remain after probability weighting. Clinical failure should therefore not receive a second adjustment through an additional failure premium in the discount rate. The selection of exactly 12% remains a modeling judgment; it has not been established through an Aktis-specific cost-of-capital calculation. Because both the revenue forecast and discount rate are nominal, the model incorporates 3% price growth in cash flows while retaining the full nominal discount rate. The pipeline valuation is calculated as: (formula in the PDF) In this equation: - D_2026 represents development spending in the starting year, thus why it was subtracted upfront. - CF_2L+,t represents commercial cash flow in year t under the later-line-only outcome, weighted across its commercial adoption scenarios. - CF_1L+,t represents commercial cash flow under the combined first-line-and-later outcome, using its separate commercial scenario weights. - E[D_t] represents expected development expenditure in year t, adjusted for the probability of incurring that expenditure. The commercial cash-flow terms aggregate the modeled asset-indication opportunities and already incorporate launch timing, adoption, price growth, revenue erosion, and the 45% cash-flow margin. The 20% and 10% approval probabilities are applied once. These probabilities operate at the asset-indication level and do not imply that the entire portfolio must succeed or fail together. The development budget includes $30 million of immediate remaining 2026 expenditure, followed by expected spending of $120 million in 2027, $120 million in 2028, $104.5 million in 2029, $88 million in 2030, $45 million in 2031, and $24 million in 2032. These annual amounts are already probability-weighted. Development spending is adjusted for the likelihood of reaching the stage at which costs arise, since expenditure can occur even when a program ultimately fails. At a 12% discount rate, the present value of expected commercial cash flows is approximately $1,582.4 million, while the present value of modeled development expenditure, including the immediate 2026 amount, is $400.8 million. The resulting pipeline rNPV is approximately $1.182 billion. To translate pipeline value into equity value, we add $517.3 million of cash, cash equivalents, and marketable securities reported as of June 30, 2026, and subtract a $100 million present-value allowance for unallocated corporate overhead. The cash balance is a dated reported figure and has not yet been reduced for subsequent cash use. No separate value is assigned to additional platform programs or future Lilly collaboration proceeds, all potential sources of significant upside. Under these assumptions, the model indicates a provisional equity value of approximately $1.60 billion, or $28.75 per share. The reported 55.62 million outstanding shares were used as the denominator. ### Addressing Key Investor Concerns How defensible is Aktis’s intellectual property? Aktis’s IP protection centers on its proprietary molecules and their uses. In its 2025 Form 10-K, the company disclosed one issued U.S. patent covering AKY-1189 and related pending applications, while AKY-2519’s applications remained pending as of March 1, 2026. The disclosed patent families have expected expirations in 2044, excluding potential adjustments or extensions. Could dilution undermine shareholder returns? Aktis reported $517.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, with management expecting its operating plan to be funded into 2029. This provides financial flexibility, although the estimate depends on spending assumptions and does not establish that the company is funded through commercialization. Favorable clinical results could allow Aktis to raise a given amount with fewer new shares. Additional non-dilutive funding can also come from milestone payments under Aktis’s collaboration with Eli Lilly, contingent on specified development, regulatory, and commercial achievements within the partnered programs. Could encouraging early data fail to translate into approval? Yes. Tumor uptake and favorable radiation-distribution measurements help establish whether a radioconjugate reaches its intended target, but they do not independently demonstrate durable tumor responses or improved survival. While Aktis’s early AKY-1189 evidence includes preclinical studies and investigator-led human imaging and dosimetry assessments, therapeutic efficacy and repeated-dose safety stand as central uncertainties and highlight the risk that comes along with biotechnology investing. Can Aktis compete with established treatments? An initial commercial opportunity does not require Aktis to replace an established first-line regimen. The company is developing AKY-1189 for patients with advanced urothelial cancer, including a setting where patients progressing after therapies such as Padcev have limited options. This creates a potential entry point in later-line disease, provided Aktis demonstrates a clinically meaningful benefit. Its use of a radioactive payload offers a different therapeutic mechanism. Full commercial adoption would depend on efficacy, tolerability, treatment logistics, and the competing options available at launch. Is isotope supply an issue? Actinium-225 access is a material operating consideration. Aktis has announced supply agreements with NorthStar, Niowave, and TerraPower, using suppliers with different production approaches. This diversification provides a reasonable basis for reducing dependence on any single source. Furthermore, the company also reported plans for an internal GMP manufacturing facility to become operational in the second half of 2026 as part of its broader manufacturing strategy. ### Investment Strategy Our estimated intrinsic value of $28.75 per share represents approximately 55.2% upside from the $18.52 reference share price used in this report. This estimate reflects the present value of Aktis’s future cash flows under our probability-weighted assumptions and provides the valuation basis for our Buy recommendation. We believe the gap between market price and modeled value offers an attractive opportunity to invest ahead of clinical evidence. However, $28.75 is not a forecast that the shares will reach that price within a specific timeframe. There remains a high risk and high reward setup, although we believe that this is an opportune time to invest with a positive expected return under our calculations. The overall investment strategy is to establish a long position in Aktis Oncology ahead of clinical milestones that could prompt investors to reassess its probability of success. The investment rests on the view that Aktis’s molecular design, preliminary human delivery evidence, and approach to patient selection justify greater confidence than conventional development-stage benchmarks imply. We seek to capture the difference between the clinical prospects reflected in the share price and our own probability-weighted assessment. Biotechnology’s sensitivity to clinical information creates an additional consideration for implementation. When valuation depends heavily on uncertain future outcomes, changing expectations can produce substantial price movements. Investor enthusiasm, fear, and positioning may amplify these movements, potentially creating temporary discrepancies between market price and fundamental value. However, volatility alone does not establish an investment advantage. Our strategy requires a favorable relationship between the probability and magnitude of potential gains and the corresponding downside. Within this broader long thesis, we identify a tactical opportunity over the next six months, centered on the preliminary AKY-1189 Phase 1b results expected in the first quarter of 2027. The AI discovery research discussed earlier, which reported Phase I success for 21 of 24 molecules completing that stage, provides supporting context for our confidence. Its observed 87.5% success rate does not establish an Aktis-specific probability but strengthens the rationale for examining whether conventional benchmarks understate the potential of differentiated discovery approaches. Considered alongside Aktis’s preliminary human delivery evidence and approach to patient selection, these findings support our conviction in the prospect of favorable early clinical results. A readout demonstrating meaningful antitumor activity and acceptable tolerability would, in our assessment, likely support an upward reassessment of the program’s value, particularly if the findings exceed expectations already reflected in the share price. We would therefore initiate a position ahead of the readout, preserving additional capital as evidence develops. If favorable results produce a meaningful price increase, we would seek to sell a modest portion of the position into that strength, promptly realizing gains while retaining a core holding for subsequent development milestones. The size of this reduction would depend on the magnitude of appreciation relative to the improvement in our valuation, as well as personal risk tolerance. This approach combines participation in a potential near-term repricing with continued exposure to the platform’s longer-term clinical and commercial prospects. Additionally, when making exit decisions after-tax returns must also be considered. For U.S. individual investors in taxable accounts, selling appreciated shares within our proposed six-month window would generally generate short-term capital gains, with net short-term gains taxed at ordinary income rates. Gains on shares held for more than one year generally qualify for potentially lower federal long-term capital-gains rates. Before reducing exposure, we would weigh the potential tax savings from extending the holding period against the expected return and downside risk of continued ownership. This consideration supports selectively realizing gains following a favorable catalyst while retaining a core position when the thesis and valuation remain attractive. Tax efficiency would inform the timing and size of sales but would not justify maintaining an overvalued position or delaying an exit after material deterioration in the clinical outlook. Similarly, tax-lot selection when reducing the position must also be considered to maximize possible returns. Lastly, following the initial readout, additional investment would depend on response magnitude, durability, repeat-dose tolerability, and the valuation available after the results. Stronger evidence could justify a higher valuation and continued ownership, while market enthusiasm that outpaces improvements in fundamentals would support more substantial profit-taking. However, inadequate therapeutic activity or an unfavorable safety profile would trigger reassessment and potentially an exit. The remaining position would be held according to its prospective return and risk, with partial sales reducing overall exposure without eliminating the downside of the shares retained. We believe Aktis’s breakthrough science and financial foundation position it to advance cancer treatment, create long-term shareholder value, and improve the lives of patients worldwide. ## The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsy By Joy Wu, Lead Analyst at BioAsset · FDA Approval · 5 slides In brief: Oveporexton restores orexin signaling, a brain system that keeps people awake and alert, in people with narcolepsy type 1. Eli Lilly acquired Centessa for more than $7.8 billion to gain its experimental orexin drug, and companies such as Alkermes are testing the pathway in ADHD. Morgan Stanley projects a potential $16 billion annual orexin market by 2035. Text page: https://bioasset.info/research/the-fda-has-approved-takeda-s-oveporexton-the-first-orexin-agonist-for-narcolepsy.html The FDA has approved Takeda's oveporexton, the first orexin agonist for narcolepsy. Orexin is a brain signaling system that helps keep us awake and alert. Oveporexton works by restoring this signal in people with narcolepsy type 1. The pharma world sees potential beyond a single narcolepsy treatment. Eli Lilly acquired Centessa for $7.8B+ to gain its experimental orexin drug. Orexin might also regulate attention, motivation and the brain's reward system, and companies such as Alkermes are testing whether the same pathway can treat conditions such as ADHD and other neurological disorders. The opportunities mapped out for the orexin pathway run from sleep disorders and neuropsychiatry to neurodegeneration, addiction, and metabolic and cognitive health. Morgan Stanley projects a potential $16B annual orexin market by 2035. On that view, the first approval signals a new neuroscience drug platform rather than a one-drug opportunity. ## Designer-ish Babies: Will it be the Future? By Jingqiu Tian, Research Analyst at BioAsset · Industry Trends · 7 slides In brief: A growing number of startups, including Nucleus Genomics, screen IVF embryos for diseases such as breast cancer and diabetes and for controversial traits such as height, hair color and IQ. Results reflect statistical probability, since most traits involve many genes and few have proven causal links. Many countries maintain much stricter regulations on the technology. Text page: https://bioasset.info/research/designer-ish-babies-will-it-be-the-future.html There has been an unprecedented increase in the number of startups offering genetic screening services for IVF embryos. Nucleus Genomics is one example of a company selling these services. These startups do not only screen for diseases such as breast cancer and diabetes. They also screen for more controversial traits, including height, hair color and IQ. The predictions come from technologies such as whole-genome sequencing and gene association studies, which generate trait predictions from an embryo's gene sequences. The results need careful interpretation. Most traits involve many genes, few have proven causal links, and much of what these tests produce reflects statistical probability rather than certainty. The applications of this screening technology have drawn countless arguments, especially concerns about morality once traits like height and IQ are involved. The future of designer-ish babies remains uncertain: the screening startups keep growing, while many countries maintain much stricter regulations on the technology. ## FDA Approves Rasonque: The First RAS-Targeted Drug for Pancreatic Cancer By Neev Mohindroo, Research Analyst at BioAsset · FDA Approval · 4 slides In brief: Pancreatic cancer has a five-year survival rate of 13% and until now had no targeted therapy for the mutation driving it. Rasonque, a once-daily pill, reached median survival of 13.2 months versus 6.7 on chemotherapy and cut the risk of death by 60%. It costs $477,000 a year, and a CVS spokesman warned the price could severely limit access. Text page: https://bioasset.info/research/fda-approves-rasonque-the-first-ras-targeted-drug-for-pancreatic-cancer.html The FDA has approved Rasonque, the first RAS-targeted drug for pancreatic cancer. It arrives in a disease that has resisted almost everything medicine has thrown at it. Pancreatic cancer has a five-year survival rate of just 13%. Symptoms are vague and appear late, there is no routine screening, and until now no targeted therapy addressed the mutation driving the disease. In trials, Rasonque nearly doubled median survival, 13.2 months versus 6.7 months on chemotherapy, and cut the risk of death by 60%. It is also a once-daily pill rather than an IV infusion, which changes what treatment looks like day to day for patients. The catch is the price: $477,000 a year, more than double Keytruda, the top-selling cancer drug. A CVS spokesman called Rasonque a breakthrough, then warned that the price could "severely limit" who gets access. ## The Parkinson’s Bet That Couldn’t Hold $15: Aspen Neuroscience’s IPO By Judy Dalati, Research Analyst at BioAsset · Company Analysis · 5 slides In brief: Aspen turns a patient's own skin cells into dopamine neurons as a one-time Parkinson's treatment. Early results look strong but come from the first eight patients in an open-label trial with no control group, and earlier fetal cell transplants showed no overall benefit once tested against sham surgery. With losses of roughly $73 million a year and Bayer's BlueRock already in Phase 3, the post expects another raise before Phase 3 data arrive. Text page: https://bioasset.info/research/the-parkinson-s-bet-that-couldn-t-hold-15-aspen-neuroscience-s-ipo.html Aspen Neuroscience's IPO landed in the hottest biotech market since 2021. Within two weeks, it was trading about 17% below its IPO price. ### Skin cells to brain cells Aspen Neuroscience is developing a one-time Parkinson's treatment that replaces the dopamine neurons the disease destroys, using a patient's own skin cells. Today's drugs, like levodopa, control symptoms but don't replace lost neurons or slow the disease. Aspen takes a skin sample, reprograms the cells into stem cells, then turns those into dopamine neurons that mature once placed back in the patient. Because the cells are the patient's own, the body shouldn't reject them. ### An IPO on markdown Aspen marketed its shares at $15-$17, then priced at $15, the low end, raising $140.6M. It closed its first day at $14.89, then fell another 12% to $13.04 on Nov. 2. By Nov. 9, it was trading at about $12.40, roughly 17% below the IPO price. The timing made it stranger. Twenty-nine biotechs have gone public in the U.S. this year, the most since 2021. Investors are clearly buying biotech again, just not this one at full price. ### The data problem The early results look strong. At 12 months, patients gained about two more hours of well-controlled symptoms a day, and motor scores improved by 13.5-15.5 points with no severe dyskinesia. But those results are from the first eight patients, in an open-label trial with no control group. Parkinson's responds strongly to placebo, so it's hard to separate the cells' effect from expectation. History serves as a warning. In the 1990s, fetal cell transplants also looked promising in uncontrolled studies. Once tested against sham surgery (fake surgery used as a placebo), the transplants showed no overall benefit, and in 2003, 56% of patients developed uncontrolled movements that persisted even off medication. Aspen's lab-grown cells are a different technology, but investors haven't seen them beat a control group yet. ### $488M in, $361M out Aspen raised about $347M privately before its IPO, plus $140.6M in the offering, roughly $488M in total. By Nov. 9, it was valued at about $361M, and about $213M of that was cash ($72.4M at the end of June plus the IPO proceeds). The market was paying only about $150M for the pipeline itself. Aspen has no revenue and lost $36.5M in the first half of 2026, a pace of roughly $73M a year. That means it had only about one year of cash left before the IPO. Aspen says its cash will last into the second half of 2028, about a year after its Phase 3 trial starts in the second half of 2027. We expect another raise, and dilution for shareholders, before the Phase 3 data arrive. That's our estimate. The therapy is also hard to scale. Each dose is made from one patient's own cells, so there's no mass production. That makes it slow and costly to scale, even if it ends up working. ### The verdict Seventeen biotechs raised at least $250M in IPOs this year, but cell and gene therapy companies haven't drawn the same interest. Aspen's $140.6M was $109M short of that mark. Scribe, the only other genetic medicine company to go public this year, raised about $129M. Same-day peer Bambusa, an antibody company that raised $168.9M, also dipped on its debut but was back near its $16 IPO price within days. Aspen is still about 17% below its $15 IPO price. There is a competitor ahead of it, too. Bayer's BlueRock already has its Parkinson's cell therapy in Phase 3. BlueRock uses donor cells, which are easier to mass-produce. Aspen bets its approach is safer because it avoids a long course of immunosuppressants. It's safety vs. scale. What to watch: Aspen plans to start Phase 3 before its long-term data arrive in 2028. Whether that trial includes a control group will show whether the science holds up and whether Aspen can become a business. The science might work. Now it has to beat a placebo and BlueRock. ## A $1.3B Bet: Merck KGaA Buys Silence Therapeutics By Viren Jain, Research Analyst at BioAsset · Company Analysis · 5 slides In brief: Merck KGaA is paying $20.00 a share in cash for U.K. biotech Silence Therapeutics, 130% above its last close of $8.70. The prize is divesiran, a Phase 3-ready siRNA drug for polycythemia vera that drew an 88% response rate versus 19% on placebo in Phase 2 and is dosed once every three months. The deal gives Merck an entry point into hematology and follows its 2025 purchase of SpringWorks Therapeutics. Text page: https://bioasset.info/research/a-1-3b-bet-merck-kgaa-buys-silence-therapeutics.html Merck KGaA, the German pharma giant, agreed on October 19 to acquire Silence Therapeutics for $20.00 per U.S.-listed share in cash. That values the U.K. biotech at about $1.3B in equity ($1.1B enterprise value), a 130% premium over Silence's last closing price before the announcement. The gap is easy to see in the share price. Silence closed at $8.70 on October 16, and its 30-day average was $10.99. Merck's $20.00 offer is 82% above that average. ### What Merck is buying The prize is divesiran, a Phase 3-ready siRNA drug for phlebotomy-dependent polycythemia vera (PV), a rare blood cancer where the bone marrow overproduces red blood cells. Divesiran isn't approved yet. Merck is buying a drug candidate rather than a product on shelves. The case for it rests on strong Phase 2 results: 88% of patients responded, versus 19% on placebo. It is also dosed once every three months, compared with weekly injections for Takeda's rival drug, Mimrylo. The drug uses siRNA, which "silences" a gene's message so the protein is never made, instead of blocking the protein afterward. Divesiran silences TMPRSS6, a liver gene that controls iron supply, and that limits how many red blood cells the bone marrow can make. ### Why pay double Merck doesn't have a hematology business today. This deal gives it an entry point into a new disease area, plus Silence's siRNA platform for future drugs, not just one product. Buying Silence is faster than building this drug internally, but it is not risk-free: divesiran still has to succeed in Phase 3. This isn't Merck's first move like this, either. It bought SpringWorks Therapeutics in 2025, a $3.9B deal by equity value, using the same playbook. Large pharma companies increasingly prefer buying promising small biotechs over building new drugs in-house, since early research is expensive and failure-prone. For a small biotech, this is often the real payoff: not selling a finished drug, but getting acquired before the drug is even approved. A 130% premium is the acquirer's way of saying it believes the drug is worth more than Silence could capture alone. ### The takeaway A drug doesn't need FDA approval to be worth over a billion dollars; strong trial data and the right disease category are enough. Phase 2 data, not Phase 3, was enough to trigger this deal. Acquirers sometimes move before a company's hardest clinical test is finished if the risk looks acceptable. The price of a deal also tells you as much about the buyer's strategy as it does about the drug itself. Watch the acquirer's pattern, not just the target: Merck doing this twice in two years, with SpringWorks and now Silence, tells you more about its strategy than any single deal does. ## From the Space Race to the Biotech Race: China Guards Its Lead By Judy Dalati, Research Analyst at BioAsset · Industry Trends · 5 slides In brief: On Oct. 16, 2026, Beijing proposed blocking foreign buyouts of proprietary cell and gene therapy, siRNA and pathogen gain-of-function platforms, while leaving licensing open. China's share of the innovative drug pipeline rose from 4% in 2015 to around 30% by 2025, and its out-licensing deal value reached $135.7 billion in 2025. The post argues Big Pharma becomes a renter rather than an owner of Chinese science, and that Western platforms may become more valuable. Text page: https://bioasset.info/research/from-the-space-race-to-the-biotech-race-china-guards-its-lead.html Recruiting foreign talent helped the U.S. win the Space Race. China is making sure that can't happen in biotech. On Oct. 16, 2026, Beijing proposed blocking foreign acquisitions of proprietary cell and gene therapy (CGT), siRNA, and pathogen gain-of-function platforms. Put simply, China wants to stop foreign companies from buying its most valuable biotech "engines." ### What the engines are - CGT: reprogramming a patient's own cells to fight disease. - siRNA: small RNA molecules that "silence" a disease-causing gene. - Platforms: a drug-making machine, not one drug. These are reusable technologies that can support the development of multiple drugs. Why CGT and siRNA? Because that's where China is winning. In stem cell therapies, gene therapies, and RNA-based medicines, China accounts for almost one-third of the global pipeline in Phase I and II clinical development. China is banning the sale of exactly what it's winning at. Licensing is still open, however, so U.S. companies can rent China's drugs but can't buy the machine. The real story is that China has gone from copying drugs to inventing them, and now it's protecting that lead. ### China is catching up fast According to McKinsey, China had just 4% of the world's innovative drug pipeline in 2015, rising to around 30% by 2025. The U.S. share declined from 47% in 2018 to 36% by 2026. A gap of 39 points between the two in 2018 is down to 6 points. In early-stage science, China now leads. Goldman Sachs estimates Chinese companies contributed 46% of all new drug molecules entering human trials in the first half of 2025, compared with 17% a decade earlier. China has also passed the U.S. in clinical trials: in 2024 it listed more than 7,100 trials in the WHO registry, versus about 6,000 for the U.S. Speed is China's advantage. With a 30-working-day review to start trials and high patient density, Phase I trials that often take two years in the U.S. are frequently completed in nine months in China. But China's trials are mostly local: 70%+ are China-only. The U.S. still leads in global reach. ### The money Big Pharma needs new drugs, and fast. When a drug's patent expires, competitors can sell cheap copies, known as generics, and the original drug's sales crash. Deloitte estimates Big Pharma could lose $236B in revenue by 2030 as patents expire on 190 drugs. So Big Pharma is shopping in China. China's out-licensing deal value grew from $51.9B in 2024 to $135.7B in 2025, and China held about 50% of global out-licensing deal value in 2025. Chinese assets have traded at 40-50% lower deal values than Western equivalents, but China's leverage is growing: average upfront payments rose from $52M in 2022 to $172M in 2026, which is 3.3x more cash upfront. The difference between buying and renting matters here. Acquire a platform and you own 100% of the profits plus every future drug the platform creates. License a drug and you pay a cut of every sale, and the platform stays in China. The new rule removes the "acquire" option for China's best platforms. AstraZeneca's $1B Gracell buyout, for example, likely couldn't happen today. ### What this means for the U.S. After WWII, the U.S. ran Operation Paperclip, bringing German rocket scientists like Wernher von Braun to America. He later led the development of the Saturn V rocket that took Apollo to the Moon. Acquiring the minds behind the rockets helped the U.S. win. China is making sure no one can do that to its biotech platforms. Who wins and who loses is my opinion. Big Pharma still gets Chinese drugs, but as a renter paying fees, not an owner, which leads to less control and thinner margins. For U.S. biotechs with CGT and siRNA platforms, if China can't be bought, Western platforms become rarer and possibly more valuable. For the U.S. as a whole, the more dependent it gets on licensing from China, the more leverage China has over future medicines and innovations. That's why U.S. lawmakers proposed the Biotech Investment National Security Act to scrutinize Chinese biotech deals. My outlook, again an opinion: the U.S. is no longer clearly ahead on early-stage innovation. Its advantage now is capital, global approvals, and the world's most profitable drug market. The comment deadline on China's draft rule was Nov. 15, 2026. In the Space Race, the winner was whoever controlled the talent. In biotech, it's whoever controls the platforms. ## The Shovel Sellers of AI Biology: Twist Bioscience By Neev Mohindroo, Research Analyst at BioAsset · Company Analysis · 5 slides In brief: Anthropic is funding lab tests of 5,000 AI-designed proteins built from Twist's synthetic DNA, and Twist also joined Lilly TuneLab as its preferred antibody-testing partner. Claude's designs showed a binding hit rate of 22% to 35%, against 10% to 15% typical in the field, and every design starts with a DNA order. The average analyst target of about $110 sits roughly 40% below the stock, and the company is still unprofitable. Text page: https://bioasset.info/research/the-shovel-sellers-of-ai-biology-twist-bioscience.html Twist Bioscience surged after Leerink named it the top beneficiary of Anthropic's biology push. On Sept. 24, Leerink raised its price target from $120 to $160, and the stock rose 16% to $184. In the rush into AI biology, Twist is the one selling the shovels. ### Claude designs, Twist builds Anthropic is funding lab tests of 5,000 AI-designed proteins, each one built from Twist's synthetic DNA. The work runs as a loop. Claude writes amino acid sequences as text. Twist turns each design into synthetic DNA. The proteins are expressed and screened for binding. Then Claude reads the lab data, which it did in under 23 minutes when results came back. Each loop takes days, not months. Design and analysis now run at computer speed, but the physical build in between is a step every lab still has to pay for. ### Code can't bind, DNA can Claude's output is just text, a string of amino acid letters. To learn whether a design works, someone has to write it into physical DNA, express the protein, and measure binding. As AI makes designs cheap, the bottleneck moves to the lab, and Twist is one of the few suppliers built for that volume. The designs are also landing more often. In its first protein design run in August, Claude hit 14 of 15 targets, with the designs built and tested by Twist and Adaptyv. Of 1,320 Claude designs built and tested by independent labs, 354 bound. Claude's designs showed a binding hit rate of 22% to 35%, against 10% to 15% typical in the field. More hits per design means more campaigns worth running, and every one starts with a DNA order. Twist CEO Emily Leproust summed up what AI is doing to demand: "It just creates more sequences." ### Two giants, one supplier On Sept. 16, Twist joined Lilly TuneLab as its preferred antibody-testing partner. There, 75+ companies can order antibody testing on Twist's preferred protocols and pricing, and the results feed back into Lilly's shared AI models. Anthropic's 5,000-design program runs on Twist DNA too. Being the default inside both workflows means recurring orders instead of one-off pilots. The business was already growing. On Aug. 3, Twist reported third-quarter revenue of $118.4M, up 23% year over year and its 14th straight quarter of growth. ### Wall Street can't keep up Twist closed at $184, while the average analyst target sits near $110, about 40% below the stock. Even Leerink's raised target trails it by 13%. The gap keeps widening. In March, the average target sat 6% above the stock. By June it was 28% below. Since then, the price has run and analysts have been chasing it. The bull case is that every AI design still needs real DNA, the fiscal 2026 revenue guide is $456-457M, and AI drug-discovery orders have more than doubled again. The bear case is that the company is still not profitable, the Anthropic work is already in its guidance, and cloud labs like Adaptyv could push testing prices down. The stock may be priced for a future the business hasn't reached yet. ## The Price to Pay to End an mRNA Vaccine Fight: Up to $2.25B to be Paid by Moderna By Jingqiu Tian, Research Analyst at BioAsset · Company Analysis · 5 slides In brief: Moderna agreed to pay $950 million upfront and up to $1.3 billion more, depending on an appeal, to Arbutus Biopharma and Roivant subsidiary Genevant Sciences, with no future royalties. The post calls the settlement a win because the companies were seeking roughly $5 billion at trial. Arbutus and Genevant still have suits against Pfizer and BioNTech. Text page: https://bioasset.info/research/the-price-to-pay-to-end-an-mrna-vaccine-fight-up-to-2-25b-to-be-paid-by-moderna.html Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Genevant Sciences, a Roivant subsidiary, in a settlement that ends the legal dispute over the technologies used in its vaccines. The sum is large, but the deal is a win for Moderna because it avoids a much worse outcome. ### Moderna's rise Moderna is a biotechnology company founded in 2010 that works on mRNA medicines. The name incorporates "modified" and "RNA," emphasising that focus. Success came quickly. In 2015, Moderna initiated the first-in-human dose of an mRNA vaccine candidate for H10N8 flu, and in 2019 it announced dosing of the first antibody encoded by mRNA in a clinical trial. What brought Moderna to prominence was its development of one of the world's first COVID vaccines. In 2022, the company received full approval from the U.S. Food and Drug Administration for Spikevax, an mRNA vaccine designed to prevent COVID-19. ### Why lipid nanoparticles matter Traditional vaccines work by injecting a weakened or inactivated virus (or a virus subunit) to prepare the immune system against the disease in advance. mRNA vaccines work by injecting mRNA wrapped in lipid nanoparticles for delivery. The body can use this mRNA to create the virus's spike proteins, which prepares the immune system in advance. The lipid nanoparticles are key to mRNA vaccines, because mRNA is fragile and hard to transport into the cell. Their use is also what has been causing problems for Moderna. The nanoparticles that are essential for its drugs, Spikevax among them, were pioneered by other companies, including Arbutus. ### The settlement Moderna will make an upfront payment of $950 million in the third quarter of this year. Another $1.3 billion payment may follow, depending on the outcome of Moderna's appeal to the federal circuit court. Following this payment, Moderna will not have to pay future royalties to the two companies on its sales of mRNA vaccines. The settlement came just before the start of a trial in which Arbutus and Genevant were seeking roughly $5 billion. In that worst-case scenario, Moderna would have had to pay roughly $5 billion and future royalties, which would have added to the company's financial stress. Moderna shares rose by 9% on Wednesday, reflecting its success in avoiding that scenario. A one-month price chart shows the stock at $57.80 on Mar 4, 2026. ### Insights The development of lipid nanoparticles has been a crucial breakthrough in mRNA vaccine development. Companies that hold the key technologies for developing them are now involved in suits against companies producing mRNA vaccines, and could pocket even more payments. Arbutus and Genevant, for instance, have settled with Moderna but are still in ongoing suits against Pfizer and BioNTech, which are among the other companies that developed mRNA vaccines for COVID. For Moderna, the settlement is definitely a win. The company has been under financial stress for years, since COVID vaccine sales declined, and a larger payment with additional royalties would have left it in even more financial stress. The rise in its share price reflects a successful settlement. Moderna now expects to end the year with roughly $5 billion in cash and cash equivalents. Moderna's case makes one thing clear. Companies that were brought to prominence by developing mRNA COVID vaccines now face lawsuits over key technologies and financial pressure from declining COVID vaccine sales. They need to actively seek new growth drivers to cope with that stress. Moderna, for its part, is now well-funded for several of its cancer vaccine trials. ## $6.7B: Merck’s Leukemia Drug Acquisition That Could Shake Up The Market By Alay Galvankar, Lead Analyst & Vice President at BioAsset · Company Analysis · 5 slides In brief: Merck is acquiring Terns Pharmaceuticals for $53 a share to gain TERN-701, an early-stage oral therapy for chronic myeloid leukemia aimed at Novartis' Scemblix. The deal follows purchases of Cidara and Verona as Keytruda's core patents near expiry. The post models $800 million to $1.2 billion in base-case peak sales and flags the low 6% premium as a bidding-war risk. Text page: https://bioasset.info/research/6-7b-merck-s-leukemia-drug-acquisition-that-could-shake-up-the-market.html Merck announced last week that it is acquiring Terns Pharmaceuticals for $53 a share in a roughly $6.7B deal, and the asset at the center of it is worth paying close attention to. TERN-701, a tyrosine kinase inhibitor developed by Terns, is an oral targeted therapy for chronic myeloid leukemia, currently in early-stage trials. Early data presented at the American Society of Hematology last year showed improvements in both efficacy and safety over existing options, with the potential for once-a-day dosing. That puts it on a direct collision course with Novartis' Scemblix, a drug projected to hit $4B+ in peak annual sales. Merck is not simply acquiring a pipeline asset. It is making a calculated move to challenge one of pharma's most formidable franchises. Novartis scaled Scemblix into a dominant market position remarkably quickly, and Merck's willingness to compete directly signals strong belief in TERN-701's potential. ### Who else is at risk Besides Scemblix, a few other drugs are on the radar after this acquisition. Scemblix (asciminib) carries the highest risk, as the direct competitor for first-line CML, because TERN-701's dosing and tolerability profile attacks its biggest vulnerability. Pfizer's Bosulif (bosutinib) and Bristol Myers Squibb's Sprycel (dasatinib) carry moderate risk: these older second-generation inhibitors are already losing share to Scemblix, and further damage is likely if TERN-701 advances. Novartis' Gleevec faces the least risk, since the generic version is a cheaper option and TERN-701 targets patients seeking superior efficacy despite the price. The global CML market is about $5.8B annually and growing. A drug with best-in-class efficacy and tolerability could capture 25-35% market share within five years of approval. That is $1.5-2B in peak annual sales for Merck. ### Merck's buying spree In the last two years, Merck has spent around $25B purchasing smaller companies. It bought Cidara Therapeutics in 2025 for $9.2B, for the preventive antifungal rezafungin, which addresses hospital-acquired infections and diversifies the company beyond oncology. It bought Verona Pharma in 2025 for $10B, for ensifentrine in COPD, the first new mechanism in pulmonary disease in decades and another non-oncology anchor. And now it is buying Terns in 2026 for $6.7B, bringing it back to oncology but targeting a different mechanism than Keytruda's checkpoint inhibition. The reason for the spree is straightforward. Keytruda generated over $25B in 2024 and is Merck's single largest revenue driver, but its core patents expire later this decade. CEO Rob Davis has called the result the "broadest pipeline" in the company's recent history, targeting $70B in annual revenue next decade. ### Three possible scenarios In the bull case, TERN-701 reaches $1.8-2.4B in peak sales. Phase 3 confirms a best-in-class profile, the drug displaces Scemblix in first-line treatment, and Merck expands significantly. In the base case, peak sales land at $800M-$1.2B. Phase 3 data is solid and the drug is approved in second-line CML, capturing patients who discontinue Scemblix. It competes but does not dethrone, and still validates the $6.7B price tag. The main risk is a bidding war. The deal included a 6% closing premium, paying $53 a share when the market had shares at $50, which is unusually low. For reference, a typical biotech acquisition premium ranges from 30% to 100% above the current share price. AbbVie and BMS are logical suitors. If a competing bid emerges before the shareholder vote, Merck may have to raise the offer. ## UK Biobank: Turning Biological Data into Drug Discovery By Brendan Seo, Research Analyst at BioAsset · Deep Dive · 5 slides In brief: UK Biobank holds health, genetic and lifestyle data from over 500,000 UK participants recruited between 2006 and 2010, and has supported over 18,000 peer-reviewed studies. Its scale helps researchers link genes, lifestyle and disease risk and select drug targets with higher confidence, which can reduce clinical trial failures. The post also raises questions around data access and control. Text page: https://bioasset.info/research/uk-biobank-turning-biological-data-into-drug-discovery.html UK Biobank is one of the largest biomedical databases in the world, containing health, genetic and lifestyle data from over 500,000 participants in the United Kingdom. It has become a foundational resource for studying disease, and it is changing how early-stage drug discovery is approached. ### What the database holds Participants were recruited between 2006 and 2010 and agreed to share their biological samples and health records over time. The dataset includes blood, urine, imaging data and detailed medical histories, which allows researchers to study how diseases develop over decades. Today, UK Biobank provides access to researchers worldwide, who use it to study conditions such as cancer, heart disease and neurological disorders. The range of data types is wide. It runs from sociodemographics, lifestyle factors, mental health and cognitive tests to brain and heart MRI, carotid ultrasound and whole-body DXA scans of bones and joints. There are measures of blood pressure, arterial stiffness, heart and lung function, physical activity, and body size and composition. Urine and blood samples provide genetics, proteins, biochemical measures and low-molecular-weight metabolites. All of it is linked to primary and secondary care records and to death and cancer registers. ### Connecting genes to health outcomes UK Biobank allows researchers to connect genetic data with real health outcomes at scale. That makes it possible to identify links between genes, lifestyle and disease risk. The database contains thousands of variables per participant, including imaging, genomic sequencing and biomarker data. This depth lets researchers run large-scale studies that would not be possible in smaller datasets. UK Biobank has supported over 18,000 peer-reviewed studies and is widely used in research on cancer, cardiovascular disease and aging. ### A new starting point for drug discovery Drug development moves through five phases: discovery and development, preclinical research, clinical research, FDA review and FDA post-market safety monitoring. UK Biobank is changing the earliest of these. Instead of relying on small clinical samples, researchers can now identify disease patterns using large population-level data. The database includes over 15 million biological samples and tens of petabytes of data, making it one of the most comprehensive resources for biomedical research. That scale improves the ability to identify drug targets with higher confidence. By improving target selection, large datasets like UK Biobank can help reduce failure rates in clinical trials. This is critical in an industry where drug development can take over a decade and requires significant capital investment. ### Data as a core asset UK Biobank shows how biological data is becoming a core asset in biotechnology. The value is no longer just in physical samples, but in the ability to generate insights from large datasets. At the same time, this model raises important questions around data access and control. Over 30,000 researchers across more than 90 countries now use UK Biobank data, which highlights its global influence. Looking forward, the competitive edge in biotech may depend on who can best use large-scale biological data. Platforms like UK Biobank are shaping how future discoveries are made. ## Saliva, Stress, and Startups: The Rise of Cortisol Testing By Joy Wu, Lead Analyst at BioAsset · Industry Trends · 5 slides In brief: Salivary tests measure free, active cortisol and can be done at home several times a day, while blood tests remain the gold standard for diagnosing disease. The global cortisol testing market reached $2.1 billion in 2024 and is projected to hit $4.3 billion by 2033. Companies named include ReMinded Inc and Eli Health. Text page: https://bioasset.info/research/saliva-stress-and-startups-the-rise-of-cortisol-testing.html Cortisol is the body's primary stress hormone, and testing for it no longer has to mean a needle. Alongside the traditional blood draw at a clinic, labs and startups now measure it in saliva, in some cases at home. Saliva-based testing is identified as one of the fastest-expanding segments of the cortisol testing market. ### Background Cortisol is produced by the adrenal glands and regulates metabolism, immune response and sleep cycles, among other things. Its level is highest in the early morning and lowest at midnight. Testing is used for adrenal dysfunction diseases such as Cushing syndrome (excessive cortisol) and Addison's disease (insufficient cortisol), and in research on sleep disorders, stress physiology and mental health. The traditional test measures total cortisol, which includes hormone bound to proteins as well as "free" hormone. It needs venipuncture, a needle draw at a clinic or lab, and usually gives a single morning snapshot at 8:00 AM. Stress bias is high, because the "white coat effect" or needle phobia can spike results. It is the gold standard for diagnosing diseases, and it is inexpensive and usually covered by insurance. The salivary test measures free cortisol, the active hormone available to tissues. Collection means spitting into a tube, which can be done at home, and multiple samples throughout the day capture the diurnal rhythm. Stress bias is low because the test is done in a familiar, relaxed environment. It is excellent for assessing HPA-axis dysfunction (burnout and stress), though it is often paid out of pocket and multi-sample kits cost more. ### The technology About 90% of the cortisol in the body is bound to proteins like corticosteroid-binding globulin (CBG) and albumin. That portion is inactive and is only being transported. The remaining 10% is active cortisol, whose molecules pass easily through the lipid membranes of the gland cells and into the saliva. This is what a salivary test measures. The challenge is that cortisone in saliva interferes with cortisol detection. Once a sample is obtained, biochemical assays detect the cortisol level. ELISA (enzyme-linked immunosorbent assay) is the most common method. The lab uses antibodies designed to "grab" cortisol molecules, and a color-changing enzyme signals how much cortisol is present. LC-MS/MS (liquid chromatography-tandem mass spectrometry) is the gold standard for high precision. It separates the chemicals in the saliva and identifies them by their specific molecular weight and "fingerprint", ensuring that no other steroids, like cortisone, are accidentally counted. ELISA is what labs use. Consumer tests such as Eli Health's use lateral flow strips, in the style of a pregnancy test, and clinical startups such as ReMinded Inc use a biosensor reader that takes an electronic measurement. ### The market The global cortisol testing market reached $2.1 billion in 2024 and is projected to hit $4.3 billion by 2033, a CAGR (mean annual growth rate) of 8.4%. Saliva-based testing is growing fast because it is non-invasive and because diagnostics are shifting toward the home. ReMinded Inc is building a clinical point-of-care diagnostic that pairs a saliva strip with a dedicated reader device. It returns results in minutes (the exact time is not public), targets hospitals and mental health clinics, and is at the prototype stage, preparing for FDA clearance. Eli Health offers consumer hormone tracking, with a saliva strip read by phone camera AI in about 20 minutes. Its customers are consumers, biohackers and the wellness market, and the product is an FDA-registered wellness device, not a diagnostic. ZRT Laboratory, Ayumetrix and Genova Diagnostics offer lab-based hormone testing. Their multi-timepoint saliva cortisol tests are commercial lab tests for functional medicine doctors, patients and physicians, with results in 7+ days. ### What comes next One market opportunity is point-of-care (POC) testing, where there is huge potential for rapid test kits in primary care and corporate wellness programs. Another is preventative health, with testing integrated into routine wellness check-ups rather than used only for disease diagnosis. Biohacking and everyday monitoring is a third. Salivary hormone testing is also moving from single tests toward continuous monitoring. Researchers are developing technologies that allow continuous or repeated hormone monitoring, and they are exploring multiplex sensors that measure cortisol, testosterone, estrogen and other hormones. Multi-hormone testing could expand applications in areas such as reproductive health and endocrine disorders. A Growth Market Reports forecast for 2019 to 2034 shows the global market growing each year, segmented by product type (ELISA kits, immunoassay analyzers, rapid test kits), sample type (blood, saliva, urine, hair), end user (hospitals and clinics, diagnostic laboratories, research institutes) and distribution channel (direct sales, online retail). ## Tectonic Therapeutic (TECX): Long Thesis Memo & Financial Model By Benjamin Shar, Research Analyst at BioAsset · Memo + Model · 12 pages · PDF + XLSX In brief: The memo recommends a long position in Tectonic Therapeutic, arguing the market wrongly marked down TX45 after Eli Lilly and AstraZeneca discontinued adjacent relaxin programs. It cites Phase 1a/b data that differentiate TX45, patient enrichment for CpcPH, and a cash runway into Q4 2028. It estimates a roughly 30% probability of success against a market-implied 12%. Text page: https://bioasset.info/research/tectonic-therapeutic-tecx-long-thesis-memo-financial-model.html Full Memo (PDF): https://bioasset.info/files/TECX-Memo-Benjamin-Shar.pdf Financial Model (XLSX): https://bioasset.info/files/TX45-financial-model.xlsx ### Investment Overview Tectonic Therapeutic (NASDAQ: TECX) is a clinical stage biotech working on a GPCR (G-Protein Coupled Receptor) platform aimed at a wide range of pulmonary diseases. TECX's price is currently derived around their flagship Phase 2 TX45 PH-HFpEF program, which targets the relaxin hormone. The stock traded down on the back of Eli Lilly and AstraZeneca program failures in adjacent relaxin analogs, which in my view mispriced TX45 as guilty by association. The recently published Phase 1a/b results show pharmacokinetics and pharmacodynamics that meaningfully differentiate TX45 from both prior failures. Dosing sits in a window that is high enough to produce the efficacy signal missing from AZD3427, but well below the supratherapeutic levels that drove the congestion signal in volenrelaxin. Patient enrichment for CpcPH mirrors the design of the successful CADENCE sotatercept trial, the only positive Phase 2 ever run in PH-HFpEF/CpcPH. A cash runway into Q4 2028 limits downside around a failed readout, and a thin float with roughly 22.7% short interest sets up favorable squeeze dynamics on a positive APEX print. My work implies a ~30% PoS against a market-implied ~12% PoS, and I recommend a long position in TECX. ### Business Overview Tectonic Therapeutic is a clinical-stage biotech founded in 2019 that went public through a reverse merger with AVROBIO, a gene therapy company, in June of 2024. Tectonic focuses on developing proteins to modulate the activity of GPCRs, a transmembrane receptor family that remains the target for nearly 50% of modern FDA-approved drugs. Tectonic's lead asset, TX45, uses an engineered relaxin to target the RXFP1 receptor, which is associated with vasodilation and anti-fibrotic effects. Though relaxin is naturally at its highest concentration in the body during pregnancy, Tectonic and other companies have engineered biologic forms of relaxin intended to redirect those effects toward Pulmonary Hypertension, a lung disease that can ultimately lead to heart failure. AstraZeneca and Eli Lilly both advanced engineered relaxin analogs into the clinic, only to discontinue their programs; AZD3427 for insufficient efficacy and volenrelaxin for safety concerns. Tectonic is specifically targeting Group 2 PH-HFpEF, with enrichment for CpcPH, which I explain below. ### Background on Pulmonary Hypertension, PH-HFpEF, Relaxin, RXFP1, and TX45 Pulmonary Hypertension (PH) represents a state of high blood pressure in the lung arteries, which ultimately makes the right side of the heart work harder than it normally has to. Blood has to travel from the right ventricle into the lung circulation and then into the left side of the heart. When the pressure inside that path is higher, less blood gets through, and other organs have to work harder to get the necessary amount of oxygenated blood across the body. PH is categorized into multiple groups based on cause. In Group 2 PH, the left ventricle is either unable to eject blood efficiently or is unable to relax and fill adequately. This raises left ventricular end-diastolic pressure, which over time backs up into the left atrium and ultimately the pulmonary veins and capillaries, causing the lung vessels to constrict as well. Within Group 2 PH, there are two subsets called Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF). The two categories are determined by Ejection Fraction (EF), with EF < 40% for HFrEF and EF > 50% for HFpEF. Ejection Fraction is defined as how much blood the left ventricle pumps out with each beat. HFrEF patients have a weaker ventricle that cannot eject blood well, while HFpEF patients have fibrotic issues with stiffening of the ventricle or nearby arteries. Tectonic is specifically focused on Group 2 PH-HFpEF. There is currently no approved therapy specifically for Group 2 PH-HFpEF. True "treatment" today is limited to controlling blood pressure and general decongestion, commonly SGLT2 inhibitors. A TX45 approval would therefore be a first mover. Going deeper into the biology of HFpEF, comorbidities such as obesity create a state of chronic inflammation that injures the endothelium. This causes the endothelium to make less nitric oxide, which makes the arteries and arterioles stiffer and less able to dilate. The arteries also get stiff in a second way. Fibroblasts, the cells responsible for repairing inflammation with collagen, are designed to patch an inflamed area and then stop depositing collagen. Under chronic inflammation, fibroblasts turn into myofibroblasts and continuously deposit excess collagen to inflamed areas, making blood vessels stiffer over time. Endothelial dysfunction and excess matrix deposition together increase vascular stiffness, worsen microvascular function, and contribute to the elevated filling pressures and exercise intolerance seen in HFpEF. This is where relaxin comes in. Relaxin is a hormone usually secreted in pregnancy to facilitate the physical changes necessary for delivering a baby. It is associated with vasodilation, increased renal blood flow, and anti-fibrotic tendencies, all of which theoretically address core parts of HFpEF biology. This was the thesis when scientists first developed an engineered form of relaxin called serelaxin. Serelaxin was created through recombinant DNA and therefore closely resembled native relaxin. That resemblance left it with a very short half-life and a high isoelectric point. The short half-life of only a few hours drove a fast decline in concentrations and lower receptor occupancy. The high isoelectric point gave serelaxin a strong net positive charge, which caused it to stick to negatively charged glycosaminoglycans on many cell surfaces. This is a likely reason it was difficult to sustain clinical benefit within the large Phase 3 RELAX-AHF-2 trial. Since then, scientists have been experimenting with a different form of treatment called Fc-fusion proteins. An antibody has two parts: Fab, which binds to a target, and Fc, the tail region. The Fc region does not usually recognize an antigen, but it gives the antibody important physical characteristics. One of the most important is recycling through FcRn. The Fc region can bind to FcRn, which protects the antibody from lysosomal degradation and recycles it back into circulation, dramatically increasing half-life. AstraZeneca's AZD3427 bound relaxin to an antibody Fc tail, while Eli Lilly's volenrelaxin bound to serum albumin. TX45 is also an Fc-fusion protein. TX45 binds to the RXFP1 receptor, which activates signaling pathways that increase nitric oxide, stimulate matrix metalloproteinases that degrade collagen, and increase renal blood flow in the kidneys. Some of these features, such as the anti-fibrotic effects, have no proof of concept in human trials thus far. Since all past trials failed to indicate efficacy in humans, the main proof of concept in the current investor debate is the Phase 1 data for TX45. Before walking through those results, some definitions: - PCWP: Pulmonary Capillary Wedge Pressure - An indirect estimate of left atrial pressure and often a proxy for left-sided filling pressure. - mPAP: mean Pulmonary Arterial Pressure - The average pressure in the pulmonary arteries. - CO: Cardiac Output - The amount of blood the heart pumps per minute. CO = Heart Rate x Stroke Volume - PVR: Pulmonary Vascular Resistance - The resistance the right side of the heart has to pump against through the pulmonary circulation. PVR = (mPAP – PCWP)/CO ### Investment Thesis: Phase 1 Results Contain More Negatives Than Positives, Lack Reliable Proof of Efficacy, and Rest on a Weak Surrogate Endpoint The market currently prices TX45 at roughly a 12% chance of approval, based on patient enrichment and the Phase 1 pharmacokinetic and pharmacodynamic results. The bear case discounts those Phase 1 results as not differentiated from AZD3427 or volenrelaxin, and assigns TX45 to the same failure bucket. I will be disputing that bear case. The Phase 1 data, combined with where TX45 sits on the relaxin dose-response curve relative to failed competitors, and a trial design that mirrors the only positive Phase 2 ever run in this indication, together support a meaningfully higher PoS than what the market implies. In January of 2025, TECX released interim Phase 1b PH-HFpEF results for TX45, and the full results in May of 2025. The hemodynamic profile over an 8-hour window was strong. The interim readout reported a 17.9% average decrease in PCWP across the overall group, which moved to 19.0% in the full dataset. PVR fell 32% in patients with PVR > 2 WU (IpcPH enrichment) and 35% in patients with PVR > 3 WU (CpcPH enrichment). CO moved 17.4% from baseline in the interim data and 18.5% in the full dataset. At face value these results are very impressive. In heart failure, the body detects a heart that cannot pump adequately and responds by constricting blood vessels, retaining fluid, and raising heart rate, which drives up PVR and PCWP. In TX45's Phase 1 data, the right ventricle appears to be facing far less resistance, blood is flowing more easily, and PVR, PCWP, and mPAP all fall. The question the bears raise is whether the CO increase is the right kind of CO increase. Since CO = HR x SV, it matters whether CO rose via stroke volume or via heart rate. This distinction matters because of how RAAS (the Renin-Angiotensin-Aldosterone System) behaves, which is the pathway responsible for congestion and blood backup in the pulmonary area. Renin is an alarm signal the kidneys use to raise blood pressure when they sense something is wrong. Once renin is in circulation, it cleaves angiotensinogen into angiotensin 1, a relatively inactive decapeptide, which then passes through the lungs and encounters angiotensin-converting enzyme, which chops off two amino acids to produce angiotensin 2. Angiotensin 2 directly constricts blood vessels, forces the kidneys to retain salt and water, and raises blood pressure. This compensatory response can counteract the drug over time, and is likely what happened in the volenrelaxin trial. The response is driven by two sensors: the arterial baroreceptors, which respond to mean arterial pressure and pulse pressure, and the renal afferent arterioles, which respond to perfusion pressure and trigger renin. If CO rises via stroke volume, the ventricle is filling well, cardiopulmonary receptors sense good stretch, and both the sympathetic nervous system and RAAS get suppressed. A larger SV also widens pulse pressure, which fires more baroreceptors and further inhibits SNS. If instead CO rises via heart rate, tachycardia already activates the SNS, and shorter diastolic filling may actually pull SV down, reducing baroreceptor stretch. If we do the math based on phase 1 data, baseline HR = 3740 mL/min / 50.7 mL = 73.8 bpm. If our new CO is 3.74 + 0.65 = 4390 mL/min, and new SV = 57.7 mL (50.7 baseline + 7 change), then 4390 / 57.7 = 76.1 bpm, 76.1 - 73.8 = 2.3, or a 3.1% change in bpm. Given that stroke volume increased by 13%, and that this is in the first 8 hours, this is actually a good sign when compared with the fact that the heart rate increase is likely caused by baroreflexes, but is still concerning once we compare it to AZD3427. Tectonic also reported their own 29-day echo data to rebut the acute data concern, and Tectonic actually did not report any HR data for days 2, 15, and 29 of their echo analysis, which is a small red flag (For the record, this data is from the HFrEF phase 1, not HFpEF). In February 2026, AstraZeneca discontinued AZD3427 following its Re-PHIRE Phase 2 readout, citing insufficient efficacy. This is the single most important recent data point for assessing TX45. AZD3427 was a long-acting Fc-relaxin fusion, architecturally nearly identical to TX45, and tested the exact hypothesis on which the TX45 bull case rests: that extending relaxin's half-life rescues its clinical efficacy. That hypothesis has now failed its first controlled Phase 2 test, and the scoreboard for long-acting relaxin biologics in cardiovascular disease sits at 0-for-3: serelaxin (short half-life), AZD3427 (long half-life Fc-fusion), and volenrelaxin (long half-life, supratherapeutic dosing). This is where I diverge from consensus. Comparing TX45 Phase 1 data to AZD3427 Phase 1 data, AZD3427 showed no change in heart rate with trends toward increased stroke volume. The most likely explanation for the difference in heart rate is dosing: AZD3427 was mostly subcutaneous, while TX45 was dosed IV, which hits the system more quickly. TX45 was also being dosed to higher pharmacologically equivalent concentrations than AZD3427. Lilly, by contrast, gave volenrelaxin at levels pharmacologically equivalent to thousands of times peak pregnancy relaxin, and the resulting supratherapeutic dosing plausibly explains the congestion signal that emerged. The cleanest way to evaluate where TX45 sits is to calculate the relaxin concentrations used in each program relative to natural pregnancy levels. The more TX45 differentiates from AZD3427, the higher the chance of congestion appearing in the APEX Phase 2 trial, and the more it differentiates from volenrelaxin, the better. Attached is an excerpt from the application for AZD3427’s patent, describing the dosage that was used in the RE-PHIRE Phase 2 trial for AstraZeneca. We note that the relaxin levels were 0.5x, 2.5x, and 15x the levels of natural relaxin in pregnancy. Now we have to analyze this for TX45 and volenrelaxin. To estimate the (xPREGNANCY) numbers for TX45, we can estimate using AstraZeneca’s data as a reference. We will use AZ’s 0.2 ng/mL reference to calculate for the Q2W and Q4W dosing, using 110x less potency as a number for TX45 (cited here: https://www.jhltonline.org/article/S1053-2498(25)00927-1/fulltext), and using an 11-fold adjustment for molecular weight: (formula in the PDF) Q2W numbers imply 33x pregnancy at 0.2 ng/mL reference. My total comparison comes out to: - AZD3427: 0.5x, 2.5x, 15x pregnancy levels - TX45: 8.25x, 33x pregnancy levels - Volenrelaxin: ~1500x pregnancy levels, using 8.7x less potency and around 3.7-fold molecular weight. Given AstraZeneca's own comments about finding the balance between efficacy and congestion, AZD3427 was likely dosed too low relative to natural pregnancy, especially because commonly cited native relaxin concentration in pregnancy is closer to 1 ng/mL. On that reference, TX45's true multiples are closer to roughly 2x and 7x natural pregnancy, which is the target zone. TX45 is also orders of magnitude below the concentrations used in volenrelaxin, where safety was the main concern. TECX also has by far the most granular description of dose selection. AZD cited basic PK/PD analysis, while TECX used an Emax model built on over 200 RPF measurements per subject, producing a maximum effect of 33% (SE 3.3%, p<0.0001). That is unusual specificity, and it points to a dose level with the highest likelihood of clinical success. One fair bear counter is that the AZD3427 patent application also reports that at doses above 45 mg QW, hematocrit and hemoglobin fell below the acceptable safety profile, implying a threshold for congestion was being approached in the AZ trial. There are two issues with extrapolating that straight across to TX45. First, that data was not recorded at steady state. Running the math, fraction of steady state reached after n doses with a 14-day half-life: (formula in the PDF) 2830/80 (80 = 0.2 x 40 x 10) = 35.3x steady state So the highest TX45 dose, at 33x natural pregnancy, actually sits below the threshold cited for renin activation in the AZ patent. Second, the N supporting the monotonic dose response on hematocrit and hemoglobin in the patent is low double digits to high single digits, which makes statistically meaningful conclusions difficult. TX45's dosing is far below volenrelaxin's congestion zone, and sits comfortably under the AZD3427-implied threshold, while being high enough to drive the efficacy signal AZ likely missed. This is the best-positioned shot relaxin has had at combining safety with efficacy. Given the dose positioning, safety should not be the primary concern. On efficacy, the Phase 1a trial showed Renal Plasma Flow increases of up to 42%. In the Phase 1b Part A, PCWP decreased by 19%, CO increased by 17.4%, stroke volume increased by 13.8%, mPAP decreased by 15.9%, and TPR decreased by 26.3%. For comparison, volenrelaxin actually saw PCWP increase (E/e′ +1.7). As a side note, this shows also that nothing in TX45's 8-hour Phase 1b data is consistent with congestion. PVR fell 32% in the PVR > 2 WU subgroup (IpcPH) and 35% in the PVR > 3 WU subgroup (CpcPH), which is a clean signal that the enriched population responds. Favorable signals also showed up in both the EF < 40% and EF > 41% subgroups, while in AZD3427, the EF > 41% group showed no effect on stroke volume, cardiac output, or eGFR. This both weakens the congestion concern and strengthens the efficacy case. On the concern that acute benefits could reverse, TECX reported echocardiographic data on days 2, 15, and 29 in the HFrEF trial that showed LVEF up 19.4%, RVFAC up 20.3%, and TAPSE/SPAP up 36.3%, which implies PVR fell, since TAPSE/SPAP moves inverse to PVR. The other major leg of my thesis is trial design. TECX is enriching for roughly 70% of the APEX population to have CpcPH, with the primary endpoint defined in the enriched subgroup. AZD3427's Re-PHIRE had no enrichment and likely skewed IpcPH. The CADENCE Phase 2 trial for Merck's WINREVAIR (sotatercept), whose MoA focuses on inhibiting signals that drive abnormal pulmonary vessel wall cell growth, was enriched for CpcPH. In that trial, PVR decreased by a statistically significant 1.02 WU over 24 weeks, PCWP improved, LVEF stayed stable, and functional capacity improved. That was the first positive Phase 2 ever run in PH-HFpEF/CpcPH. Sotatercept at 0.3 mg/kg also outperformed 0.7 mg/kg, with the difference tied to safety-driven interruptions, which is evidence that dose response in CpcPH can be non-monotonic. Trial design comparison is also favorable: APEX enriches for PVR WU > 3, CADENCE enriched for PVR WU > 4 (both CpcPH signals), patient populations are broadly similar, the mean age in CADENCE was 75, and APEX allows enrollment up to 80 so APEX will likely skew older. Overall, APEX looks structurally like the trial that has actually worked in this indication, which is a major point for Tectonic. Back on AZD3427, relative relaxin concentrations were 0.5x, 2.5x, and 15x natural pregnancy. AZD3427 was discontinued in February 2026, and other than a comment about efficacy, nothing has been published since. Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, commented: “You really have to find that perfect space between efficacy and congestion, and we think we've put in the hard yards to really understand the posology there, and we're moving forward with our existing program.” AstraZeneca also has a small molecule relaxin, AZD5462, which should theoretically be easier to advance given what they have learned through AZD3427, and which runs on a 3-6 hour half-life with BID dosing. I think there is a very high chance that the two lowest AZD3427 doses produced no efficacy but the 15x native dose did, and that poor enrichment prevented that signal from reaching statistical significance. AstraZeneca can either rerun an expensive Phase 2 that enriches for CpcPH and compete head-to-head with TECX, or pivot to a cleaner MoA (AZD5462) while holding back full AZD3427 data. In their shoes, I take the second path. That means there may have been an efficacy signal in AZD3427 we will not see, which further supports the case that a 12% market-implied PoS on TX45 is too low. A further point on upside sizing: because of the unusual hemodynamic profile of this drug, strong Phase 2 results are likely to be priced in at a higher PoS than the standard ~50% Phase 3 to approval assumption typically used in cardiovascular trials, which means the stock re-rate on a positive APEX print should exceed the modeled implied upside. On top of that, TECX already sits with ~22.7% short interest of float on a thin float of roughly 10-12 million shares after stripping out insider holdings, which layers meaningful short squeeze risk on top of the fundamental re-rate. Finally, TECX has an anticipated cash runway into Q4 2028. A poor APEX Phase 2 readout would not immediately force the stock to trade to cash, which softens the downside of the residual failure risk. Combining the dose positioning, CpcPH enrichment, Phase 1 hemodynamics, short interest, and cash runway, I recommend a long position in TECX. Valuation: At the current $27.50, with a risked NPV of $154 at PoS=100% and $13.52 at PoS=0%, the market is pricing approximately 12% PoS. My analysis implies 30%, an approximately 18pp gap to consensus. To value TECX, I used TD Securities assumptions for the revenue build and DCF through 2035, then projected based on analyst estimates out to 2042. Since my differentiation is on PoS, I did not differentiate on the revenue build. Applying a risk-adjusted analysis to the UFCFs gives a base case of 103.31% upside, a bear case of 30.56% upside, and a bull case of 226.44% upside. ### Risks & Catalysts Risks - APEX Phase 2 Trial is either delayed or completely cancelled due to concerns of congestion, or lack of efficacy. Similar result to volenrelaxin / AZD3427. Catalysts - APEX Phase 2 Trial data is released and shows tangible efficacy without safety risks. It is shown that the cardiac output increase is actually helping the heart produce more blood in accordance with its healthy capacity, and the congestion risk thesis is proved to be wrong. NT-proBNP levels show no statistically significant increase. - Acquisition chance, if a big pharma wants RXFP1 exposure after key competitors (Eli Lilly, AZD3427 subcutaneous injection) have been eliminated, TX45 shows strong hemodynamics in Phase 1 trials. ## CRISPR’s Fatal Test: Intellia’s In-Vivo Reality Check By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides In brief: Intellia Therapeutics paused its Phase III trial of an in vivo CRISPR therapy that silences the TTR gene for transthyretin amyloidosis after a patient in their early 80s died from liver complications. The FDA placed a clinical hold on the trial. The post views the setback as a recalibration for gene editing and expects tighter FDA oversight. Text page: https://bioasset.info/research/crispr-s-fatal-test-intellia-s-in-vivo-reality-check.html Intellia Therapeutics has paused its Phase III in vivo gene-editing trial after a patient, in their early 80s and with other medical conditions, died from liver complications. The FDA has placed a clinical hold on the trial, and the stock closed at $9.52, down 22.73% on the day from a previous close of $12.32. Intellia's therapy uses in vivo CRISPR editing to silence the TTR gene, which causes a rare protein misfolding disease called transthyretin amyloidosis. It is one of the first human trials using CRISPR inside the body rather than outside it. That is why the death matters beyond one company: it raises new questions about the safety of delivering CRISPR edits directly to human organs. ### Growth and risk together The U.S. gene-editing market has expanded rapidly, rising from $5B in 2020 to $53B by 2025. That growth reflects surging investment, new clinical programs and early signs of commercialization. Reported safety incidents have climbed in parallel, from about six in 2020 to roughly 20 in 2025. More in vivo trials mean greater visibility into potential side effects such as liver toxicity, immune response and off-target DNA edits. Regulatory focus is shifting with it: the FDA is expected to tighten oversight on CRISPR-based therapies, particularly for direct human applications. Investors now weigh both promise and risk more carefully. ### What to take from it Intellia's setback highlights the dangers of fast-paced innovation, but it also shows the importance of long-term resilience in biotech. The death in the trial is tragic, and it does not erase the progress of gene editing. Every major advancement in medicine has faced moments of risk. For investors, regulatory delays and increased inspection could lead to short-term instability, but companies that prioritize transparency and data integrity will emerge stronger. For scientists, these events reinforce the need for improved delivery systems, safer vectors and long-term patient monitoring protocols before commercial rollout. For the public, the future of CRISPR depends on trust, and further education, realistic expectations and honest communication between companies, regulators and patients will shape public confidence. The setback is not an end, it is a recalibration. The gene-editing field will evolve, but how it learns from this moment will define its credibility for years to come. ## $11 Insulin: California Rewrites the Prescription on Big Pharma By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides In brief: Starting January 1, 2026, CalRx will offer long-acting insulin pens for about $11 each, or about $55 for a five-pack, insured or not. The glargine biosimilar is produced through a partnership between CalRx, nonprofit Civica Rx and manufacturer Biocon Biologics. The post calls it a warning shot for legacy insulin makers and notes CalRx may expand to other drugs. Text page: https://bioasset.info/research/11-insulin-california-rewrites-the-prescription-on-big-pharma.html Starting January 1, 2026, California's CalRx will offer long-acting insulin pens for about $11 each, or about $55 for a five-pack. With that move the state enters the drug supply chain as a manufacturer and brander, directly challenging the major insulin makers and their pricing models. The insulin is a biosimilar to glargine, an insulin that has been chemically altered to last longer. It is produced through a partnership between CalRx, the nonprofit Civica Rx and the manufacturer Biocon Biologics. ### The price gap The U.S. average insulin price per standard unit was around $98.70 in 2018, accounting for all options. That compares with about $12 in Canada and under $10 in many other countries. NIH data on average list prices show how U.S. prices have moved over time. Insulin from Eli Lilly (Humalog, Basaglar), Sanofi (Lantus) and Novo Nordisk (Levemir, Tresiba) climbed steeply from 1996 into the early 2020s, before the price cuts of 2024 brought list prices sharply back down. CalRx's $11 pen, projected for 2026, comes in below all of them. For patients, the average monthly insulin cost is $25 to $75 with insurance and $275 to $500 without. CalRx is a flat $11 per pen, insured or not. ### What it means For patients, this is a major win on cost and convenience. For legacy insulin manufacturers, it is a warning shot: their pricing models may face real structural competition. About 3.6 million Californians have been diagnosed with diabetes. That figure includes type 2 diabetes, where other treatments may be used, and tens of thousands are already on insulin. The launch of $11 insulin under CalRx could affect hundreds of thousands of people. A few things are worth watching: - Whether CalRx eventually expands beyond insulin into other drugs, such as naloxone, asthma treatments and possibly GLP-1s, which would open an even larger market with bigger strategic implications. - How Big Pharma reacts and adjusts to the change. - Whether California can roll this out smoothly without further delays. The original rollout was planned for early to mid-2024. ## Roche Pill Delays Tumor Progression in Closely Watched Breast Cancer Study By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: In Roche's Phase 3 evERA trial in ER-positive, HER2-negative breast cancer, giredestrant plus everolimus lowered the risk of progression or death by about 62% in the ESR1-mutated subgroup and about 44% overall. The benefit in non-mutated patients was small and not statistically strong. The post sees the result as a major step and names tolerability as the remaining concern. Text page: https://bioasset.info/research/roche-pill-delays-tumor-progression-in-closely-watched-breast-cancer-study.html Roche's breast cancer pill giredestrant, given together with everolimus, reduced the risk of tumor progression by 62% in patients whose cancer carries an ESR1 mutation and by 44% across all patients in a closely watched Phase 3 study. ### The company, the disease and the drug Roche is a Swiss healthcare company that develops and sells treatments for multiple diseases, and it is a powerhouse in biotech and cancer research. The disease in question is ER-positive, HER2-negative breast cancer, a common type. The cancer cells have estrogen receptors (ER) and grow in response to the hormone estrogen. They lack the HER2 protein, which means they are driven by hormones instead of HER2. About 70% of breast cancer cases are ER-positive. ESR1 is a mutation within a mutation, a gene change that these cancer cells develop after hormone therapy. The treatment under review pairs two drugs. Giredestrant blocks and breaks down the ER in cancer cells, which makes the cell go dormant or even die. Everolimus blocks the cell's internal growth pathway, the one that helps it survive even without its ER. ### What the trial showed The standard first-line treatment for ER-positive, HER2-negative breast cancer is endocrine therapy plus a CDK4/6 inhibitor. The Phase 3 evERA trial, in the post-CDK4/6 inhibitor setting, compared the new combination of giredestrant and everolimus against older endocrine therapy plus everolimus. These are Roche's results only. According to the company's data, the combination lowered the risk of progression or death by about 62% in the ESR1-mutated subgroup and by about 44% in the overall population, which includes both ESR1-mutated and non-mutated patients. In the ESR1-non-mutated subgroup the benefit was small, a 15% risk reduction that was not statistically significant. ### Outlook For breast cancer research and treatment, this trial marks a major step forward. Progress in the field continues to accelerate, and in the future we may even see giredestrant replaced by an even more effective therapy. Roche as a company will greatly benefit. If it continues to develop more treatments for major illnesses, exponential growth will definitely be on the horizon, and its valuation will go through the roof. As a treatment, slowing cancer progression by 62% is an amazing feat, one that giredestrant's rivals Inluriyo (38%) and Orserdu (45%) cannot compete with. Right now it caters mainly to people in the ESR1-mutated subgroup of breast cancer, but it may be refined to serve the overall population far more in the future. The only concern for now is how well people tolerate the drug. ## Blackstone x TPG Make Hologic Private ($18.3B) By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides In brief: Blackstone and TPG will buy Hologic for $76 per share in cash plus up to $3 per share in contingent value rights, a 46% premium, with closing expected in the first half of 2026. The post views the deal favorably, citing growing attention to women's health and noting that only about 2% of VC funding goes to the sector. Text page: https://bioasset.info/research/blackstone-x-tpg-make-hologic-private-18-3b.html Blackstone and TPG have announced that they will buy out all outstanding shares of Hologic and take the women's health company private, in a deal valued at up to $18.3 billion. The offer is $76 per share in cash plus up to $3 per share in contingent value rights, or as much as $79 per share. That is a 46% premium, the extra amount the buyers are offering above what the market valued the shares at. ### The deal A take-private deal means Hologic is being made into a private company. The buyers are both American alternative asset managers. Blackstone is the world's largest, with $1.1 trillion worth of assets under its management, and TPG manages $230 billion. Hologic is a leading med-tech company in women's health. It is involved in breast health (mammography and biopsy), cervical cancer screening, infectious disease diagnostics, and surgical and gynecological products. The deal is expected to close in the first half of 2026, depending on shareholder and regulatory approvals. ### Money moving into women's health Venture capital, the funding that investors provide to early-stage or growing startups with high potential but also high risk, has been growing in this sector. PitchBook and Deloitte data on U.S. and EU venture funding in women's health show the number of deals rising from 63 in 2019 to 110 in 2021, 161 in 2023 and 172 in 2024. In 2024, healthtech drew $988M, biopharma $879M, devices $457M and diagnostics and tools $268M. Even so, only about 2% of VC funding currently goes to women's health. That shows how under-invested the area is, and how much potential it has for growth. ### What to make of it Overall, this is a great move by Blackstone and TPG. Global awareness about women's health is growing, with more treatments and more government coverage in areas such as screening, molecular diagnostics and AI imaging. On return on investment, the buyers will have to be patient. Hologic's earnings show an 11.5% return on equity, a measure of return on the money invested. Those returns are very modest, but positive overall, and it will take time to turn the company into a very profitable one. COVID hit Hologic very hard, but the company is growing in a positive direction. Two questions are worth watching. One is how private ownership will affect Hologic's innovation, capital deployment and further global expansion. The other is whether this deal will spark further M&A in women's health and foster more growth in the industry. ## Inside China’s Transformative Global Biotech Boom By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides In brief: In the first quarter of 2025, assets sourced from China made up roughly 32% of global biotech out-licensing deal value, up from roughly 21% in 2023-24. Takeda's $11.4 billion deal with Innovent Biologics is cited as an example. The post flags risks including trade restrictions, reliance on government spending, and trial quality and ethics compliance. Text page: https://bioasset.info/research/inside-china-s-transformative-global-biotech-boom.html Chinese biotech firms are transforming from generic producers into global innovators. An uptick in licensing deals, regulatory reform and a return of talent have combined to position China as a rising powerhouse in therapeutic R&D (research and development) and global drug licensing. China-based drugmakers have been licensing out drug candidates to U.S. and European companies at a rapidly increasing rate. These are often early-stage therapeutics in oncology and immune disease. A recent example is Takeda Pharmaceutical Company's $11.4 billion deal with China's Innovent Biologics for ADCs and bispecifics, as of October 2025, which is intended to commercialize next-generation cancer therapies globally. In the first quarter of 2025, assets sourced from China accounted for roughly 32% of global out-licensing deal value in biotech, up from roughly 21% in 2023-24. Western pharma companies are increasingly licensing from China because Chinese drug candidates offer speed, lower cost and a more appealing risk-return profile. That is challenging established Western drugmakers on cost and access. ### The big picture Two charts from The Economist, based on Citeline and LEK data, show the scale of the change. In active drug development by country of origin, the United States' share has slipped since 2010, while China's share grew from a thin sliver to a wide band over the same years. The value of deals for drugs licensed from China has jumped as well. It was far higher from 2022 onward than in any earlier year shown, and 2024 was the largest year of all. ### What to watch Trump's recent policies on the federal budget, including slashing funds for the NIH and implementing immigration restrictions (bans on H-1B, J and L visas), may contribute to scientific talent leaving the U.S. That would make the research ecosystem more uncertain in the future, and some major names are already shifting to Chinese firms. Watch for more large-scale licensing and milestone deals between Chinese firms and Western partners, especially in oncology, bispecifics and ADCs. There are open questions about how long this can last. One is how the boom would hold up in the long run under a continuing trade war, or an outright ban on pharmaceutical imports from China, with restrictions on Chinese biotech firms' access to U.S. and European markets. The other is whether Chinese firms' reliance on heavy government spending on biotech can prove sustainable. Despite the speed and volume of China's output, researchers warn that trial quality and ethical compliance in many cases lag global norms. Fewer than 1% of Chinese-trial publications in the past decade had undergone ethics review. As China's biotech firms get more involved globally, close compliance with reviews and quality standards will become more of a challenge. ## The $30 Million Bet: How Valthos and AI Are Rewriting Biodefense By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides In brief: Valthos develops AI-driven biointelligence systems meant to cut the time needed to identify and counter biological threats such as viruses and bacteria. It received $30 million in backing from OpenAI Startup Fund, Lux Capital and Founders Fund. The post notes the biodefense market is forecast at about $22.8 billion by 2030 and says Valthos must still prove its claims. Text page: https://bioasset.info/research/the-30-million-bet-how-valthos-and-ai-are-rewriting-biodefense.html Valthos, a company that uses AI to identify and counter biological threats, has received $30 million in backing from the OpenAI Startup Fund along with Lux Capital and Founders Fund. The OpenAI Startup Fund is an investment vehicle associated with OpenAI, the maker of ChatGPT. Lux Capital and Founders Fund are both venture capital firms. ### What Valthos does Valthos is an applied biointelligence company. It specializes in identifying biological threats in real time, and it designs pathogen sensing, molecular modeling and countermeasures with AI systems that go head-to-head with a given threat. Biodefense refers to the technologies, systems and materials used to detect, prevent and respond to biological threats, such as viruses, bacteria and other pathogens that can endanger public health or national security. Valthos develops AI-driven biointelligence systems designed to greatly reduce the time required to identify and counter those threats, enabling real-time detection and a rapid biomedical response. ### Why investors are interested The biodefense and biotechnology sector is growing rapidly, and the addition of advancing AI is attracting investors such as the OpenAI Startup Fund. Backing Valthos and its AI-enabled biodefense platform reflects OpenAI's bold push into areas where AI meets national security and rapid biological threat response. The forecasts point the same way. Data from Precedence Research (2025) show the global biodefense market growing to around $22.8 billion by 2030. The market for AI in biotechnology is charted rising every year from 2024 to 2034. With the industry growing, OpenAI and its VC partners might be getting ahead of their competitors. The deal is also another example of a trend we have noted before: investment in biomedicine by venture capital and asset management firms keeps growing. ### What to be aware of Valthos claims that it will minimize these threats in real time with frontier AI. That is a great picture to paint, but Valthos will have to make sure it delivers on that picture with efficiency. Competition is coming as well. Many big names are expected to enter biodefense, especially with AI emerging, and Valthos will have to prove its worth in order to survive and become a powerhouse in this part of biomedicine. AI is still a double-edged sword to many. For as many good things as can be done with it, an equal number of negative exploitations may arise. In the coming years, the impact of AI in this field will become very clear. ## Eli Lilly vs Novo Nordisk: Who Will Win the GLP-1 Race? By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: Eli Lilly's oral GLP-1 pill orforglipron showed an average 9.2% weight reduction in adults with type 2 diabetes, against 5.3% for Novo Nordisk's oral semaglutide in comparable early-stage trials. Analysts project the global obesity drug market could reach $150 billion by 2030. The post expects rapid adoption if orforglipron wins FDA approval. Text page: https://bioasset.info/research/eli-lilly-vs-novo-nordisk-who-will-win-the-glp-1-race.html The market for GLP-1 drugs, which mimic the naturally occurring hormone GLP-1 to regulate appetite and glucose, has exploded in recent years. Novo Nordisk once dominated it with Ozempic and Wegovy. The sector is now shifting toward Eli Lilly, and the next contest is over who can deliver the therapy as a pill. ### Where the two companies stand Analysts project the global obesity drug market could hit $150 billion by 2030, rivaling the cholesterol and diabetes markets combined. A projection based on data from Axios and Morgan Stanley shows the global GLP-1 market rising steadily from 2023 through 2030. Lilly's drugs, Mounjaro and Zepbound, target multiple hormonal pathways for stronger effects. Its new oral GLP-1 pill, orforglipron, showed an average 9.2% weight reduction in adults with type 2 diabetes. That is nearly double the 5.3% seen with Novo Nordisk's oral semaglutide in comparable early-stage trials. The results put Lilly as a front-runner in the race to deliver effective, non-injectable obesity and diabetes therapies in pill form. Both pills still trail the injectables: a comparison using data from Yahoo Finance, Axios and NEJM shows the average injectable GLP-1 producing more weight loss than either pill. Lilly's estimated 2026 sales are $18B, against $16.5B for Novo Nordisk. The share prices have moved apart as well. Over five days through Oct 24, Google Finance shows Lilly up 3.38% at $830.91 and Novo Nordisk down 4.39% at $52.98. Lilly's stock has surged on trial results, while Novo's recent slowdown highlights investor focus on innovation and novel therapy modes. ### Why the pill race matters - Ease of use: no injections, which makes the treatment preferable and supports broader adoption. - Production scalability: pills are easier to manufacture and distribute globally. - Healthcare access: oral forms may lower costs, improving coverage potential in insurance and public health programs. The first company to deliver scalable, affordable and accessible oral GLP-1 therapy could dominate not just obesity, but related metabolic diseases. ### Outlook If Lilly's orforglipron gets FDA approval, expect rapid adoption, with the oral GLP-1 becoming the dominant therapy. Oral GLP-1s are harder to absorb and deliver effectively than injectables, so both Eli Lilly and Novo Nordisk continue to innovate aggressively to close the efficacy gap with next-generation pill formulations. Pills can also enter markets where injectables face supply chain or storage issues, such as Africa and Southeast Asia. After the oral GLP-1 is introduced, the next innovation race may include agents targeting three hormone pathways (GLP-1, GIP and glucagon), promising greater weight loss and metabolic benefits. Some questions remain open. One is whether Lilly or Novo, with their dominance, will settle on a pill cheap enough for insurance coverage or price it like luxury wellness. Another is whether developing countries will gain access or stay behind in the "pharma fitness gap." The short- and long-term effects of the oral pills on weight loss and obesity-related diseases also deserve a close eye. ## From Chips to Clinics: Nvidia Expands Its Healthcare Ambitions By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: Nvidia is partnering with Eli Lilly to train AI models for drug discovery, manufacturing and clinical trials through Lilly TuneLab. Other partners include Verily, Johnson & Johnson, which is training surgical robots, Innovaccer and the Chan Zuckerberg Initiative. The post expects AI to cut discovery costs and asks how the FDA and drug prices will respond. Text page: https://bioasset.info/research/from-chips-to-clinics-nvidia-expands-its-healthcare-ambitions.html Nvidia, now the world's first $5 trillion company, is reshaping healthcare and research through a network of recent AI partnerships across pharma, life sciences and medtech. ### The Lilly deal The largest of them is with Eli Lilly. The two will train biomedical foundation and frontier models to speed up discovery, imaging, trials and even biomanufacturing. Nvidia's infrastructure will be implemented through Lilly TuneLab, built on more than $1B of Lilly data and located in Lilly's Indianapolis data center. The goal is to train proprietary AI models for drug discovery, automated manufacturing and clinical-trial optimization, significantly reducing development and approval timelines that traditionally take a decade or more. ### The rest of the network Verily, part of Alphabet, is integrating Nvidia AI into its precision-health platform for personalized medicine. Johnson & Johnson is using Nvidia models to train surgical robots and improve real-time decision-making. Innovaccer is partnering with Nvidia to build multimodal AI for patient data, increasing insights across imaging, EHR and genomic data, and integrating AI at provider frontlines through ambient scribing, OCR and agentic workflows. Nvidia is also backing academic initiatives: CodonFM for RNA medicine development, La-Proteina for 3-D protein-structure generation, medical imaging models for radiology and pathology AI, and a Chan Zuckerberg Initiative collaboration on virtual cell models for researchers worldwide. The scale of the opportunity shows up in two numbers. On average, target discovery takes about five years traditionally and roughly one year with AI; preclinical work drops from about 3.5 years to 1.5; and clinical phases I through III fall from about 6.5 years to 3.5, according to data from McKinsey, Nature Biotechnology and Deloitte Life Sciences. Global investment in AI-driven drug discovery has risen from $0.9B in 2019 to $2.3B in 2021, $4.8B in 2023 and $9.5B in 2025, per NVIDIA, EvaluatePharma, CB Insights and PitchBook Biotech. ### What happens next Nvidia is not just entering healthcare. It is establishing itself as the backbone of biology's next industrial revolution. Expect novel drugs to arrive more frequently, with each iteration cutting discovery costs and bringing drugs to market faster and potentially cheaper. In the short term, through 2025 and 2026, pharma companies race to integrate Nvidia AI stacks, with early results in molecule prediction and manufacturing efficiency. In the mid term, from 2027 to 2030, AI factories become standard across more top pharmas globally and the drug-discovery cost curve drops 20-40%. Longer term, past 2030, the entire healthcare economy shifts toward predictive value chains, where AI designs the drug, tests it virtually and guides some surgical operations. That raises questions worth sitting with. If computing accelerates biology this much, will the FDA adapt with a new AI fast-track review pathway? Who will own the IP, the company that designed the molecule or the AI that generated it? And if AI factories shorten development and approval timelines by 60-70%, will drug prices actually drop? Keep a close eye on next year's updates on AI integration and drug discoveries. ## Breaking Bones: Inside J&J’s Orthopedics Spinoff By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: Johnson & Johnson plans to separate its orthopedics unit, which generated about $9.2 billion in sales last year, into a standalone company named DePuy Synthes within 18 to 24 months. The unit is capital-intensive and slower-growing than J&J's other businesses. The post says the split lets each company focus but will require flawless execution. Text page: https://bioasset.info/research/breaking-bones-inside-j-j-s-orthopedics-spinoff.html Johnson & Johnson plans to separate its orthopedics business into a standalone company named DePuy Synthes, with the split expected to take 18 to 24 months. The orthopedics business designs and sells medical devices and implants used to treat injuries or disorders of the bones, joints and spine: hip and knee replacements, implants for facial reconstruction, instruments for spinal fusion and the like. The unit generated about $9.2B in sales last year, roughly 10% of J&J's total. Although that is a sizable share of the portfolio, the ortho unit is capital-intensive and slower-growing than J&J's other medtech or pharma areas, which is why it is being spun out into its own focused company. The split lets each side concentrate on higher-growth, higher-margin areas: medtech at DePuy Synthes and pharma at J&J. The most recent separation before this one was Kenvue, the consumer health business, in 2023. ### Why split The growth gap is the argument. Across J&J's divisions, the ortho unit grows at about 2.5% a year, against roughly 6% for J&J MedTech overall and about 8% for pharma, according to Orthoworld data. Splitting a slower-growth unit can lift J&J's margins and capital efficiency, and the new company and team get a new identity to run M&A, portfolio clean-ups and commercial focus specifically in joints, trauma and spine. Medtech has seen similar moves recently: the GE HealthCare spin, Medtronic's diabetes split plans and ZimVie from Zimmer Biomet. Pure-plays, companies focusing on one area, often trade on clearer comps, meaning analysts can directly compare them with similar companies such as Stryker and Zimmer Biomet, and on operating KPIs. These splits are complex, involving systems, supply chain and salesforce separation, and the orthopedics market depends heavily on hospital budgets. On 2024 estimates, DePuy Synthes sits second among orthopedics market leaders at $9.2B in revenue, behind Stryker at $21.0B and ahead of Zimmer Biomet at $7.4B. The broader global medical devices market, which includes ortho, is forecast to grow from roughly $540B in 2024 to about $885B by 2032, per Fortune Business Insights. ### What to watch As an independent company, DePuy can dedicate leadership, capital and strategy solely to orthopedics rather than competing for resources within J&J's broader portfolio, while J&J focuses more on its own projects. These kinds of spin-offs tend to perform well when the separated company operates in a mature but innovation-driven market such as medtech. An open question is whether this spin-off triggers a new wave of medtech restructurings, with other diversified giants like Medtronic or Siemens Healthineers carving out slower-growth units next. The past integrations of DePuy in 1998 and Synthes in 2012 created a giant in orthopedics, and unwinding it now will require flawless execution. Any slip in robotics or pricing strategy could weaken the spin-off's promise. On the other side, DePuy Synthes gains its own independence to pursue AI, specifically in implant design and surgical robotics. With players like NVIDIA partnering across medtech, the next leap could blend hardware with intelligent, data-driven surgical systems. ## From One Drop to Fifty Diagnoses: How Blood May Be the Next Frontier of Cancer Detection By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: GRAIL's blood test reads methylation and fragmentation patterns in circulating DNA to detect more than 50 cancer types. In a trial of over 23,000 symptom-free adults aged 50 and older, it flagged 216 people, 133 of whom had cancer confirmed, with a false positive rate of about 0.4%. Full regulatory approval and real-world testing remain ahead. Text page: https://bioasset.info/research/from-one-drop-to-fifty-diagnoses-how-blood-may-be-the-next-frontier-of-cancer-detection.html A biotech company, GRAIL, Inc., has developed a blood test capable of detecting 50+ types of cancer, even in people without signs of symptoms. In a large trial of over 23,000 people in the U.S. and Canada, all aged 50 and older and none showing symptoms, the test identified cancer signals in 216 people. Of those, 133 were confirmed to have cancer, a positive predictive value of about 61.6% in that cohort. More than half of the cancers the test detected were in early stages (Stage 1 or 2), including many cancers for which no standard screening currently exists. The false positive rate, which tells us how often the test flags cancer by mistake, was very low in that early data set, at about 0.4%. Using AI algorithms, the test also correctly determined the tissue or organ of origin in about 92% of confirmed cases in the study. ### How the test works Your blood carries tiny bits of DNA from cells that die every day. If a person has cancer, some of those bits come from cancer cells. This is called circulating tumor DNA (ctDNA). The test looks for three clues: - DNA patterns (methylation): Cancer cells change the way certain genes are switched on or off by adding tiny chemical tags called methyl groups to the DNA. These methylation patterns act like fingerprints. Each cancer type leaves its own distinct mark that the test can recognize. - DNA shapes (fragmentation): When cells die, their DNA breaks into pieces. In cancer, these fragments are often shorter or cut in unusual ways. The test studies these DNA "shapes" to spot irregular patterns linked to cancer. - Where it came from (tissue of origin): A computer algorithm (AI) compares the DNA pattern to thousands of known profiles from different organs. This helps the system predict which body part, like the lung, liver or breast, the DNA most likely came from. In practice, a blood sample is collected, DNA is extracted from it, and that DNA is analyzed for methylation patterns and fragmentation. If no cancer signal is detected, the person carries on with regular monitoring. If a signal is detected, the test predicts the tissue or organ of origin, the finding is confirmed clinically with imaging or a biopsy, and the result is an early diagnosis and treatment planning. ### Why it matters Detecting cancers at Stage 1 or 2 means much higher survival and more treatment options than late-stage disease. If further approved, this test could significantly shift the cancer survival rate. Many cancer types, such as cancers of the pancreas, liver and ovaries, currently lack routine screening, and a broader test like this fills a major gap. If widely adopted, this blood test may become the standard way to detect cancer in the mass population. Early-stage intervention could also reduce downstream treatment costs and shift investment toward initial diagnostics and early detection. And the test could give underserved populations and areas convenient, affordable access. The data is promising, but full regulatory approval (for example by the U.S. Food & Drug Administration) and large-scale real-world deployment tests remain ahead. Watch for more data in the future, including results from larger and more diverse population pools and more clinical applications. ## Biotech X Beauty: The Future of Skincare By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: The global biotech skincare market was valued at about $5.45 billion in 2024 and is forecast to reach about $8.25 billion by 2031. Recent activity includes Debut Biotech's partnership with IMAGE Skincare and its $20 million raise for AI-driven ingredient discovery. The post cautions that many formulations lack high-quality long-term data. Text page: https://bioasset.info/research/biotech-x-beauty-the-future-of-skincare.html The global biotech skincare market, the subset of skincare that uses biotech-derived ingredients, has been growing slowly and recently saw a spike of action. NewBeauty has highlighted "DNA-driven skin care", meaning strategies that use polynucleotides (PN) or DNA fragments for skin repair, regeneration and texture improvement. Debut Biotech, a biotech ingredient company, is partnering with IMAGE Skincare to bring a new biotech active, produced via fermentation, into mainstream skincare. Debut, which makes lab-made ingredients for industries like skincare, beauty, nutrition and fragrances, has also raised US $20 million for AI-driven discovery of skin longevity ingredients. The shift mirrors what is happening in healthcare. Personalized medicine is unfolding there as targeted cancer and disease therapies, and the same wave is now reaching skincare. With DNA testing, microbiome analysis and smart diagnostic devices, skincare is rapidly evolving into a data-driven, personalized system rather than a one-size-fits-all routine. ### The numbers The global biotech skincare market was valued at around USD 5.45 billion in 2024, and forecasts project it reaching approximately USD 8.25 billion by 2031, a CAGR (average growth per year) of about 5.8%. The broader personalized skincare products market is projected to grow from USD 26.2 billion in 2022 to about USD 48.65 billion by 2030, a CAGR of about 8.0%. The data is from Grand View Research. Plotted together, the personalized skincare line climbs steadily from about USD 26 billion in 2022 to nearly USD 49 billion in 2030, while biotech skincare stays below USD 10 billion through 2031. Growth is moving slowly, but it may spike with the integration of AI and funding. ### How DNA-driven skincare works Polynucleotide (PN) therapy is a skincare and medical treatment that uses short strands of DNA to repair and rejuvenate skin, usually through microinjections. The DNA fragments repair skin cells, help boost cell regeneration, improve hydration and stimulate collagen. The result is improved texture and elasticity, with skin that looks smoother, firmer and healthier. From there the chain leads to personalized skincare solutions and to consumer products and serums. PN therapy is one branch of DNA-driven skincare innovation. Other biotech skincare methods include microbiome balancing formulas, AI-formulated skin treatments, lab-grown ingredients, and peptide and protein engineering. ### Outlook Biotech skincare claims are compelling, but many formulations lag in high-quality long-term data or head-to-head comparisons. More intensive research and trials need to be conducted on larger and more diverse populations to confirm the results. Novel biotech products may also carry higher cost or complexity, so brands must balance price, margin and consumer uptake. What to watch: - Near term (1-2 years): more testing with higher quality data and compelling results, and some novel products hitting the shelves. - Personalization will deepen: DNA, skin imaging and AI will drive potential "tailored" skincare kits or subscriptions. - Biotech ingredients may migrate from premium to more mass tiers as cost and time decrease. - New advancements may shift dermatology closer to regenerative therapy, not just symptom relief, furthering targeted treatments for conditions like rosacea, atopic dermatitis and acne (for example, peptides modulating inflammation or microbiome balance). Personalized skincare treatment is still in the early stages, but it can exceed expectations with AI advancements and integration in the field. ## America’s GLP-1 Paradox: Obesity Falls, Diabetes Rises By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: According to Gallup, the US adult obesity rate fell from about 39.9% in 2022 to 37.0% in 2025, while self-reported GLP-1 use rose to about 12.4%. Diabetes diagnosis rates kept climbing to 13.8%; possible reasons offered include lifelong prevalence, better screening and unequal access to costly GLP-1 drugs. The post cautions that the obesity data are self-reported. Text page: https://bioasset.info/research/america-s-glp-1-paradox-obesity-falls-diabetes-rises.html After years of increases, the U.S. adult obesity rate is falling. According to a recent Gallup survey, part of its National Health & Well-Being Index, the rate dropped from about 39.9% in 2022 to 37.0% in 2025, which translates to roughly 7.6 million fewer adults classified as obese. Diabetes is not following. Diagnosis rates continue to climb, to about 13.8%, despite falling obesity rates. ### Obesity breaks its upward trend The decline comes after a long climb. The national adult obesity rate rose from 25.5% in 2008 to nearly 40% by 2022. Compared with the early 1960s, when it was just around 13%, prevalence has tripled. The turn has come with the spread of GLP-1 (glucagon-like peptide-1) drugs such as Ozempic and Wegovy, which are mainly used for weight loss and for insulin control after meals. Self-reported use of GLP-1 weight-loss drugs (semaglutide and tirzepatide, under brands like Ozempic, Wegovy and Zepbound) rose from about 5.8% in early 2024 to about 12.4% in 2025. Plotted together for 2018 to 2025, Gallup's data show obesity rising for years, peaking near 40% in 2022, then falling to 37% as more than 12% of adults began using GLP-1 medications. The biggest obesity drops occurred among 40 to 49 and 50 to 64 year olds (declines of about 4.3 and 5.0 percentage points), the groups that also had the highest uptake of these medications. The drop in points may not seem significant. But breaking the upward trend in obesity is a major public health and economic breakthrough. ### Why diabetes is still rising Gallup's figures show the diabetes rate moving the other way, from 11.4% in 2017 to 13.6% in 2023 and 13.8% in 2025. There are a few possible reasons: - Chronic condition: once diagnosed, patients stay in prevalence data for life. - Better screening: more early pre-diabetic testing means more reported cases. - Access gap: GLP-1 drugs are costly and not fully covered by insurance. - Inequality: wealthier groups see obesity drops, while lower-income groups still face higher diabetes risk. ### Reading the numbers with care This is a positive update on the U.S. obesity rate, but Gallup's figures use self-reported height and weight, which tends to underreport BMI and mischaracterize weight loss. Higher-quality, long-term data is needed. If the trend continues, a potential $170B health-cost reversal may be underway. Obesity is associated with substantial direct medical costs, about $170 billion or more annually in the U.S. Several questions follow. How will the pill form of GLP-1 affect this trend? Can the progress be sustained and made equitable, or will cost and access barriers slow the momentum? And how durable is the weight loss from GLP-1s after people stop taking them? That last question is the one to keep following. Studies show that when patients stop, they regain about two-thirds of their lost weight within one year. Any interruption in supply, whether from manufacturing delays, insurance pauses or shortages, could mean a population-wide weight rebound within 6 to 18 months. ## AI’s Early Footprint: Optimized Peptides for Efficient Protein Production By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: A research group at Japan's Nagoya University found that adding short tetrapeptides to the start of a protein can prevent ribosome stalling and improve foreign protein production in E. coli. They used AI to analyze 250 experimental datasets and predict the performance of all 160,000 possible sequences. The post expects cheaper manufacturing of biologics and enzymes. Text page: https://bioasset.info/research/ai-s-early-footprint-optimized-peptides-for-efficient-protein-production.html A research group at Japan's Nagoya University has found that adding a four-amino-acid tag to the start of a protein can stop ribosomes from stalling and significantly improve how much protein E. coli produces. It is a small change with large consequences for how biologics are manufactured, and AI did much of the work of finding it. ### Why E. coli matters E. coli, a species of bacteria found in the gut, is essential for producing proteins that are later used as enzymes, antibodies and vaccine components. It is the workhorse of the field because it grows fast, is cheap to culture, is easy to genetically modify, produces large quantities of protein, and is one of the most researched organisms there is. The problem comes during foreign protein production. The amount of protein produced is often reduced when ribosomes stall during translation, a common phenomenon when microbes are made to produce proteins that are not their own. When ribosomes pause or get stuck on the mRNA, protein synthesis stops, which means lower yield, higher cost and weaker efficiency. Trailing ribosomes stack up behind the stalled one, and the cell responds by cleaving the mRNA and tagging the ribosomal protein RPS3 for ubiquitination by HEL2. The Nagoya group found that adding specific short peptide sequences, tetrapeptides that are four amino acids long, to the N-terminus of a protein (the start of the protein; the C-terminus is the end) can prevent this stalling and significantly improve expression. They initially found one sequence that works, Ser-Lys-Ile-Lys, and are now investigating other combinations that could boost translation further. ### How they found it The method started with a library of 160,000 different tetrapeptides. There are 20 natural amino acids and four slots, so 20^4 gives 160,000 unique sequences, every possible combination. The group then used AI to analyze 250 experimental datasets, identify which peptides prevent stalling, and predict the performance of all 160,000 sequences. The relevance is that a tiny four-amino-acid tag that increases protein yield makes research and production considerably more efficient and faster. That includes cheaper manufacturing of biologics such as complex proteins and enzymes, more efficient enzyme production for biofuels and bioplastics, and more consistent biomanufacturing pipelines. ### What comes next Companies will begin screening these peptide chains with AI to predict which proteins need which tetrapeptide so ribosomal stalling does not occur. In theory that should make protein manufacturing cheaper and more efficient overall, especially for difficult-to-express proteins such as membrane proteins and complex enzymes. This can push AI further into biopharma: designing peptides in an instant, predicting expression levels, and using CRISPR to insert these tetrapeptide sequences straight into DNA. Expect biotech startups and institutions to secure patents for peptide and tetrapeptide combination libraries and to build their own AI-enhanced sequence design tools and platforms. Keep an eye out for further developments and new tetrapeptide discoveries, and for any M&A among the companies becoming leading candidates in this approach to protein production. ## BioAsset VC Dive: Predict Before You Test — Axiom and AI Toxicology By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: Axiom has raised roughly $15 million in seed funding to replace slow, costly toxicity testing, especially animal tests, with AI models trained on human liver cell data. Its dataset covers more than 115,000 small molecules. The post sees the dataset as Axiom's main advantage but says the FDA may be slow to accept AI toxicity models as a primary gatekeeper. Text page: https://bioasset.info/research/bioasset-vc-dive-predict-before-you-test-axiom-and-ai-toxicology.html Axiom is a seed-stage biotech and AI startup based in San Francisco with a direct pitch: predict a drug's toxicity before you test it. The company has raised roughly $15M so far, in seed rounds of $7M in 2023 and $8M in late 2024. It sits at the intersection of AI, drug discovery and predictive toxicology, and it is aiming at one of pharma's biggest and most expensive problems: preclinical safety. Axiom says its main goal is to replace slow, expensive and outdated toxicity testing, especially animal tests, with in-silico AI models that are more accurate, more scalable and more relevant to humans. Roughly 90% of drugs fail, and 40-55% of those failures are linked to toxicity, especially liver toxicity. Axiom claims that widespread methods such as animal testing predict human liver injury poorly, and that they are slow (weeks to months) and expensive (thousands to millions per program). The US Congress and the FDA are also beginning to phase out the legal requirement for animal testing, and have explicitly called out AI-based computational toxicity models as an alternative. That gives Axiom an opportunity to be at the forefront of the transition. ### The dataset Axiom's biggest edge is its dataset, which it describes as the "atlas of human cell toxicity". By the company's own figures, it currently includes: - 115,000+ unique small molecules - 394 million+ individually labeled cells - 9 billion+ labeled mitochondria - 5,200+ clinical DILI labels - 38,400+ liver enzyme elevation datapoints - a public dataset (June 2025) of 130,000+ compounds Axiom runs high-content imaging, or "cell painting"-style assays, to capture morphological and organelle-level features. Those features are used to train ML/AI models on its liver dataset. The models predict clinical liver injury, both as a classification (toxic vs non-toxic) and by severity. They also cover dose-response and exposure, meaning how a molecule's toxicity changes with concentration or exposure, and phenotypic profiles, meaning how each molecule affects cell morphology. ### Inside the toxicology engine The process starts with a small-molecule structure, supplied as a SMILES or structure file. Axiom's internal wet lab screens the molecule in primary human hepatocytes, and high-content imaging captures cell and organelle morphology. Feature extraction converts those images into high-dimensional phenotypic profiles, which are then linked to outcomes: clinical DILI labels, liver enzyme elevations and exposure data. ML/AI models are trained on this atlas of human liver toxicity data and deployed in Axiom's app and API. When a user uploads a new molecule, the model predicts clinical liver injury risk (DILI), dose-response and exposure (AUC, Cmax). It also identifies toxic phenotypic signatures and structural motifs (toxicophores). Axiom currently has a live demo available. Researchers can upload a small molecule and see its predicted liver risk, exposure profile and phenotypic effects. They can also compare molecules, explore the dataset and generate explanations. ### Outlook Many other biotech companies are racing to complete a reliable AI toxicology system. So far Axiom has an impressive primary human hepatocyte dataset, which may give it an edge if it continues on a positive trajectory. There are caveats. Although the FDA is vouching for software like this, it may be slow to accept AI toxicity models as a primary gatekeeper until more solid results are proven. Larger companies such as Eli Lilly and Novo Nordisk already have tons of proprietary data and could train similar models of their own if needed. And producing novel data for every drug toxicity scenario requires expensive new lab infrastructure and technological equipment for AI training and usage, which in turn means more funding and more time before Axiom can develop further. For now, Axiom's biggest advantage is the dataset. If the company keeps scaling it, it may build an AI tool no one else can match. Further updates to its AI datasets, or partnerships that expand its data, are the things to watch. ## AI x Drug Discovery: From Computation To Cure By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides In brief: Insilico Medicine cut preclinical development of rentosertib from 4.5 years to 18 months, and Variant Bio secured a deal worth over $120 million with Boehringer Ingelheim. AI-discovered molecules are showing 80-90% early trial success versus 40-65% historically. The post says that rate needs validation in larger, more diverse trials. Text page: https://bioasset.info/research/ai-x-drug-discovery-from-computation-to-cure.html The pharma industry faces inefficient economics: an average cost of $2.8B per successful drug, 90% clinical trial failure rates and preclinical timelines of 4-5 years. AI transformer models, the same architecture behind ChatGPT, are now being widely deployed across drug discovery and promise significant changes to those economics. ### Recent news Insilico Medicine pioneered AI-discovered drugs, reducing preclinical development from 4.5 years to 18 months for rentosertib, a drug that treats a scarring lung disease. Variant Bio launched its "Inference" agentic AI platform and secured a $120M+ deal with Boehringer Ingelheim, a major German pharmaceutical company, for kidney disease drug discovery. GSK developed Phenformer, an AI tool that links genomics with disease mechanisms, while AstraZeneca reports that 90%+ of its small molecule pipeline is now AI-assisted. On clinical success rates, AI-discovered molecules are showing 80-90% early trial success, against a historical 40-65%. ### The big picture Data from The Economist and Reuters sets the traditional and AI approaches side by side. The preclinical phase takes 4.5 years the traditional way and 1.5 years with AI assistance, 67% faster. Full drug development falls from 12.0 years to 8.0 years, 33% faster. In early clinical trials, the success rate is 85.0% for AI-discovered drugs against 52.5% for traditional ones, 62% higher. Overall success to market is 13.5% against 7.5%. The market is being transformed in several ways: - AI implementation is compressing preclinical phases from 3-5 years to 12-18 months. - Success probability for molecules could increase from 5-10% to 9-18%, a major leap in de-risking. - Annual investment is projected to jump from $3.8B (2025) to $15.2B (2030). - Companies can now screen tens of billions of molecules in record time in silico (by computation), removing expensive wet lab work. - Lower development costs make previously expensive therapeutics more accessible. ### Outlook OpenAI's recent entry, partnering with Moderna, and Nvidia's massive deal with Eli Lilly signal that tech giants see this as the path to AGI in biology. Drug discovery is becoming one of AI's highest-value applications, and it is increasing demand for CS/ML practitioners with deep scientific literacy. Companies that successfully integrate AI could see pipeline velocity that is 2-3x faster. Clinical trial risk and assessments remain real, however, and the 80-90% early success rate needs further validation across larger and more diverse trials. The patent cliff facing big pharma becomes more solvable when pipelines can be filled quicker and cheaper. This could shift M&A dynamics. Expect more acquisitions of AI-discovered late-stage assets and projects. Real success here depends on whether AI can truly solve and produce novel biological concepts, or whether we are just optimizing within known chemical space more efficiently. Insilico's rentosertib is proof of the concept, but scaling from 1 successful drug to 40+ will reveal whether this is transformative or just slightly better. ## BioAsset Autopsies: The Intarcia Story By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: Intarcia raised $1.9 billion to develop ITCA 650, a matchstick-sized implanted pump delivering exenatide for type 2 diabetes. After FDA rejections in 2017 and 2020, it filed for bankruptcy. The post blames complex manufacturing, dependence on one product, dual drug and device regulation, and competition from weekly GLP-1s such as Ozempic. Text page: https://bioasset.info/research/bioasset-autopsies-the-intarcia-story.html Intarcia Therapeutics raised $1.9 billion to put up to a year of diabetes medication into an implant the size of a matchstick. The FDA turned the product down twice, and the whole firm went under. This autopsy, part of a new series, treats it as a $1.9B+ lesson in relying on a single product. ### The company and its technology The company was founded as BioMedicines in 1995 and renamed Intarcia Therapeutics in 2004. Its technology was ITCA 650, a matchstick-sized osmotic pump implanted under the skin that continuously delivered exenatide, a GLP-1 agonist, for Type 2 diabetes for 6-12 months. An osmotic pump is a miniature, implantable device or oral tablet that delivers drugs or agents continuously at a controlled rate using osmotic pressure. In the implant, a semipermeable membrane sits at one end, followed by an osmotic engine, a piston and a drug reservoir, with the drug formulation released at the other end. Instead of daily or weekly injections (like Ozempic), one tiny implant gives steady medication for a year. This technology was very enticing for patients. All of the $1.9 billion in funding depended on FDA approval. After Intarcia filed for bankruptcy and proceeded to liquidation, its assets were acquired by i2o Therapeutics, which continued to revamp the implant pump technology and tried to prove that it works. The FDA rejected it in 2024, and the program is now fully dead. ### Timeline - 1995: Founded as BioMedicines - 2004: Renamed Intarcia Therapeutics - Aug 2006: Licenses the DUROS pump from ALZA - 2007: ITCA 650 development begins - 2009: Phase 1b trials - 2010: Phase 2 results (ADA) - 2012: Kurt Graves CEO; $210M raised - 2014-2015: Major funding rounds ($425M) - 2014-2016: Phase III FREEDOM trials - 2016: NDA submitted; valuation ~$5B - Sep 2017: FDA CRL (manufacturing) - 2020: Second FDA CRL; operations shut down - Nov 2020: Chapter 11 bankruptcy - 2023: Assets acquired by i2o Therapeutics - 2023-2024: FDA rejection; program terminated ### What went wrong The manufacturing process was complex. The osmotic pump required highly precise manufacturing with no room for error, because tiny variations lead to inconsistent drug delivery, and that is a patient safety risk. The FDA's manufacturing standards for implantable devices are extremely strict. The company depended on one product. Intarcia put all its funds and energy into one basket, with no backup pipeline, and when ITCA 650 failed the entire company fell with it. It had other programs and "products," but they all required ITCA 650 approval to advance further. The regulatory burden was doubled. ITCA 650 had to satisfy both drug and device FDA standards, since combination products face stricter scrutiny, in this case double. The timing was bad. By 2017-2020, weekly GLP-1s like Ozempic were being commercialized and gaining popularity. The industry began to move faster than Intarcia could pivot, which further shrank the convenience advantage of ITCA 650. ### Survival tips Partner earlier for manufacturing. Intarcia should have attempted to partner with big pharma companies that had manufacturing expertise. Pride and equity concerns brought the company downhill. Diversify. It should have developed multiple products that were not fully dependent on the osmotic pump platform, as a potential safeguard. Use a licensing strategy. Intarcia could potentially have licensed the pump technology to other firms, generating some revenue while revamping and fixing ITCA 650. Pivot after the first rejection. The FDA's first rejection in 2017 should have served as a warning sign and a push toward another direction. Intarcia could have attempted to sell assets and focus on a different delivery system, yet stubbornness resulted in its end. In another universe, Intarcia shakes hands with a partner such as Lilly, J&J, Pfizer or Novo Nordisk. ## BioAsset Weekly: The Pricing Wars, Regulation and M&A By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides In brief: The Trump administration launched TrumpRx.gov to direct cash-pay patients to discounted drugs, adding price pressure on Novo Nordisk and Eli Lilly. Hims & Hers pulled a low-cost copycat GLP-1 pill after FDA blowback, and its stock fell about 15%. GSK agreed to acquire Rapt Therapeutics for about $2.2 billion for its anti-IgE antibody for food allergies. Text page: https://bioasset.info/research/bioasset-weekly-the-pricing-wars-regulation-and-m-a.html Four stories defined the week in biopharma: a new government price hub, a profit shift between the two giants of weight loss, an FDA crackdown on copycat GLP-1s, and another sizable acquisition. ### TrumpRx Donald Trump's administration launched TrumpRx.gov as a hub directing cash-pay patients to discounted drugs through coupons and manufacturer links rather than direct selling. The site has not rolled out all planned drugs yet, and many of the most visible discounts are on GLP-1 drugs. A sample page offers 43 drugs sorted by best deal, with Cetrotide at $22.50 (down from $316.12, 93% off), the Wegovy pill starting at $149.00 (down from $1,349.02, 89% off) and Bevespi at $51.00 (down from $458.05, 89% off). This is effectively a new pricing reference point in the US cash-pay channel. Watch how it changes manufacturer net pricing strategies and the price pressure on big pharma. ### Novo and Lilly A chart from The Economist showing net profit in billions of dollars for Novo Nordisk and Eli Lilly from 2020 through 2025 captures the GLP-1 profit shock. Novo led the early obesity boom in 2023 and 2024 with a great margin. The 2025 projections flip that, with Lilly overtaking as scale kicks in. Novo is warning that profits and sales in 2026 could decline amid price pressure and fierce competition, while Lilly is still guiding growth. Both face the same margin headwinds from cash-pay price caps, compounding crackdowns and TrumpRx-driven reference pricing. This is current market sentiment, not a locked-in projection. Expect more fluctuations as the year goes on, because pricing pressure, access and channel shifts, supply and regulatory enforcement can all swing margins. ### Hims & Hers versus the FDA Shortly after Hims & Hers Health, a telehealth platform that provides personalized online medical consultations and prescription treatments for various conditions, launched a very low-cost copycat GLP-1 pill, it faced regulatory blowback almost immediately from the FDA. The company has since taken the GLP-1s off the market, with some reports saying Novo Nordisk signaled potential legal action. Hims' stock fell about 15% on the news around February 6 amid legal and regulatory pressure, including the FDA probe and enforcement angle. It closed at $23.02 on February 6, down 14.64% over five days, and slid further to $19.37 after hours. This shows the serious action being taken by the FDA against companies marketing illegal copycat versions of weight loss drugs, and it highlights the safety, quality and legal concerns around mass-compounded GLP-1s. ### GSK buys Rapt GSK has agreed to acquire Rapt Therapeutics for about $2.2B in a $58-per-share cash deal, mainly for Rapt's long-acting anti-IgE antibody ozureprubart (RPT904). IgE drives allergic reactions, and the half-life-extended antibody is in Phase 2b, the mid-stage trial and dose selection phase, for food allergies. Its differentiator is less frequent dosing, targeting roughly every 12 weeks. The acquisition deepens GSK's respiratory and immunology portfolio while keeping the biotech M&A scene hot. Keep an eye out for further clinical trial updates and any progression in IgE tests. ## Update: Revolution Medicines By Brendan Seo, Research Analyst at BioAsset · 1 slide In brief: Patients receiving daraxonrasib achieved median overall survival of 13.2 months versus 6.7 months with chemotherapy. The study met its primary endpoint and could support future regulatory submissions. The post says the results highlight growing momentum behind RAS-targeted therapies. Text page: https://bioasset.info/research/update-revolution-medicines.html Revolution Medicines has reported positive Phase 3 data for its cancer drug daraxonrasib in metastatic pancreatic cancer, with the results featured at the 2026 ASCO Annual Meeting. Patients receiving the drug achieved a median overall survival of 13.2 months, compared with 6.7 months for those on chemotherapy. The study met its primary endpoint, and the data could support future regulatory submissions. The results also highlight the growing momentum behind RAS-targeted therapies, one of the most important areas in oncology today. ## Parasites as Biotech Assets: From Disease to Drug Discovery By Brendan Seo, Research Analyst at BioAsset · 5 slides In brief: Parasites produce proteins and metabolites that regulate human immune responses, and researchers are studying these compounds for autoimmune conditions and cancer research. Advances in genomics and biobanking let such samples feed drug discovery pipelines. The post raises questions of ownership, access and benefit sharing, since regions where parasitic diseases are most common often receive limited benefits. Text page: https://bioasset.info/research/parasites-as-biotech-assets-from-disease-to-drug-discovery.html Parasites have mostly been studied as something to eliminate. They are now also being treated as a source of molecules for drug discovery, and that raises a question about who benefits from them. Parasitic diseases affect over 200 million people worldwide, with the highest prevalence in sub-Saharan Africa, South Asia and parts of Latin America. Malaria alone caused over 249 million cases and 600,000 deaths in 2022, according to WHO figures. A prevalence map of intestinal parasites (Seay, 2018) puts much of sub-Saharan Africa, along with parts of South and Southeast Asia and Latin America, in its very high band of more than 25%. Most research has focused on eliminating parasites because of their role in causing disease. However, parasites also interact closely with human biological systems and produce molecules that influence how cells and immune responses function. ### What researchers have found Parasites produce specialized proteins and metabolites that allow them to survive inside the human body and avoid immune detection. One illustration from Nature Reviews Immunology shows a helminth releasing cytokine mimics, non-protein signatures and cystatins that act on immune cells such as macrophages and dendritic cells. These molecules can regulate immune responses. That is important, since over 50 million people are affected by autoimmune diseases globally. Researchers are now studying parasite-derived compounds for use in autoimmune conditions, and for emerging applications in cancer research. ### From threat to input Advances in genomics and biobanking have made it possible to collect and store biological samples at scale. Today, more than 500 million samples are stored in biobanks worldwide. These samples are used in drug discovery pipelines, where compounds are tested for medical applications. Developing a new drug can take 10 to 15 years, which makes access to diverse biological data critical. The process runs through nine stages: discovery, preclinical studies, a first regulatory filing, three phases of clinical trials, a regulatory filing for approval, access to the drug and post-approval studies. This shift has changed how parasites are viewed. Instead of only being studied as threats, they are now seen as valuable inputs in the early stages of drug development, with the potential to contribute to multiple therapeutic areas. ### Who benefits Parasitic diseases are most common in regions such as sub-Saharan Africa, yet much of the value generated from these biological resources is concentrated in developed countries. The global pharmaceutical industry generates over $1.5 trillion annually, while the regions supplying key materials often receive limited direct benefits. As biotechnology advances, compounds from parasites are becoming more important in early-stage research, especially in areas that involve immune regulation and disease treatment. Biological materials are playing a growing role as valuable inputs in drug discovery. The challenge moving forward is how these resources are managed. Questions around ownership, access and benefit sharing will play a key role in shaping future outcomes. ## Replimune’s Stock Crash After FDA Rejection By Brendan Seo, Research Analyst at BioAsset · 5 slides In brief: The FDA rejected Replimune's cancer therapy again, finding the clinical evidence insufficient to demonstrate effectiveness. The stock fell about 19% in a single session and is down more than 50% year-to-date. The post argues the sustained decline shows investors lowering the perceived probability of approval, a key driver of biotech valuation. Text page: https://bioasset.info/research/replimune-s-stock-crash-after-fda-rejection.html Replimune's cancer therapy has been rejected again by the FDA, and the market's response was sharp. The stock fell approximately 19% in a single trading session, taking total losses past 50% year-to-date. The drop reflects a major shift in investor expectations around the drug's likelihood of approval, and a significant repricing of the company. The FDA's decision, reported by the Wall Street Journal in April 2026, was based on insufficient clinical evidence to demonstrate effectiveness. Early data showed potential, but the submitted results did not meet the level of statistical confidence required for approval. The case highlights how biotech outcomes are driven by whether progress meets regulatory standards. ### What went wrong The core issue was not a clear failure of the drug. It was a gap between early signals and regulatory expectations. The FDA requires strong, well-supported clinical datasets to approve new therapies, and here the available data was insufficient to confirm effectiveness. That creates uncertainty about both the drug's performance and its path forward. As a result, the market revised down the probability of approval, which is a key driver of valuation in biotech. That shift led to a rapid decline in investor confidence and contributed directly to the stock's multi-day sell-off. ### Market impact Yahoo Finance data for REPL show the shares closing at $4.76 on April 10, down $1.15, or 19.46%, on the day. After-hours trading that evening showed $1.75, down a further 63.24%. Over the five-day view the stock was down 43.40%, stepping lower from above $7.50 at the start of the period. The reaction was not limited to a single day. Losses continued over multiple days following the announcement, which indicates that investors kept reassessing the company's outlook after the initial news. This reflects a broader dynamic in biotech markets, where valuation is tied to the probability of future success. When that probability declines, pricing adjusts quickly and often continues to trend downward as new expectations are formed. ### What the decline says Replimune's stock decline reflects more than a reaction to a single FDA decision. A drop of about 19% in one day, followed by continued losses and a decline of over 50% year-to-date, suggests the market is actively reassessing the company's future rather than responding to short-term news. When the FDA determines that clinical data are not sufficient, it directly lowers confidence in the drug's approval path. Investors adjust their expectations quickly, which leads to sharp and sustained price movements. The multi-day decline shows that this process is not immediate. Valuation keeps adjusting as more investors interpret the implications of the decision, and biotech markets are driven by how such outcomes change expectations over time. ## Atavistik Bio: $160M to Drug the Undruggable and Cure a Rare Blood Disorder By Jingqiu Tian, Research Analyst at BioAsset · 5 slides In brief: Atavistik Bio raised $120 million in Series B financing in December 2025 and added $40 million from RA Capital Management in March. Its drug ATV-1601 is an oral allosteric inhibitor of AKT1 for Hereditary Hemorrhagic Telangiectasia, a bleeding disorder affecting 1.6 million people. The post says its selectivity avoids the toxicity of pan-AKT inhibitors. Text page: https://bioasset.info/research/atavistik-bio-160m-to-drug-the-undruggable-and-cure-a-rare-blood-disorder.html Atavistik Bio, a biotechnology startup developing allosteric small-molecule therapeutics, has secured $160 million in Series B funding as of March 2026. The money will support ATV-1601, its drug for a rare bleeding disorder called hereditary hemorrhagic telangiectasia (HHT), along with a second drug for myeloproliferative neoplasms. ### A different way into the protein Atavistik focuses on precision allosteric therapeutics. Despite significant advances in drug discovery, approximately 90% of disease-causing proteins are not properly drugged, because they lack traditional binding sites. Atavistik develops drugs that target alternative sites on those proteins, known as allosteric sites. A protein's function is largely determined by the shape of its active site. Allosteric sites are other sites on the protein that, when bound by a molecule, can change the shape of the active site and so alter the protein's function. To develop these drugs, the company first identifies functional sites on a proprietary platform, then further engineers the drug using a combination of wet lab work and computation. Bryan E. Stuart is the chief executive officer. ### ATV-1601 and HHT ATV-1601 is one of the allosteric drugs Atavistik has developed, and it is designed to treat HHT, a severe bleeding disorder that affects 1.6 million people globally. Its target is AKT1, an enzyme that regulates the function of the endothelial cells that line blood vessels. In HHT, genetic mutations spur AKT overactivation and cause abnormal blood vessels to form, leading to bleeds, anaemia and other problems. ATV-1601 is taken orally and selectively inhibits AKT1. By blocking AKT1 activity, the drug broadly addresses the mutations that cause the disease and so tackles the root cause of HHT. Its precision also makes it more tolerable than pan-AKT inhibitors. It spares the related variants of AKT, which prevents toxicity and allows long-term use. ### The Series B In December 2025, Atavistik announced that it had raised $120 million in Series B financing. The round was led by Nextech Invest and The Column Group, with existing investor Lux Capital and new investor Regeneron Ventures participating. In March, the company announced an extension of the round with an infusion of $40 million from RA Capital Management. The financing will be used to advance ATV-1601 and the company's drug for myeloproliferative neoplasms (MPNs), a V617F mutant-selective JAK inhibitor. The company's pipeline shows ATV-1601 at the clinical stage for HHT and vascular malformations and the MPN program in lead optimization. It also lists an oncology partnership with Pfizer, on an undisclosed target, at the discovery stage. ### Why it looks promising ATV-1601 is one of Atavistik's most promising drugs so far. It is currently in clinical trials, which points to a potentially promising future in treating HHT. There are currently no highly effective treatments for HHT. Some of the current treatments are pan-AKT inhibitors, which target a family of AKT proteins, and that broad targeting leads to potential toxicity. The specificity of ATV-1601 sidesteps the toxicity issue and allows for long-term use, which makes it a highly promising drug. The way the company works matters too. By using proprietary platforms to identify protein target sites, then a combination of computation and wet lab work to engineer the drug, Atavistik has been able to develop multiple promising drugs. This method brings together multidisciplinary research and some of the most advanced technologies available, following the framework used by top pharmaceutical companies. Allosteric small-molecule therapeutics, specifically, show a very promising future. ## Alternative Prostate Cancer Treatment: Targeting Thyroid Hormone Receptors By Jingqiu Tian, Research Analyst at BioAsset · 5 slides In brief: Standard prostate cancer treatment suppresses androgen signalling, but up to 20% of patients develop castration-resistant disease. A 2025 paper found that a thyroid hormone receptor drives tumour growth and that the antagonist NH-3 reduced cancer cell proliferation, including in castration-resistant models, and was synergistic with enzalutamide. NH-3 remains limited to research. Text page: https://bioasset.info/research/alternative-prostate-cancer-treatment-targeting-thyroid-hormone-receptors.html Prostate cancer treatment is built around cutting off androgens, and up to 20% of patients become resistant to it. A 2025 paper points to a different target, the thyroid hormone receptor TRβ, and to a compound called NH-3 that blocks it. ### Where current treatment falls short Prostate cancer is the second most frequent malignancy in men and the sixth leading cause of death worldwide. It involves the growth of abnormal cells in the prostate. Its progression depends on androgen receptor (AR) signalling, which regulates cell proliferation: testosterone and dihydrotestosterone (DHT) activate AR, and that drives cell proliferation and cancer progression. The first-line treatment is androgen deprivation therapy (ADT), which suppresses testosterone and DHT by surgical castration or anti-androgen drugs. Further treatment uses second-generation AR inhibitors such as enzalutamide. The problem is drug resistance. Up to 20% of patients develop castration-resistant prostate cancer (CRPC) due to resistance to ADT, and 50% of CRPC patients develop metastatic CRPC in 3 years. ### The thyroid hormone link Recent studies show that thyroid hormones (TH) regulate androgen signalling and the pituitary-gonadal axis. Altered serum levels of THs and thyroid-stimulating hormone (TSH) are linked with an increased risk of prostate cancer, and in vitro, THs promote prostate cancer cell proliferation and tumour progression. Targeting the receptor is already recognised as a therapeutic strategy. The FDA recently approved resmetirom, a thyroid hormone receptor β (TRβ) agonist, for treating non-alcoholic steatohepatitis. The basis for the research and drug development involves CRYM, a negative regulator of TH. Previous findings showed reduced expression of CRYM in prostate cancer, and CRYM overexpression has been found to reduce TRβ expression. That makes TRβ a key driver of prostate cancer progression. Since TH promote prostate cancer, CRYM overexpression should be induced to treat it. The metabolic pathway involving CRYM and TRβ has also been shown to crosstalk with AR signalling. ### What the 2025 paper found The paper revealed the role of TRβ in prostate cancer proliferation and tumour development. Human datasets showed increased TRβ protein levels in prostate cancer cells, which points to a tumour-driving role for TRβ. NH-3, a TRβ-selective antagonist, significantly reduced prostate cancer cell proliferation and suppressed tumour growth. It causes AR degradation and downregulates AR target genes. NH-3 was highly effective in castration-resistant prostate cancer models, and its combined use with AR inhibitors such as enzalutamide was synergistic. The paper's summary figure shows NH-3 lowering proliferation and AR in prostate cancer cell lines. In xenograft models (LNCaP and 22Rv1), tumour growth is lowest with NH-3, below both enzalutamide and control. Patient samples show higher TRβ mRNA and protein. The figure labels NH-3 a novel treatment option for prostate cancer and CRPC patients. ### Outlook Current prostate cancer treatment centres on androgen deprivation, including castration and anti-androgen drugs such as enzalutamide. These treatments are ineffective against castration-resistant cancer. Researchers have found an alternative pathway, targeting thyroid hormone receptors, that sidesteps the resistance. NH-3 has proven to be an effective compound using this mechanism, and its combined use with current anti-androgen drugs such as enzalutamide is synergistic. The method is not available as a treatment for prostate cancer yet. It is still strictly limited to research. With strong evidence of its effectiveness, NH-3 has the potential to become an effective drug for treating prostate cancer. Moving from promising lab results to an approved therapeutic drug, however, still requires rigorous clinical trials and countless rounds of reengineering. The development of NH-3 for prostate cancer will be an interesting front to watch, and one with high potential. ## Treating the Impossible: Novel Treatments Potentially Curing Type 1 Diabetes By Jingqiu Tian, Research Analyst at BioAsset · 5 slides In brief: Type 1 diabetes, in which the immune system attacks insulin-producing beta cells, has no cure. The post reviews teplizumab, approved in 2022, Vertex Pharmaceuticals' zimislecel cell therapy in a phase 3 trial, the antibody tegoprubart, and gene-edited islet cells from Sana Biotechnology and CRISPR Therapeutics. It concludes researchers are closer to a cure than ever before. Text page: https://bioasset.info/research/treating-the-impossible-novel-treatments-potentially-curing-type-1-diabetes.html Type 1 diabetes has no cure, but a run of breakthroughs since 2020 has brought the field closer to one than ever. The work now runs from antibody drugs to cell transplants, selective immunotherapy and gene editing. ### What type 1 diabetes is Some 9.5 million people are living with type 1 diabetes. The body needs insulin to break down sugars, and type 1 diabetes is a condition in which the body cannot synthesize it. The cause is the body's own immune system attacking the beta cells in the pancreas, which produce insulin. Normally the immune system protects the body. In this case, it attacks it instead. Patients rely on constant insulin intake to manage their blood sugar levels. There is currently no cure, meaning insulin independence, because the disease arises from immune system dysfunction. Since 2020, there have been numerous breakthroughs in treating type 1 diabetes, including teplizumab, baricitinib, GAD-Alum, cell therapy and selective immunotherapy. ### Drugs that protect beta cells Teplizumab was approved in 2022. It is a monoclonal antibody that can bind to the surface of immune cells and alter their behavior, which reduces the immune system's attack on beta cells. The drug could delay or even halt the disease for some people. It doesn't work for everyone, though, and it could be quite costly ($205,000 for a full course) and time-consuming (at least 30 minutes for 14 consecutive days). Multiple other monoclonal antibodies are also being tested. Baricitinib, approved for rheumatoid arthritis in 2018, has demonstrated success in preserving beta cells. GAD-Alum, an immune-modulating drug, is still in trial. It reprograms the immune system to preserve beta cells, prompting it to ignore an enzyme that activates the attack on them. ### Cell therapy, immunotherapy and gene editing Cell therapy involves transplanting insulin-producing cells from donors or from the patient. In 2024, in phase 1 or 2 clinical trials, findings showed effective treatment from transplanting stem cell-derived beta cells. (Stem cells are cells that can form nearly all cell types in the body.) By 2025, zimislecel (formerly VX-880) from Vertex Pharmaceuticals was in a phase 3 clinical trial. It uses lab-grown islets, which are clusters of cells that include beta cells, made from donor stem cells. Immune suppression is required to prevent transplant rejection. Tegoprubart, a monoclonal antibody in a phase 1 clinical trial in 2025, is used in selective immunotherapy, which targets specific cells or pathways and so brings milder side effects. It blocks the pathway behind the attack on transplanted beta cells. Gene editing was also in phase 1 clinical trials in 2025. Sana Biotechnology is gene-editing transplanted islet cells so that they evade the immune system, and CTX211, developed by CRISPR Therapeutics, pursues a similar approach. ### Outlook The concept of a "cure" varies widely, with some considering insulin treatment sufficient while others count only insulin independence. Whichever definition is used, recent medical advances make it safe to say that researchers are closer to a cure for type 1 diabetes than ever before. The general trend of treatment development can be largely summarized as monoclonal antibodies, cell therapy and transplants, immunotherapy, and gene editing. There is also a general trend toward multidimensional therapy in pharmaceuticals. Type 1 diabetes treatment will likely follow these patterns, so drugs that involve multidimensional therapy, such as tegoprubart, are worth looking out for. Gene editing is another interesting front to watch. As a relatively new technique, its application in treatment has not been developed as fully as the others. The coming years will therefore be a critical time to observe whether gene editing, a powerful tool in biological research, will be similarly significant in pharmaceuticals. ## Update: BMS x Anthropic By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 1 slide In brief: Bristol Myers Squibb will roll out Anthropic's Claude across R&D, manufacturing, clinical development and commercial teams, covering more than 30,000 employees. The post says the aim is to build AI into the day-to-day workflows that move drugs through the pipeline, and that the rest of the industry is taking note. Text page: https://bioasset.info/research/update-bms-x-anthropic.html Bristol Myers Squibb has struck a deal with Anthropic to roll out Claude across the entire company. The rollout covers R&D, manufacturing, clinical development and commercial, all of it, and reaches more than 30,000 employees. The point isn't another chatbot. BMS is building AI directly into the day-to-day workflows that actually move drugs through the pipeline. A $120B pharma giant has gone this far, and the rest of the industry is certainly taking notes. The enterprise AI era in drug development has arrived. ## Growth: Radioisotope Supply Boost By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 1 slide In brief: Niowave, a Michigan-based radioisotope supplier, is building a $75 million Actinium-225 production facility in Lansing, expected to come online in 2028. The move follows long-term supply agreements with Novartis and AstraZeneca signed within the last six months. The plant will house multiple superconducting linear accelerators and employ 70 specialized staff. Text page: https://bioasset.info/research/growth-radioisotope-supply-boost.html Niowave, a Michigan-based radioisotope supplier, has broken ground on a $75 million Actinium-225 (Ac-225) production facility in Lansing, MI. The plant is expected to come online in 2028. Ac-225 is used in targeted alpha therapies, a next generation of cancer treatment. The move follows back-to-back long-term supply agreements with Novartis and AstraZeneca, both signed within the last six months. The facility will house multiple superconducting linear accelerators and employ 70 specialized staffers across R&D, engineering and QA. ## Update: Replimune Stock Surges By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 1 slide In brief: Replimune said it has aligned with the FDA on a path forward for resubmitting its application for RP1, with the agency agreeing to treat the review as an urgent matter. The news follows the departure of FDA Commissioner Marty Makary, whose agency had rejected the drug twice. Shares spiked over 90% on Friday. Text page: https://bioasset.info/research/update-replimune-stock-surges.html The FDA is giving RP1 a "third" chance. Replimune (REPL) announced that it has aligned with the FDA on a path forward for resubmitting its application for RP1, and the agency has agreed to treat the review as an urgent matter. Shares spiked over 90% on Friday. The news comes directly on the heels of FDA Commissioner Marty Makary's departure earlier this month. Makary was the commissioner whose agency had rejected the drug twice. ## Novo X Hims: From Lawsuit to Partnership — What It Means for GLP-1 By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 5 slides In brief: As of March 9, Novo Nordisk dropped its suit over compounded semaglutide, and Hims & Hers will offer Novo's branded GLP-1 medicines instead. Hims stock rose as much as 47% in a day, though lower-margin branded products may compress its margins. Novo gains a distribution channel, but its stock sits near a 52-week low as Eli Lilly's Zepbound leads. Text page: https://bioasset.info/research/novo-x-hims-from-lawsuit-to-partnership-what-it-means-for-glp-1.html Novo Nordisk and Hims & Hers have gone from courtroom opponents to business partners in about a month. Novo had been suing Hims for selling compounded, custom-made versions of semaglutide, which it called knockoff products that infringed the patents for Ozempic and Wegovy. As of March 9th, that lawsuit has been dropped and the two companies have struck a deal: Hims will offer Novo's authorized, branded GLP-1 medicines on its platform. The agreement moves Hims away from compounded products and toward approved, branded drugs. It also follows increased scrutiny from the FDA over the safety and necessity of compounded GLP-1 drugs. ### What it means for Hims Hims & Hers stock spiked as much as 47% in a single day after the news. That is a significant resurgence after a rocky six months in which legal battles with Novo and mounting FDA pressure had drastically weighed down the shares. Google Finance data from March 10 showed the stock near $23, up about 46% over five days but still down about 34% over the past year. The deal provides much-needed relief, but it comes with real trade-offs. It reshapes the company's business model significantly, moving it away from the high-margin compounded drugs that had been a major revenue driver. Hims generated $2.35 billion in revenue in 2025, and top-line growth is expected to remain strong. Branded products carry higher price tags but lower margins, though, so the shift may compress gross margins and reduce profit per prescription. The price difference is large. Before insurance, Ozempic (intended for type 2 diabetes) costs roughly $900 to $1,200 a month and Wegovy (for weight loss) roughly $1,300 to $2,000, both from Novo Nordisk. The Hims product is listed at about $199 a month. ### What it means for Novo For Novo Nordisk, the resolution was a clear win strategically. CEO Mike Doustdar noted that the company now has more than 600,000 Wegovy pill prescriptions. Gaining Hims' large consumer platform as a distribution channel expands Novo's reach while shutting down a major compounding competitor. FDA commissioner Marty Makary also publicly praised the deal. Novo is valued at $173 billion, more than 25 times Hims, and as expected it did not see the same kind of stock surge. The shares have risen slightly since the deal, up about 3% over five days to around $38.70. But with competitor Eli Lilly's Zepbound producing better results for patients, and with the FDA recently issuing warnings to Novo, the stock is sitting around its 52-week low, down about 51% over the past year. ### The GLP-1 race The GLP-1 market is almost entirely a two-horse race between Eli Lilly and Novo Nordisk. With Wegovy on the market in 2021, Novo took a strong lead and coasted until 2025, when Eli Lilly's Zepbound took over on superior weight loss results. Novo launched an oral Wegovy pill in late 2025, but Lilly's faster manufacturing expansion and superior efficacy (20.2% weight loss compared to 13.7% for Wegovy) have given it a dominant position as of early 2026. Lilly's Zepbound now holds about 57% of the market and Novo's Wegovy about 36%. The remaining 7% belongs to others, including AstraZeneca and Sanofi, with Roche, Pfizer, Viking Therapeutics and Amgen emerging. With the Hims deal, we expect an increase in branded products on shelves. That would likely help both Novo and Eli Lilly, since it gets rid of a third-party competitor. The GLP-1 market is currently valued at $101.4 billion. With experts projecting a compound annual growth rate of about 8.7%, we can expect a $180 billion valuation by 2035. ## Fast-Tracked: How Hernexeos Won FDA Approval in 44 Days By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 5 slides In brief: Hernexeos (zongertinib) became the second drug approved under the FDA Commissioner's National Priority Voucher program, which aims to cut reviews from 10-12 months to 1-2 months. Trial data showed 76% of previously untreated patients had a meaningful reduction in tumor size. The oral HER2 inhibitor serves a small lung cancer population, with projected peak revenue of about $1 billion. Text page: https://bioasset.info/research/fast-tracked-how-hernexeos-won-fda-approval-in-44-days.html Boehringer Ingelheim's lung cancer drug Hernexeos (zongertinib) won FDA approval on January 13th, just 44 days after receiving a special voucher on November 6th. It was the second drug approved under the FDA Commissioner's National Priority Voucher (CNPV) program, which is built to shorten reviews for drugs that match national priorities. ### The voucher behind the speed Launched in June 2025, the CNPV program is a pilot initiative aimed at dramatically cutting drug review timelines, from 10 to 12 months down to just 1 to 2 months. It targets drugs that align with key national priorities, including responses to public health emergencies, efforts to bring pharmaceutical manufacturing back to the U.S., and improving the affordability of medications. Clinical trial data submitted to the FDA showed that 76% of previously untreated patients experienced a meaningful reduction in tumor size. Existing standard-of-care treatments see a response rate of roughly 30 to 45%. FDA Commissioner Marty Makary said of the approval that patients and sponsors deserve "an efficient FDA process that cuts out idle time" and delivers powerful treatments safely and quickly for the American people. ### A small market with strong revenue density Lung cancer is the leading cause of cancer deaths in the U.S. and the second most common cancer in men and women. The American Cancer Society estimates approximately 230,000 new lung cancer cases and 125,000 lung cancer deaths in 2026. Hernexeos addresses a narrow slice of that group. About 85% of lung cancers in the U.S. are non-small cell lung cancer (NSCLC), and HER2 mutations account for roughly 4% of NSCLC, or about 3.4% of all lung cancers. That means 4,000 to 8,000 new U.S. patients a year. The population is small, but this is a high-value precision oncology niche: annual therapy costs run $150K to $250K or more per patient. The current commercial competitor is Enhertu, from AstraZeneca and Daiichi Sankyo, a HER2-directed antibody-drug conjugate given by intravenous infusion every three weeks. Hernexeos is an oral, selective HER2 inhibitor. It has an opportunity to move into first-line treatment, where it could compete directly with chemo-immunotherapy in HER2-positive patients, and earlier-line adoption would mean a larger addressable revenue pool. Experts project peak revenue of approximately $1B, based on a $100,000 price tag and 10,000 eligible patients. The drug also adds to the trend of treating lung cancer based on specific genetic mutations rather than one general approach. ### What the approval sets in motion The approval is expected to change both the way lung cancer is treated and the market for lung cancer therapies. Strong early efficacy from Hernexeos sets a high bar for follow-on therapies. It also validates HER2 mutations as a target, which should draw big pharma companies to develop their own rival treatments over the next few years. There is a caveat. Hernexeos has accelerated approval based on early clinical trial data, so it carries some regulatory risk until confirmatory trials succeed. Even so, Boehringer now has a several-year lead in HER2-mutant therapy, which lets the company influence guidelines and everyday use. ### What the CNPV means for pharma Faster approvals let pharma companies launch products sooner in lucrative markets and capture earlier sales for high-demand drugs such as oncology treatments or antibiotics. The program's qualifiers target public health crises, breakthrough therapies, unmet needs, supply chain resilience and affordability, covering areas like cancer, obesity and gene therapies. Unlike Priority Review Vouchers (PRVs), which are transferable, CNPVs cannot be sold, but they are strategically superior for U.S.-focused pipelines. The U.S. pharmaceutical market has maintained a strong upward trajectory over the past two years. State Street's XPH, a commonly referenced pharmaceutical ETF, is up almost 32% over the past year, at $57.56 according to Google Finance. For reference, it stood at $40.75 on June 17th, 2025, the day the CNPV went into effect. With the CNPV now in place, companies have a unique window to significantly accelerate their drug development timelines and reach the market sooner. Other medications that have completed or are completing the CNPV process include Wegovy (obesity), Casgevy (sickle cell) and Bedaquiline (drug-resistant TB). ## BioAsset VC Dive: Xaira Therapeutics — Can AI Crack the Drug Discovery Code? By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 5 slides In brief: Xaira Therapeutics was built as an AI-native company, combining large-scale biological data with computational models to design proteins and antibodies. It released X-Atlas/Orion, a public single-cell dataset of about 8 million cells. The post is optimistic but notes Xaira has 189 employees, no products on the market, and funding that can deplete quickly. Text page: https://bioasset.info/research/bioasset-vc-dive-xaira-therapeutics-can-ai-crack-the-drug-discovery-code.html Xaira Therapeutics launched with more than $1B in capital, one of the largest debuts in biotech history, to take on a core problem in healthcare. Despite advances in science, drug discovery remains expensive, slow and highly unpredictable. Many promising drugs fail late in development because biology is complex and often poorly understood. Founded in 2024, Xaira took an unorthodox approach. Most companies today layer AI onto traditional biotech workflows. Xaira was built as AI-native from the ground up, bringing together leaders in biology, AI and medicine to create a unified platform where computation and experimentation continuously inform each other. The leadership reflects that mix, with former Genentech executives and Nobel Prize-winning scientists. CEO Marc Tessier-Lavigne is a former Genentech executive and Stanford professor, and director Carolyn Bertozzi is a Nobel laureate and Stanford professor. The company is backed by top-tier venture firms including ARCH, Sequoia and NEA, and it has unicorn status. It is headquartered in San Francisco, with more locations in Seattle and London. ### Making biology computable By combining large-scale biological data with computational models, Xaira can simulate how cells, proteins and diseases behave. That allows the company to predict outcomes more precisely than traditional trial-and-error methods, and to keep improving its models through a feedback loop with experimental data. In other words, Xaira is making biology "computable" to design better medicines faster. One of its most innovative capabilities is generative protein design. Using advanced AI models, Xaira can create new proteins and antibodies that conventional methods cannot reach, unlocking potential therapies for previously "undruggable" diseases. The platform builds on foundational science from the Institute for Protein Design at the University of Washington, which lets Xaira rapidly translate computational predictions into real-world experiments. With the help of Oracle Cloud Infrastructure, the company is also able to train large AI models. ### The models behind the platform X-Atlas/Orion is the largest Perturb-seq dataset and the largest single-cell dataset publicly available, at around 8 million cells. It covers all human protein-coding genes and powers AI that predicts cell behavior and disease biology. That gives Xaira and the broader scientific community an unprecedented foundation for predictive models. Generative protein design uses AI models to create novel proteins and antibodies beyond natural possibilities, and it integrates prediction with experimental validation. It moves drug discovery from trial and error to engineered design, opening entirely new therapeutic possibilities. Virtual cell modeling, on the AI-native platform, uses AI and large datasets to simulate cellular responses digitally. It predicts how genes, proteins or drugs behave before lab tests and supports end-to-end drug discovery, from target to molecule to validation. That dramatically speeds up discovery, reduces costs and increases success rates. ### The outlook Xaira is still a relatively young company, and the majority of its products and prototypes are in the developmental stage. But as funding increases, leadership strengthens and the technology advances, this company could be the next big thing. Releasing X-Atlas/Orion publicly also builds goodwill with the scientific community and positions Xaira as a data infrastructure leader, not just a drug company. There is a bearish case too. Even with its rapid growth and optimistic forecast, Xaira has 189 employees, offices in San Francisco, Seattle and London, and zero products on the market. Funding of $1B+ depletes fast in biotech. Drug discovery is a graveyard for well-funded early-stage companies, so keep an eye on any future successes or failures in clinical trials. The market around it is expanding. Experts project a 38.90% compound annual growth rate (CAGR) for the AI in healthcare market from 2026 to 2032. Grand View Research's chart of that market, which is split into software solutions, hardware and services, shows it at $36.7 billion in 2025 and $50.7 billion in 2026, reaching $505.6 billion in 2033. ## Regeneron x CytomX By Neev Mohindroo, Research Analyst at BioAsset · 5 slides In brief: On June 3, 2026, Regeneron expanded its 2022 collaboration with CytomX to develop bispecific cancer therapies that activate only inside tumors, paying $37 million upfront with up to $4 billion in milestones. The post places it among recent large licensing deals. Its view on Regeneron stock is lean bullish, noting shares are down 20% year to date. Text page: https://bioasset.info/research/regeneron-x-cytomx.html On June 3, 2026, Regeneron Pharmaceuticals expanded its existing 2022 collaboration with CytomX to develop bispecific cancer therapies. The licensing agreement carries up to $4B in milestone potential. ### Licensing over acquisition The deal fits a pattern. Recent biopharma licensing agreements include Regeneron and CytomX at up to $4B in oncology (June 2026), Novo Nordisk and Vivtex at up to $2.1B for oral delivery technology for next-generation obesity drugs (February 2026), AbbVie and RemeGen at up to $5.6B in oncology (January 2026), and Pfizer and YaoPharma at up to $2B in obesity (December 2025). All four are structured as licensing agreements, with milestone payments contingent on program success. AbbVie and RemeGen is the largest of the group, followed by Regeneron and CytomX. Licensing has clear advantages for both sides. The acquirer pays only when programs succeed, so risk is shared. The platform company keeps its independence and can partner with multiple other companies. Execution is faster. And AI-driven analytics are making early-stage platforms immensely valuable. Three ideas sit behind the science here. Bispecific antibodies are cancer drugs engineered to bind two targets instead of one, which makes them more effective. Conditional activation keeps a drug inactive in healthy tissue and switches it on at the tumor site. ADCs are targeted cancer drugs that combine a tumor-seeking antibody with a cancer-killing chemical. ### The companies and the terms CytomX is a clinical-stage oncology company based in San Francisco. It also partners with Amgen and Moderna, its pipeline includes Varseta-M for colorectal cancer and CX-801 for melanoma, and it developed the Probody therapeutic platform. Regeneron is a New York-based biopharma founded in 1988. Its VelociSuite drug development platform accelerates antibody development, and its key products include Dupixent, Otarmeni, EYLEA HD and Libtayo. The agreement is a licensing deal for smarter cancer drugs: therapies that only activate inside tumors, reducing toxic side effects. CytomX receives $37M upfront, guaranteed, with $4B in milestone potential if all programs succeed. Regeneron has the option to nominate six additional targets. The $4B breaks down across target nomination, development, regulatory and commercial stages, with development and commercial accounting for the largest shares. Regeneron is down 20% year to date against an industry average of about 3.5%. ### What it means for each side For CytomX, a $37M upfront payment against a market cap of roughly $650M is significant validation. The Probody platform is now backed by three large biopharma partners in Amgen, Moderna and Regeneron, and a $4B deal shows real belief in it. The company also gains operational capital to invest in its pipeline, and it looks like a potential go-to oncology partner for Big Pharma. For Regeneron, the stock is down 20% year to date after a melanoma trial failed to beat Keytruda. Rather than compete with Keytruda head-on, this deal gives Regeneron access to tumor types current therapies cannot reach. It diversifies the oncology pipeline beyond internal programs and invests in long-term growth on top of an already diversified platform of drugs. Q1 2026 revenue was up 19% year over year, and the fundamentals are better than the stock price implies. Regeneron's pipeline is showing momentum beyond oncology, with EYLEA HD for retinal disease, Otarmeni as the company's first gene therapy approval and Dupixent's 19% revenue growth. The CytomX deal adds a long-term oncology growth element to an already strong platform. ### Is REGN worth investing in? Regeneron has an implied volatility of 31-36%, one of the highest in healthcare, with swings of roughly $13-18 that show fear about the company's future. The bull case: fear in a company with financial strength can mean opportunity. Dupixent made $4.9B in one quarter, has nine US indications and is still growing 33% year over year. A $3B buyback was authorized in April 2026. The CytomX deal opens new oncology possibilities. And the company landed its first ever gene therapy approval in Q1 2026. The bear case: Regeneron has struggled against Keytruda, the melanoma trial failure points to broader immunotherapy pipeline struggles, the $4B in milestones is potential rather than guaranteed, and high implied volatility means any rejection or setback will hit the stock hard. The oncology pipeline currently runs from Libtayo (approved) and the fianlimab combo (phase 3) to Lynozyfic (phase 1/2) and the CytomX program (discovery). Otarmeni, also approved, is a gene therapy for hearing loss rather than oncology, included to show pipeline breadth. Bottom line: lean bullish, and watch the pipeline closely. ## Lilly Neuroscience By Neev Mohindroo, Research Analyst at BioAsset · 5 slides In brief: In one week in June 2026, Eli Lilly moved to acquire Centessa Pharmaceuticals for up to $7.8 billion for its orexin receptor 2 agonists for narcolepsy and signed a collaboration with BioArctic on its BrainTransporter platform. Shares hit an all-time high of $1,215.76 on June 26. The post is lean bullish on Lilly despite its 43x P/E. Text page: https://bioasset.info/research/lilly-neuroscience.html Eli Lilly closed one of its biggest weeks on record. Three major strategic moves, an acquisition, a collaboration and a European regulatory win, sent shares to a new all-time high of $1,215.76 on June 26, up 7.13% in a single session. Lilly is not just winning in one category. It is simultaneously dominating obesity, diabetes, oncology and Alzheimer's, and now expanding further into neuroscience by targeting sleep disorders and neurodegeneration. No other pharmaceutical company is running this many growth tracks at such a high scale. Right now, Eli Lilly stands alone in the health sector. A snapshot of its market position by therapeutic area shows roughly 60% global share in obesity (GLP-1), 53%+ ex-US share in diabetes (GLP-1), neuroscience revenue growing 160% year over year, an FDA-approved Alzheimer's drug in Kisunla, and EU approval imminent in oncology (CLL). Its therapeutic footprint as of June 2026 pairs the existing franchises, Mounjaro in diabetes at $8.7B in Q1, obesity GLP-1s, Kisunla in Alzheimer's and Jaypirca in oncology, with three areas added this week: sleep and narcolepsy, neurodegeneration and pain. Lilly's market capitalization stands at $1.14T. ### The two deals The first was the full acquisition of Centessa Pharmaceuticals, announced June 24. Centessa is a clinical-stage UK pharma company founded in 2021 that developed orexin receptor 2 (OR2) agonists, a new drug class targeting the brain's wake-promoting system, aimed at narcolepsy and other sleep-wake disorders. The target market is around $3B+ globally. The deal is worth up to $7.8B, with $6.3B upfront. The second was a research collaboration with BioArctic AB, announced June 22, centered on neurodegeneration. BioArctic is a Swedish biotech listed on Nasdaq Stockholm. Its proprietary BrainTransporter platform enables drugs to cross the blood-brain barrier, and the company previously developed lecanemab for Alzheimer's, now licensed to Eisai. Lilly pays $30M upfront with more than $770M in milestones, for a total potential value above $800M. The milestone structure breaks down into roughly $200M in development milestones, $250M in regulatory milestones and $320M in commercial milestones, plus tiered mid-single-digit percentage royalties on all global product sales. ### What each side gets For Lilly, the stock hit a new all-time high of $1,215.76 on June 26, up from a 52-week low of $623.78, nearly doubling in a year. Two neuroscience deals in a single week signal an intent to build a durable CNS franchise. The Centessa acquisition hands Lilly a clinical-stage OR2 program it can develop on its own, accelerating the path to market for a promising drug. The BioArctic deal gives Lilly a platform rather than a single drug, one that could unlock a whole new class of CNS therapeutics that previously could not reach the brain. Lilly also has a Medicare patient expansion ahead, going from 3.5M to 23.5M patients covered, a 6.7x increase. For Centessa, the acquisition removes all commercialization risk and gives the OR2 agonist best-in-class manufacturing, infrastructure and commercial reach. With Lilly behind it, the drug can reach approval faster, and Centessa shareholders received a full exit at what was likely a significant premium. For BioArctic, the $30M upfront provides immediate capital, and the $770M milestone structure means the company participates directly in the upside if the program succeeds. Having Lilly's name behind BrainTransporter also gives the platform instant credibility with other potential partners. ### Is LLY worth investing in? Lilly trades at 43x P/E, expensive by any pharma standard. But this is not a typical pharma company anymore. Lilly is dominating the largest new drug market in a generation in GLP-1s, building out a neuroscience platform, and is about to see its revenue model benefit from the biggest Medicare coverage expansion in obesity drug history. The stock carries a premium, and it still might be underpriced. Revenue backs that up: $12.73B in Q1 2025, $19.3B in Q4 2025 and $19.8B in Q1 2026, up 56% year over year. Of 31 analyst ratings as of June 2026, six are strong buy (19%), 18 are buy (58%) and five are hold (16%), with an average price target of $1,218.72. Bottom line: lean bullish, and watch their news closely. ## All Eyes On Cancer Therapy By Sharath Venkatesan, Research Analyst at BioAsset · 1 slide In brief: The 2026 ASCO Annual Meeting opened in Chicago, with four days of cancer-drug data that could reshape treatment standards and move billions in market value. The spotlight was on Revolution Medicines' pipeline and on bispecific antibodies, a fast-emerging class that blocks multiple disease pathways at once. Text page: https://bioasset.info/research/all-eyes-on-cancer-therapy.html The 2026 ASCO Annual Meeting opened last Friday in Chicago. The cancer-drug data unveiled over its four days had the potential to reshape treatment standards and move billions in market value, as investors bet on the next wave of oncology winners. The spotlight was on Revolution Medicines' pipeline and on bispecific antibodies, a fast-emerging class of drugs that block multiple disease pathways at once. The readouts from the meeting may determine which companies pull ahead in the race to define the future of cancer therapy. ## The Cost of Uncertainty: uniQure’s Battle with the FDA By Sharath Venkatesan, Research Analyst at BioAsset · 6 slides In brief: uniQure's AMT-130, a one-time gene therapy for Huntington's disease, showed a 75% reduction in disease progression at three years in phase 1/2 data. In November 2025 the FDA said that data, based on an external control, was no longer adequate, and by January 2026 it demanded a sham surgery-controlled Phase 3 study. uniQure is now seeking UK and EU approval. Text page: https://bioasset.info/research/the-cost-of-uncertainty-uniqure-s-battle-with-the-fda.html uniQure followed the plan it had agreed with the FDA for its Huntington's disease gene therapy. Then the agency changed its mind, and the stock fell 40%, then another 35%. ### A company with one moonshot Simply put, uniQure is a gene therapy company. It is not a pharma giant with thousands of drugs but a specialized lab with one moonshot: a bet on solving diseases at the genetic level, with a one-time treatment that could potentially fix the root cause of a disease forever. Its current best bet is AMT-130, a gene therapy for Huntington's disease, a fatal hereditary condition in which a mutated gene slowly destroys a person's brain cells. No treatment is currently available, and AMT-130 aims to fill that gap. AMT-130 is given once, injected directly into the brain (into the striatum, in uniQure's own description), where it delivers a genetic silencer to suppress the toxic protein that the Huntington's mutation produces. Phase 1/2 trial data showed a 75% reduction in disease progression three years after a single treatment. Those surprising results caused uniQure's stock price to triple. For a disease with zero options that modify its course, AMT-130 was considered a potential breakthrough. The company was weeks away from filing for FDA approval. ### An FDA in freefall uniQure did not just get an unfavorable ruling. It got caught in the crossfire of a deeply unstable regulatory agency. Heading into 2026, the FDA was mired in high-profile departures, feuds between top leaders, accusations of politicization and catastrophically low morale. The drug center had been led by five different people since January 2025 alone. The agency's workforce was down over 1,300 net employees from the start of 2025, and it approved only 46 drugs that year, lower than every year in the past decade except 2022. A major driver of the internal chaos was Vinay Prasad, a top deputy to Commissioner Marty Makary. Biotech companies openly don't trust him and view him as anti-innovation. Biotech stocks soared when he was briefly ousted in mid-2025, then fell when he came back. Prasad has been accused of pushing at least seven top scientists out of the agency and causing others to self-censor. This is the FDA that uniQure was trying to get approval from. ### What happened to uniQure uniQure had spent years working with the FDA, going through multiple meetings, reaching alignment on its statistical analysis plan and agreeing on the exact external control dataset to use as its comparator. Everything was set, with an approval set for Q1 2026. Then, in November 2025, the FDA changed its mind, deeming the Phase 1/2 data based on an external control no longer adequate to support an approval application. CEO Matt Kapusta called it "a drastic change" from prior guidance. The stock fell 40%. This happened even though the two parties had previously agreed on the exact protocols and statistical analyses. uniQure followed the rules the FDA gave it, and the FDA seemingly changed them without notice. Around the same time, Commissioner Makary, without naming AMT-130 directly, publicly referenced an investigational brain therapy that the agency had been "pressured" to approve despite finding no clinical benefit to patients. The comment was widely understood to be about AMT-130. By the final meeting in January 2026, the FDA was demanding a full prospective, randomized, double-blind, sham surgery-controlled Phase 3 study before any approval filing, effectively closing the door on a near-term approval. Shares fell another 35%. Google Finance shows the stock closing at $19.13 on May 1, down 44.21% over the past six months. ### Insights and impact uniQure's situation is not an isolated incident. Critics argue the FDA is now "replacing standards of safety and efficacy with fear and favor," and that the resulting unpredictability is "undermining the ability of innovators to bring medicines to market with confidence." Analysts at RBC Capital Markets warned that "continued shifts in leadership and unpredictability remain a potential headwind" for the entire sector. For uniQure, the path forward is now uncertain. The company is pursuing approval in the UK and EU, where regulators appear more open to the existing data. It is updating its statistical plan to include a four-year data readout expected in late 2026, hoping stronger long-term numbers might reopen dialogue in the U.S. It is also requesting a meeting with the FDA to discuss trial design options. The larger question is not just about uniQure but about what happens to drug development when the rulebook can change mid-game. Small biotech companies bet years of work and hundreds of millions of dollars on a regulatory framework they were told was agreed upon. An erratic FDA does not just hurt one company. It threatens America's position in biotech entirely, as companies begin considering moving their regulatory filings and funding requests to more predictable environments. Patients with Huntington's disease, a progressive and fatal condition, are the ones left waiting.